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ABBREVIATIONS 
AIF  apoptosis inducing factor 
AP-1  activator protein-1 
BAL  broncheoalveolar lavage 
BER  base excision repair  
BRCT  BRCA1 C-terminus like  
CBP  cAMP responsive element binding protein-binding protein 
COPD  chronic obstructive pulmonary disease 
CYP  cytochrome P450 
DBD  DNA binding domain 
ELISA  enzyme linked immuno sorbent assay 
ESR  electron spin resonance 
FEV1  forced expiratory volume in one second 
FVC  forced vital capacity 
HDAC  histone deacetylase  
HO  heme oxygenase 
H2O2  hydrogen peroxide 
IκB  inhibitor kappa B 
IKK  IκB kinase  
IL  interleukin 
iNOS  inducible nitric oxide synthase 
IT  intratracheal 
LPS  lipopolysaccharide 
MAPK  mitogen-activated protein kinases  
MIP  macrophage inflammatory protein 
MNNG  N-methyl-N’-nitro-N-nitrosoguanidine 
MPO  myeloperoxidase 
NF-κB  nuclear factor-kappa B 
NLS  nuclear localization signal  
PAR-polymer poly(ADP-ribose) polymer 
PARG  poly(ADP-ribose) glycohydrolase 
PARP-1  poly(ADP-ribose) polymerase-1 
PDE4  phosphodiesterase 4 
PI-3kinase phosphoinositide 3-kinase 
PKC  protein kinase C 
ROS  reactive oxygen species 
SAP  serum amyloid p component  
SOD  superoxide dismutase  
TEAC  trolox equivalent antioxidant capacity  
TNF-α  tumor necrosis factor-alpha 
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POLY(ADP-RIBOSE) POLYMERASE-1 
The enzyme poly(ADP-ribose) polymerase-1 (PARP-1; also known as poly-
(ADP-ribose) synthetase and poly(ADP-ribose) transferase, E.C. 2.4.2.30) is one 
of the most abundant nuclear proteins present in eukaryotes (reviewed in [1, 
2]). PARP-1 is a 116 kDa protein consisting of three domains: the N-terminal 
DNA-binding domain (DBD) containing two zinc fingers, the automodification 
domain and the C-terminal catalytic domain (Figure 1). PARP-1 is a member of 
the PARP enzyme family, which until now consists of 17 homologues with 
PARP-1 as the most extensively studied member [3]. Each PARP homologue is 
different in domain structure, ability to bind to DNA, cellular localization and 
function. 
 
 
Figure 1. Schematic representation of the organisation of human PARP-1. The amino (N)-terminal 
DNA binding domain contains 2 zinc fingers (FI and FII), which are responsible for DNA binding, a 
nuclear localization signal (NLS) containing the caspase-cleavage site. The automodification domain, 
which contains a BRCT (BRCA1 C-terminus like) motif and also serves as the binding place for the 
auto-poly(ADP-ribosyl)ation reaction. The C-terminal region holds the catalytic domain of PARP-1, 
which includes the active site and the NAD+-binding site. 
 
PARP-1 functions as a DNA damage signalling molecule binding to both single- 
as well as double-stranded DNA breaks. Upon binding to the damaged DNA, 
PARP-1 forms homodimers and catalyzes the transfer of ADP-ribose molecules 
from its substrate NAD+ to acceptor proteins (Figure 2). The ADP-ribose 
molecules form poly(ADP-ribose) polymers (PAR-polymers) and bind to various 
target proteins including PARP-1 itself (automodification domain). Poly(ADP-
ribosyl)ation is a dynamic process, as follows from a very short half-life (< 1 
min) of the PAR-polymer. The catabolism of the PAR-polymer is regulated by 
two enzymes, poly(ADP-ribose) glycohydrolase (PARG) and ADP-ribosyl 
protein lyase. PARG cleaves the ribose-ribose bonds of both linear and multi- 
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Figure 2. The poly(ADP-ribosyl)ation reaction catalyzed by PARP-1. A) Nicotinamide is cleaved from 
NAD+ and B) the ADP-ribose subunits form poly(ADP-ribose)polymers (adapted from [4]) 
 
branched portions of poly(ADP-ribose) and ADP-ribosyl protein lyase removes 
the protein proximal ADP-ribose monomer. The regulation of PARP-1 activity is 
primarily regulated at the level of its catalytic activity. The best-characterized 
mechanism for the downregulation of enzyme activity is through auto-
poly(ADP-ribosyl)ation at the automodification domain of PARP-1. Further-
more, the formation of nicotinamide as a result of cleavage of ADP-ribose from 
NAD+ exerts a weak negative feedback inhibitory effect on PARP-1. 
Most of the biological effects of PARP-1 relate to the various aspects of the 
ADP-ribosylation process: first, covalent poly(ADP-ribosyl)ation that influences 
the function of target proteins; second, the physical association of PARP with 
nuclear proteins to form functional complexes; third, the lowering of the 
cellular level of its substrate NAD+. 
DNA repair 
PARP-1 has long been known primarily for its role in facilitating DNA repair. 
This is supported by studies with knockout cells and mice which showed 
delayed and less efficient DNA base excision repair (BER) [5, 6]. Various 
mechanisms seem to be involved in the regulation of the DNA BER pathway by 
PARP-1. PARP-1 interacts with multiple nuclear components of the single-
strand break repair and BER complexes, such as XRCC1, DNA polymerase and 
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DNA ligase III, but also PARP-2 seems to be involved [7, 8]. In addition, the 
formation of the negatively charged poly(ADP-ribose) polymers and the transfer 
of these polymers to acceptor proteins like histones triggers chromatin-structure 
relaxation [9]. This remodeling of the chromatin architecture increases the 
access of DNA repair enzymes to the damaged DNA [10]. 
Signal transduction and gene expression 
An important physiological role of PARP-1 is the ability to regulate transcrip-
tion, and various mechanisms are involved in this role. Poly(ADP-ribosyl)ation 
confers negative charges to histones, which leads to electrostatic repulsion from 
the DNA [9]. This also leads to loosening of the chromatin and makes various 
genes more accessible to the transcriptional machinery. Furthermore, PARP-1 
participates in enhancer/promoter-binding complexes, such as its co-activator 
function of the nuclear factor-kappa B (NF-κB) mediated transcription [11]. 
Cell death 
PARP-1 has been implicated in both apoptosis and necrosis (Figure 3). Initial 
studies focused on its potential role in apoptosis, because PARP-1 was one of 
the first identified substrates of caspases [12]. During apoptosis, caspase 3 and 
7 cleave PARP-1 into two fragments, which separates its DNA binding domain 
from the catalytic domain and subsequently inactivates the enzyme. At present, 
this PARP-1 cleavage is seen as a marker of apoptosis and is independent from 
its catalytic acitivity and not influenced by pharmacological inhibition of the 
enzyme. PARP-1 cleavage prevents the overactivation of PARP-1 and thereby 
maintains cellular energy for certain energy-sensitive steps of apoptosis. 
Recently, in addition to the caspase-mediated apoptotic pathway, an alternative 
intrinsic cell death pathway has been illustrated. This apoptosis inducing factor 
(AIF)-mediated caspase-independent cell death pathway appears to be regu-
lated by PARP-1 [13]. PARP-1 activation was shown to induce translocation of 
AIF from the mitochondria to the nucleus, leading to DNA condensation and 
fragmentation and cell death. 
The most distinctive feature of necrosis is the disintegration of the plasma 
membrane. Leakage of cell content from necrotic cells into the surrounding 
tissue exacerbates the inflammatory process and may contribute to organ 
injury. Cellular ATP and NAD+ are important determinants of the mode of cell 
death, and PARP-1 directly regulates cell necrosis by regulating the levels of 
cellular energetic pools [14]. 
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Figure 3. The role of PARP-1 in cell death 
 
Inflammation 
Studies with knockout cells and mice pointed toward the regulatory role of 
PARP-1 in the NF-κB mediated gene-expression [11, 15]. Subsequently it has 
been observed that the enzyme activity of PARP-1 was not required for full 
activation of NF-κB, but PARP-1 was found to interact with histone acetyl 
transferase p300 and both subunits of NF-κB (p50 and p65) and synergistically 
coactivated NF-κB dependent transcription [16, 17]. In addition, the observa-
tion that PARP-1 itself was acetylated by the key activators of NF-κB, 
p300/cAMP responsive element binding protein (CREB)-binding protein (CBP), 
pointed towards the important regulatory role in NF-κB dependent gene-
activation [18]. However in contrast to these observations, others reported that 
the enzymatic activity of PARP-1 and so the synthesis of PAR-polymers facili-
tated the transcriptional activation properties of NF-κB [19]. Moreover, in-
hibition of PARP-1 with synthetic inhibitors has been reported to reduce the 
DNA-binding activity of NF-κB and also the transcription of NF-κB mediated 
genes [20, 21]. Overall, the contribution of PARP-1 activity to NF-κB activation 
and to the subsequent transcription of NF-κB mediated genes seems to be partly 
dependent on the tissues or cell type and the models used to investigate this. 
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PARP-1 has also been implicated in activator protein (AP)-1 mediated transcrip-
tional activity via mitogen-activated protein kinases (MAPK) [22]. Various 
studies with PARP-1 knockout cells and mice but also studies in which syn-
thetic PARP-1 inhibitors were applied showed the contribution of PARP-1 to 
these signaling cascades, such as demonstrated by a decreased MAPK activity 
and reduced AP-1 DNA binding [23-25]. 
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Figure 4. The regulatory role of PARP-1 in inflammation. PARP-1 induces chromatin relaxation and 
increases DNA accessibility for transcription factors such as NF-κB and AP-1, which are activated 
upon exposure to inflammatory stimuli. AP-1 activation is mediated by MAP-kinases. Activation of 
IκB kinase (IKK) induces the phosphorylation of IκB, the dissociation of IκB from the NF-κB/IκB-
complex and the translocation of NF-κB to the nucleus. In the nucleus, NF-κB binds to the DNA 
together with the other members of the transcription complex such as p300 and CBP, leading to 
transcription of pro-inflammmatory genes. PARP-1 interacts with this transcription complex and 
promotes also acetylation by P300/CBP. 
 
Overall, various mechanisms are responsible for the regulatory role of PARP-1 
in inflammation (Figure 4). The role of PARP-1 activation and the protective 
effects of PARP-1 inhibitors have been demonstrated in various experimental 
models of inflammation, both acute as well as chronic inflammation, including 
ovalbumin-induced asthma, myocardial ischemia/reperfusion, stroke and 
chronic inflammation in diabetes [26-28]. Previously it has been recognized 
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that PARP-1 is involved in the lipopolysaccharide (LPS)-induced acute pulmo-
nary inflammation in mice. PARP-1 gene deletion as well as pharmaceutical 
inhibition of PARP-1 has been shown to attenuate pulmonary inflammation 
[29]. Recently, Hageman et al. (2001) reported increased oxidative stress and 
increased inflammation in blood of COPD patients, which were accompanied 
by an increased number of PAR-polymer positive peripheral blood mononu-
clear cells, indicating a chronic and systemic PARP-1 activation [30]. Inhibition 
of PARP-1 might be a potential option for therapeutic application in both acute 
as well as chronic inflammatory conditions. 
PARP-1 inhibitors 
Recently, various consequences of the activation of PARP-1 have been   
discovered, that are particularly important for the drug development: first, its 
capacity to promote the transcription of pro-inflammatory genes; second, its 
capacity to deplete cellular energetic pools, which results in cell dysfunction 
and necrosis; and third, its role in DNA repair. Subsequently, pharmacological 
inhibitors of PARP-1 have the potential to down-regulate multiple pathways of 
inflammation or tissue injury, to reduce cell necrosis in for example stroke or 
myocardial infarction, and to enhance the cytotoxicity of certain DNA-
damaging anticancer drugs [21, 31-33]. 
Nicotinamide, one of the cleavage products of PARP-1 enzyme reaction, 
weakly inhibits PARP-1 competitively via product-inhibition. This fact together 
with the increased understanding of the chrystal structure of the catalytic site of 
PARP-1 led to the development of pharmaceutical PARP-1 inhibitors that are 
mainly based on the benzamide pharmacophore (Figure 5). This structure 
mimics the nicotinamide moiety of NAD+ and binds to the catalytic site of the 
protein. During the past decade, highly potent PARP-1 inhibitors have been 
synthesized with optimal potency and pharmacokinetics such as phenan-
thridinones, dihydroisoquinolinones, indoloquinazolinones and phtalazinones 
[31, 34, 35]. Also, existing medicines have been identified as PARP-1 inhibitors 
[36]. Significant therapeutic effects of synthetic PARP-1 inhibitors have been 
demonstrated in models of stroke, myocardial infarction, diabetic endothelial 
dysfunction, ovalbumin-induced asthma, hepatic ischemia/reperfusion injury, 
LPS-induced acute pulmonary inflammation and haemorrhagic and endotoxic 
shock [24, 26, 27, 29, 31, 37, 38]. Some of these synthetic inhibitors are 
currently evaluated in human clinical trials for potential treatment of reper-
fusion injury induced by myocardial infarction or the potentiation of chemo-
therapeutic agents [1, 32]. 
Not only synthetic compounds have been identified as PARP-1 inhibitors, also 
dietary compounds have been evaluated for their PARP-1 inhibiting activity 
[39, 40]. Synthetic PARP-1 inhibitors are very potent compounds which may 
increase the risk of possible negative aspects of PARP-1 inhibition. Considering 
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the long-term treatment of chronic diseases, the application of dietary mild 
PARP-1 inhibitors as nutraceuticals or functional foods would be a potential 
alternative. 
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Figure 5. Chemical structure of three important PARP-1 inhibitors 1) nicotinamide, 2) 3-
aminobenamide and 3) PJ34 (N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide. 
HCl) 
 
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 
Definition, prevalence 
The project described in this thesis focuses on the identification and evaluation 
of dietary PARP-1 inhibitors which can be applied in the treatment of chronic 
pulmonary inflammatory diseases, more specific chronic obstructive pulmonary 
disease (COPD). Therefore, this multifactorial disease will be described in more 
detail in this paragraph. 
COPD is a preventable and treatable disease with some significant extra-
pulmonary effects that may contribute to the severity of individual patients. Its 
pulmonary component is characterized by airflow limitation that is not fully 
reversible. The airflow limitation is usually progressive and associated with an 
abnormal inflammatory response of the lungs to noxious particles or gases [41]. 
COPD can be characterized by chronic and progressive dyspnea, cough and 
sputum production and includes different disease conditions varying from 
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chronic obstructive bronchitis with obstruction of small airways to emphysema 
with enlargement of air spaces, destruction of lung parenchyma, loss of lung 
elasticity and closure of small airways. In addition, COPD has also significant 
extrapulmonary (systemic) effects that lead to comorbidities and which may 
contribute to the severity of the disease in individual patients and may enor-
mously impair the quality of life [41]. 
COPD can be classified into 4 stages, which indicate the severity of the disease 
(Table 1). According to the World Health Organisation (WHO) estimates, 80 
million people have moderate to severe COPD. The WHO predicts that by 
2020 COPD will rise to the 5th most prevalent disease and to the 3rd most 
common cause of death worldwide. Increases in cigarette smoking and envi-
ronmental pollution in developing countries, but also reduced mortality from 
other diseases like cardiovascular diseases will explain the dramatic increase in 
COPD [42, 43]. 
 
Table 1. Classification of COPD severity 
Stage Spirometric characteristic 
Stage I: mild FEV1/FVC < 0.70 
FEV1  80% predicted 
Stage II: moderate FEV1/FVC<0.70 
50%  FEV1 < 80% predicted 
Stage III: severe FEV1/FVC<0.70 
30%  FEV1 < 50% predicted 
Stage IV: very severe FEV1/FVC<0.70 
FEV1 < 30% predicted or FEV1< 50% predicted plus chronic respiratory 
failure 
FEV1: forced expiratory volume in one second 
FVC: forced vital capacity 
 
Pathology 
In COPD, pathological changes can be found throughout the airways, lung 
parenchyma and pulmonary vasculature and include both chronic inflam-
mation as well as structural changes. The chronic inflammatory response is 
characterized by increased numbers of specific inflammatory cell types in 
different parts of the lungs such as neutrophils, macrophages and T-
lymphocytes and the production of inflammatory mediators, proteinases and 
reactive nitrogen and oxygen species by the airway and alveolar epithelial 
cells. These pathological changes lead to corresponding physiological charac-
teristics of the disease, including mucus hypersecretion and ciliary dysfunction, 
resulting in chronic cough and sputum production. Furthermore, airflow 
limitation, pulmonary hyperinflation, gas exchange abnormalities, pulmonary 
hypertension and cor pulmonale are important physiological changes observed 
in COPD patients. 
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In addition to the pulmonary effects, COPD is increasingly associated with 
significant systemic effects such as systemic inflammation and oxidative stress, 
cachexia and skeletal muscle weakness [44]. These systemic effects have 
important clinical relevance and are significant contributors to the impaired 
quality of life and mortality risk of COPD patients. 
Risk factors 
Cigarette smoking has world-wide been recognized as the most important risk 
factor for the development of COPD. Age at which smoking starts, total pack-
years smoked and current smoking status can all determine mortality from 
COPD. However, also occupational exposure to organic dusts is an important 
environmental risk factor for COPD. Furthermore, epidemiological studies 
show that there is increasing evidence that also non-smokers may develop 
chronic airflow obstruction [45, 46]. It has been recognized that the interaction 
between host factors and environmental exposure is responsible for basically 
all risk for COPD. The best-documented genetic risk factor is a rare hereditary 
deficiency of α1-antitrypsin, which has been shown to result in accelerated 
development of emphysema and decline in lung function in non-smokers and 
smokers [47]. Airway hyperresponsiveness and asthma are also identified as 
risk factors for the development of COPD, although it is not yet known how 
they influence the development of COPD [48]. 
Treatment 
Smoking cessation is at present the only effective measure that will reduce the 
risk for and slow down the progression of COPD. Most therapeutics in COPD 
therapy are aimed at bronchodilation and for this purpose β2-agonists, anti-
cholinergics and methylxanthines are prescribed. In addition to this treatment, 
inhaled or systemic glucocorticoids are often used for symptomatic patients 
during exacerbations. However, the effectiveness of these drugs is limited. 
Not only bronchoconstriction, but also chronic local and systemic inflam-
mation are important characteristics of the health status of COPD patients. 
However, no successful treatment has been developed yet for this increased 
inflammation. Potential candidates such as tumor necrosis factor-alpha (TNF-α) 
blockers (Infliximab) have been evaluated but were not beneficial or caused 
serious side-effects [49, 50]. 
Alternative therapies, which need to be applied chronically, are necessary. 
Dietary mild PARP-1 inhibitors might therefore be potential candidates for the 
treatment of chronic inflammatory diseases such as COPD. Furthermore, 
additional effects such as antioxidant activity might contribute to the beneficial 
effects of these compounds. 
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FLAVONOIDS 
Flavonoids are a class of food-derived polyphenolic compounds ubiquitously 
present in fruit, vegetables, red wine and tea. The chemical structure of most 
flavonoids is characterized by a three-ring structure, containing two aromatic 
rings (A+B) and one heterocyclic ring (C) (Figure 6). The various flavonoids can 
be divided in different subclasses like flavones, flavonoles, flavanoles, fla-
vanones, isoflavonoids, anthocyanidins and chalcones (Figure 6). 
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Figure 6.  Chemical structure of the various subclasses of flavonoids 
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Intake, absorption and metabolism 
The total amount of flavonoids consumed has been estimated at several 
hundreds mg per day for the Dutch population [51]. The flavonol and flavone 
intake in the Netherlands was determined at 23-24 mg/day [51, 52]. 
In foods, flavonoids are mainly present as glycosides and initially it was thought 
that the aglycones were the only form able to be taken up in the gastro-
intestinal tract [53]. However, currently it is considered that also flavonoid 
glycosides can be absorbed without preceding hydrolysis [54, 55]. After 
absorption, flavonoids are extensively metabolized in various organs such as 
small intestine and liver, resulting in the formation of sulfated, glucuronidated 
or methylated compounds [56]. 
Beneficial effects 
In epidemiological studies, the intake of flavonoids has been related to a 
reduced risk for various diseases including cardiovascular and chronic inflam-
matory diseases [51, 57]. These positive health effects have been ascribed to 
their well known antioxidant effects, but also to their anti-inflammatory effects 
and inhibiting effects on a wide range of enzymes [58, 59]. Both the anti-
oxidant effects as well as their enzyme inhibiting effects are ascribed to the 
hydroxylation pattern of flavonoids. The presence and position of hydroxyl 
groups in flavonoids are an important determinant of the antioxidant properties 
of these compounds [58]. It has become clear that flavonoids may exert their 
beneficial effects also via modulation of different components of intracellular 
signalling cascades such as MAPK, phosphoinositide 3-kinase (PI 3-kinase) or 
protein kinase C (PKC) [60]. Not only the aglycones and glycosides seem to be 
responsible for these effects, but also the conjugates and metabolites which are 
formed upon absorption may still be biologically active [61]. 
Flavonoids and pulmonary inflammation 
Various epidemiological studies have been performed to investigate the effect 
of flavonoid intake on incidence of pulmonary inflammatory diseases such as 
COPD or asthma [62, 63]. Tabak et al. (2001) studied the intake of catechins, 
flavonols and flavones from the diet in relation to impairment of pulmonary 
functions in COPD. Their results indicated that flavonol and flavone intake was 
found to be independently associated with chronic cough only. However, a 
reduced risk of a high intake of catechins and solid fruits for developing COPD 
was observed [63]. In an epidemiological study performed by Knekt et al. 
(2002), incidence of asthma was found to be inversely related to a higher intake 
of the flavonoids quercetin, naringenin, and hesperitin [62]. Experimental 
animal studies provided support for these epidemiological findings and thera-
peutic effects of various flavonoids on allergic airway inflammation were 
observed [64, 65]. 
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CAFFEINE AND OTHER METHYLXANTHINES 
Methylxanthines are a group of methylated heterocyclic aromatic organic 
compounds, which are mostly found in drinks such as coffee, cocoa, cola, 
black teas, and food products such as chocolates. Important dietary methyl-
xanthines are caffeine (1,3,7-trimethylxanthine), 1,7-dimethylxanthine (para-
xanthine), theophylline (1.3-dimethylxanthine) and theobromine (3,7-dimethyl-
xanthine). 
Absorption and metabolism 
Caffeine is rapidly and almost completely absorbed in the stomach and small 
intestine and distributed to all tissues. Caffeine metabolism occurs primarily in 
the liver where the activity of the cytochrome P450 isoform CYP1A2 accounts 
for almost 95% of the primary metabolism of caffeine (Figure 7). Caffeine is 
demethylated to its major metabolites 1,7-dimethylxanthine, theophylline and 
theobromine. Further demethylation of 1,7-dimethylxanthine results mainly in 
the formation of 1-methylxanthine and 1-methyl uric acid. 3-Methylxanthine is 
formed after demethylation of theobromine and theophylline [66, 67]. 
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Figure 7. Metabolism of caffeine in humans 
1X= 1-methylxanthine, 3X= 3-methylxanthine, 7X= 7-methylxanthine, 13X=1,3-dimethylxanthine 
(theophylline), 17X= 1,7-dimethylxanthine (paraxanthine), 37X= 3,7-dimethylxanthine (theobro-
mine), 137X= 1,3,7-trimethylxanthine (caffeine), 1U= 1-methyl uric acid, 3U= 3-methyl uric acid, 
7U= 7-methyl uric acid, 13U= 1,3-dimethyl uric acid , 17U= 1,7=dimethyl uric acid, 37U= 3,7-
dimethyl uric acid, AFMU= 5-acetylamino-6-formylamino-3-methyluracil 
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Methylxanthines and pulmonary inflammation 
The dietary methylxanthine theophylline together with its synthetic analog 
aminophylline is used in addition to corticosteroids in the treatment of COPD 
because of its bronchodilator effects. In addition, various therapeutic mecha-
nisms for potential anti-inflammatory effects of theophylline and also other 
methylxanthines have been described, such as inhibition of phosphodiesterase 
4 (PDE4) enzymes, antagonism of adenosine receptors and induction of histone 
deacetylase (HDAC) [68-70]. By inhibiting PDE4, methylxanthines block the 
hydrolysis of cAMP, leading to elevated intracellular cAMP levels and, thus, 
suppression of the proinflammatory activity of these cells, including cytokine, 
chemokine, and IgE production, enabling selective targeting of inflammation. 
PDE4 inhibitors have been successfully applied in the treatment of inflamma-
tory diseases such as COPD [71, 72]. The endogenous nucleoside adenosine 
has also been implicated in the pathogenesis of pulmonary inflammatory 
diseases such as asthma and COPD [73, 74] and it is generally assumed that 
also other methylxanthines than theophylline exert an important part of their 
effect via antagonism of the adenosine receptors [70]. Theophylline has also 
been depicted as an inducer of HDAC [69], which has been shown to result in 
restored steroid responses in alveolar macrophages of COPD patients [75]. 
Theophylline appears to have an effect on HDAC both in vivo and in vitro, 
though only at low concentrations, 10-100 times lower than those given for the 
bronchodilatory effects [69]. Nevertheless, since it was found that the health 
status of COPD patients deteriorated after discontinuing theophylline treatment, 
it is often still prescribed in addition to corticosteroids and β2-agonists [76-78]. 
AIM AND OUTLINE OF THIS THESIS 
The hypothesis of this PhD research described in this thesis is that dietary mild 
PARP-1 inhibitors are able to attenuate NF-κB mediated gene-expression and 
therefore may have beneficial effects in chronic inflammatory diseases such as 
COPD. 
 
The aims of the project described in this thesis were: 
1) to identify PARP-1 inhibiting food compounds using the purified PARP-1 
enzyme 
2) to evaluate the PARP-1 inhibiting effects of these compounds in vitro in 
cultured pulmonary epithelial cells and vascular endothelial cells and, further-
more, to investigate the effect of these PARP-1 inhibiting compounds on 
oxidative stress-induced necrotic cell death and LPS-induced inflammation in 
these cultured cells 
3) to study the effects of the oral administration of dietary PARP-1 inhibitors in 
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a mouse model of LPS-induced acute pulmonary inflammation 
4) to study the ex vivo anti-inflammatory effects of a dietary PARP-1 inhibitor in 
LPS-stimulated blood of COPD patients and healthy control subjects 
 
These resulted in research that is described in the following chapters. In 
chapter 2, the results are presented of the in vitro identification and evaluation 
of caffeine metabolites as PARP-1 inhibitors. Also, the effects of these com-
pounds on oxidative stress-induced depletion of intracellular NAD+-levels and 
necrotic cell death in cultured epithelial and endothelial cells are presented in 
this chapter. 
In chapter 3, it is described how various flavonoids were evaluated in vitro for 
their PARP-1 inhibiting activity using the purified enzyme. Furthermore, 
selected PARP-1 inhibiting flavonoids were further investigated for their PARP-1 
inhibiting effects in N-methyl-N’-nitro-N-nitrosoguanidine (MNNG)-exposed 
cultured pulmonary epithelial cells. Also, the effect of these flavonoids on NF-
κB mediated production of interleukin (IL)-8 is presented. 
In chapter 4 the in vitro effects of the PARP-1 inhibiting flavonoid flavone on 
NF-κB mediated gene-expression in LPS-stimulated pulmonary epithelial cells 
are dealt with. 
Chapter 5 describes an in vivo study in which PARP-1 inhibiting flavonoids are 
applied in a mouse model of LPS-induced acute pulmonary inflammation. Also, 
these food-derived compounds were compared to the anti-inflammatory steroid 
drug dexamethasone. 
In chapter 6, results of the in vivo application and evaluation of the PARP-1 
inhibitor 1,7-dimethylxanthine in a mouse model of LPS-induced acute pulmo-
nary inflammation are presented. The ex vivo effects of 1,7-dimethylxanthine 
on inflammation in LPS-stimulated blood of COPD patients and healthy 
subjects are described in this chapter as well. 
In Chapter 7 the present findings together with their potential implications are 
discussed. 
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CHAPTER 2 
Caffeine metabolites are          
inhibitors of the nuclear enzyme               
poly(ADP-ribose) polymerase-1 at 
physiological concentrations 
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ABSTRACT 
The activity of the nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP-1) 
(E.C.2.4.2.30), which is highly activated by DNA strand breaks, is associated 
with the pathophysiology of both acute as well as chronic inflammatory 
diseases. PARP-1 overactivation and the subsequent extensive turnover of its 
substrate NAD+ put a large demand on mitochondrial ATP-production. Further-
more, due to its reported role in nuclear factor kappa B (NF-κB) and activator 
protein-1 (AP-1) mediated production of pro-inflammatory cytokines, PARP-1 is 
considered an interesting target in the treatment of these diseases. 
In this study the PARP-1 inhibiting capacity of caffeine and several metabolites 
as well as other (methyl)xanthines was tested using an ELISA-assay with purified 
human PARP-1. Caffeine itself showed only weak PARP-1 inhibiting activity, 
whereas the caffeine metabolites 1,7-dimethylxanthine, 3-methylxanthine and 
1-methylxanthine, as well as theobromine and theophylline showed significant 
PARP-1 inhibiting activity. Further evaluation of these compounds in H2O2-
treated A549 lung epithelial and RF24 vascular endothelial cells revealed that 
the decrease in NAD+-levels as well as the formation of the poly(ADP-ribose) 
polymer was significantly prevented by the major caffeine metabolite 1,7-
dimethylxanthine. Furthermore, H2O2-induced necrosis could be prevented by 
a high dose of 1,7-dimethylxanthine. Finally, antioxidant effects of the methyl-
xanthines could be ruled out with ESR and measurement of the TEAC. 
Concluding, caffeine metabolites are inhibitors of PARP-1 and the major 
caffeine metabolite 1,7-dimethylxanthine has significant PARP-1 inhibiting 
activity in cultured epithelial and endothelial cells at physiological concentra-
tions. This inhibition could have important implications for nutritional treat-
ment of acute and chronic inflammatory pathologies, like prevention of 
ischemia-reperfusion injury or vascular complications in diabetes. 
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INTRODUCTION 
Poly(ADP-ribose) polymerase-1 (PARP-1, E.C.2.4.2.30), a nuclear enzyme 
present in eukaryotes, is highly activated upon induction of DNA strand breaks 
and activation results in the hydrolysis of NAD+ to form poly(ADP-ribose) 
polymers and nicotinamide. PARP-1 has various physiological functions; it is 
involved in base excision repair (BER), which was indicated by delayed repair 
in PARP-1 knockout mice and by interaction of PARP-1 with other members of 
the BER-machinery like XRCC1 and DNA polymerase  [6, 7]. PARP-1 is also a 
regulator of transcriptional activity, for instance, PARP-1 is reported to play a 
role in nuclear factor kappa B (NF-κB) and activator protein-1 (AP-1) mediated 
production of pro-inflammatory cytokines [17, 23, 24, 79-82]. 
The activity of PARP-1 is associated with the pathophysiology of acute inflam-
matory diseases like stroke and ischemia-reperfusion and also with chronic 
inflammation in diabetes and with pulmonary diseases such as chronic  
obstructive pulmonary disease (COPD) [29, 30, 83, 84]. PARP-1 overactivation, 
as a result of ROS-induced DNA damage, and the subsequent extensive 
turnover of its substrate NAD+ puts a large demand on mitochondrial ATP-
production and cellular energy status [85]. This can result in an energy crisis 
and lead to a necrotic cell death [86]. PARP-1 is therefore considered an 
interesting target in the treatment of these diseases. Many potent synthetic 
PARP-1 inhibitors have been developed during the last years, but several 
studies showed that food components also have PARP-1 inhibiting activity [27, 
39, 40, 87, 88]. These involve the methylxanthine theophylline (1,3-
dimethylxanthine, 13X), which has been reported to have PARP-1 inhibiting 
activity [89]. Theophylline is one of the major metabolites of caffeine (1,3,7-
trimethylxanthine), which is present in cocoa and beverages like coffee, tea and 
cola, and is extensively metabolized in the human body after oral intake. 
Caffeine is demethylated by the hepatic enzyme cytochrome P4501A2 
(CYP1A2) to its major metabolites 1,7-dimethylxanthine (paraxanthine, 17X), 
theobromine (3,7-dimethylxanthine, 37X) and theophylline. Further demethyla-
tion of 1,7-dimethylxanthine by CYP1A2 results mainly in the formation of 1-
methylxanthine (1X) and 1-methyl uric acid (1U). 3-Methylxanthine (3X) is 
formed after demethylation of theobromine and theophylline [66, 67]. 
The aim of this study was to test caffeine and several metabolites as well as 
other (methyl)xanthines (Figure 1) as possible inhibitors of PARP-1. First, the 
PARP-1 inhibitory activity of the compounds was tested using an assay with the 
purified enzyme. Second, the effect of the PARP-1 inhibitors on hydrogen 
peroxide (H2O2)-induced NAD
+-depletion and necrosis was tested in vitro in 
cultured pulmonary epithelial and vascular endothelial cells. 
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Figure 1. Molecular structure of the tested compounds 
 
 
MATERIAL AND METHODS 
Materials 
Caffeine, xanthine, 1-methylxanthine, 3-methylxanthine, 7-methylxanthine, 8-
methylxanthine, 1,7-dimethylxanthine, 1-methyluric acid, 1,7-dimethyluric 
acid, theophylline, theobromine, hypoxanthine, inosine, tween 20, acetic acid, 
3,3’,5,5’-tetramethylbenzidine, H2O2, bovine serum albumine (BSA), heparin, 
Dulbecco’s Modified Eagle’s Medium (DMEM), propidium iodide, trolox and 
2,2’-azinobis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) were all obtained 
from Sigma (St. Louis, MO, USA). Biofylline, β-NAD+ and 1,4-dithiothreitol 
(DTT) were obtained from MP Biomedicals (Irvine, CA, USA). Human rPARP-1 
and biotinylated NAD+ were purchased from Trevigen (Gaithersburg, MD, 
USA). F-12K Nutrient Mixture (Kaighn’s Modification), fetal bovine serum, 
glutamate, trypsin, Penicillin/Streptomycin and HBSS were all obtained from 
Invitrogen Life Technologies (Grand Island, NY, USA). Peroxidase-labeled 
streptavidin was purchased from Zymed (San Francisco, CA, USA). DMPO and 
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FeSO4 were obtained from Merck (Darmstadt, Germany). Polyvinylchloride 
microtiter plates and endothelial cell growth supplement were obtained from 
BD Biosciences (San Jose, CA, USA). 2,2’-Azino-bis(2-amidinopropane) 
dihydrochloride (ABAP) was obtained from Brunschwig Chemicals (Amster-
dam, the Netherlands). The 10H hybridoma was kindly provided by Dr. M. 
Miwa, via Riken Cell Bank, Tsukuba Institute BioResource Center (Ibaraki, 
Japan). The cell supernatant containing mouse monoclonal anti-PAR polymer 
antibody 10H was produced by Dr. W. Buurman (University of Maastricht, 
Maastricht, the Netherlands). Polyclonal goat anti-mouse immunoglobulin/FITC 
and fluorescent mounting medium were obtained from DAKO (Glostrup, 
Denmark). The ApoGlow kit was obtained from Cambrex (Verviers, Belgium). 
PARP-1 inhibition ELISA 
The capacity of the compounds to inhibit PARP-1 was first determined using an 
inhibition assay, as described by Decker et al. [90] and Brown and Marala [91] 
with minor modifications. In short, human rPARP was incubated with a reac-
tion mixture containing 50 µM β-NAD+ (10% biotinylated β-NAD+, 90% un-
labelled β-NAD+), 1 mM DTT and 1.25 µg/ml nicked DNA. Nicked DNA was 
prepared as follows, according to the method of Aposhian et al [92] with some 
minor modifications: Calf thymus DNA was incubated with 10 ng/ml DNase I 
at 37°C during 40 minutes. The length of the DNA-fragments (500 bp) was 
estimated using gel electrophoresis. 
To determine the optimal substrate concentration and incubation temperature 
for the PARP-1 assay, human rPARP-1 was incubated with various concentra-
tions β-NAD+ (0-150 µM; 10% biotinylated β-NAD+, 90% unlabelled β-NAD+) 
at two different temperatures (4-37 °C; Figure 2).  
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Figure 2. PARP-1 activity expressed as absorbance at 450 nm after incubating 400 ng/ml human 
rPARP-1 for one hour in the presence of various concentrations β-NAD+, 1 mM DTT and 1.25 
µg/ml nicked DNA at 4°C (●) and 37°C (■). 
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Based on this optimization, rPARP-1 was incubated with 50 µM β-NAD+ at 
4°C. Using these conditions, 100 µM 3-aminobenzamide and nicotinamide 
were used as positive controls and inhibited the enzyme 85.1 ± 0.9 and 73.5 ± 
3.6%, respectively. To determine background activity, the enzyme was also 
incubated with a reaction mixture without β-NAD+. 
After incubations with the reaction mixture, the plates were washed and the 
formation of poly(ADP-ribose) polymers was detected after a one hour incuba-
tion at room temperature with peroxidase-labeled streptavidin, followed by a 
15 min incubation with 3,3’,5,5’-tetramethylbenzidine (TMB) in the presence of 
H2O2 at 37°C. This reaction was stopped by adding 0.75 M HCl and the 
absorbance was measured at 450 nm. PARP-1 inhibition of several compounds 
was evaluated by addition of these compounds to the reaction mixture.  
Measurements were done in 3-fold. 
Cell culture 
A549 human lung epithelial cells were grown at 37°C in a humidified 5% CO2 
atmosphere and were cultured in Dulbecco’s Modified Eagles Medium (DMEM) 
with 4.5 g/L glucose, 10% fetal bovine serum (FBS), 2 mM glutamine and 50 
units/ml of penicillin and 50 µg/ml of streptomycin. RF24 human vascular 
endothelial cells were grown at 37°C in a humidified 5% CO2 atmosphere in 
gelatine-coated culture flasks and were cultured in F-12K Nutrient Mixture 
(Kaighn’s Modification) supplemented with 10% fetal bovine serum, 0.1 mg/ml 
heparin and 50 units/ml of penicillin and 50 µg/ml of streptomycin. During 
culturing at low densities, the medium was supplemented with 0.015 mg/ml 
endothelial cell growth supplement. 
Cellular NAD+ assay 
Cells were plated in a 96-wells plate (approximately 3x104 cells/well) and 
cultured for 24 h before exposure. H2O2 was used to induce DNA strand 
breaks, activate PARP-1 and deplete cellular NAD+ levels. To determine the 
optimal H2O2-concentration and incubation period for the cells, cells were first 
treated with different concentrations H2O2 (0-300 µM) for different periods of 
time (0-60 minutes), as previously described [89]. Maximal decreases in NAD+-
levels in both A549 and RF24 cells were reached after treatment with 300 µM 
H2O2 during 30 minutes. The PARP-1 inhibitor 3-aminobenzamide strongly 
prevented the decrease in NAD+-levels and served in all the experiments as a 
positive control. During the experiments, cells were preexposed to the methyl-
xanthines for 15 min and subsequently exposed to 300 µM H2O2 and the 
methylxanthines for 30 min. The maximal DMSO-concentration was 0.1% and 
was also used as a control. After the exposure, the cells were lysed in ethanol 
(50 µl/well) and stored at -80°C. During this lysis, 20 mM isonicotinic acid 
hydrazine was used to inhibit NAD-glycohydrolase and to prevent NAD+-
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hydrolysis [93]. After lysing the cells, intracellular NAD+ was determined using 
the NAD+-cycling method, as described by Jacobson and Jacobson [94] with 
minor modifications. After thawing and lysis of the cells, 100 µl reaction 
mixture without ethanol was added to the wells. The final reaction mixture in 
the microtiter plate contained 2.86 M ethanol, 114 mM bicine, 4.8 mM EDTA, 
0.95 mg/ml BSA, 47.6 mg/ml alcohol dehydrogenase, 1.9 mM phenazine 
ethosulphate and 0.48 mM MTT. The reaction was measured in time spectro-
photometrically at 540 nm at 37°C during 15 minutes. A standard curve (0-1.5 
µM) was included to calculate the NAD+-levels in the cells. The calculated 
NAD+-levels for each experiment were average values of at least 4 measure-
ments. 
Immunofluorescent staining of PAR-polymers 
To determine the effect of 1,7-dimethylxanthine on the formation of the PAR–
polymer, A549 cells (approximately 0.8x106 cells/well in 6-wellsplate) were 15 
min pretreated with 1,7-dimethylxanthine and thereafter treated with H2O2 for 
5 min. After the incubation, the cells were trypsinized, washed with PBS and 
fixed in methanol. After fixation, cells were stained as described by Hageman 
et al. [30] with some modifications. Fixed cells were washed with 0.1% BSA in 
PBS and incubated with 100 µl mouse monoclonal anti-PAR polymer antibody 
10H for one hour at room temperature. After washing with 0.1% BSA, the cells 
were incubated with 100 µl polyclonal goat anti-mouse immunoglobulin/FITC 
for one hour at room temperature. After washing again with 0.1% BSA, the 
cells were incubated for 15 minutes with 200 µl 20 µg/ml propidium iodide. 
Cells were transferred to slides and were mounted with fluorescent mounting 
medium. At least 100 cells per slide were evaluated for the presence of PAR 
polymers in their nucleus using fluorescence microscopy and Lucia GF 4.80 
software. Subsequently, the percentage of PAR polymer positive cells was 
calculated. 
Measurement of the ADP:ATP ratio 
To determine the effect of 1,7-dimethylxanthine on H2O2-induced cell death, 
A549 and RF24 cells (approximately 3x104 cells/well in 96-wellsplate) were 30 
min pretreated with 1,7-dimethylxanthine and thereafter treated with H2O2 for 
8 hours. After one hour incubation with H2O2 at 37°C, FBS was supplied to a 
10% final concentration and cells were incubated for additional 7 hours. After 
the incubation, the ADP:ATP ratio was determined using the ApoGlow kit. The 
assay is based on the bioluminescent measurement of the adenylate nucleo-
tides and can be used to determine the mode of cell death [95]. After 8 hours 
incubation, cells were lysed and processed for ATP and ADP measurements 
according to the instruction manual. 
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Electron spin resonance spectroscopy 
Electron spin resonance (ESR) studies were performed at room temperature 
using a Bruker EMX 1273 spectrometer equipped with an ER 4119HS high 
sensitivity cavity and 12 kW power supply operating at X band frequencies. 
The following instrument conditions were used: scan range, 60 G; center 
magnetic field, 3490 G; modulation amplitude, 1.0 G; microwave power, 50 
mW; receiver gain, 105; modulation frequency, 100 KHz; microwave fre-
quency, 9.85 GHz; time constant, 40.96 ms; scan time, 20.97 s; number of 
scans, 25. 5,5-Dimethyl-1-pyrroline N-oxide (DMPO) was used for trapping 
hydroxyl radicals and was purified in nitrogen flushed milli Q water by mixing 
with 30 mg/ml charcoal during 20 min at 35 °C. This procedure was used three 
times to remove background ESR signals. Finally, the concentration of DMPO 
was determined spectrophotometrically at 234 nm. Incubation mixtures (total 
volume 200 µl) consisted of FeSO4 (0.5 mM), H2O2 (0.55 mM) and DMPO (100 
mM) in the absence or presence of methylxanthines (100 µM). Quercetin was 
used as a positive control. ESR spectra were recorded using 100 µl capillary 
glass tubes. Quantitation of the spectra (in arbitrary units) was performed by 
peak integration using the WIN-EPR spectrum manipulation program. 
TEAC assay 
The TEAC assay (Trolox Equivalent Antioxidant Capacity assay) was used to test 
the total radical scavenging capacity of the compounds. This assay is based on 
the ability of a compound to scavenge the stable ABTS radical (ABTS•+). The 
blue-green ABTS•+ was produced through the reaction between 0.36 mM 
ABTS and 1.84 mM ABAP in 145 mM sodium phosphate buffer, pH 7.4, at 
70°C until the absorption of the solution reached 0.70 ± 0.02 at 734 nm. In the 
assay, 50 µl of the tested compounds was added to 950 µl of the ABTS•+ 
solution. The reduction in absorbance at 734 nm was measured in time for 5 
min and was compared to a blank where 50 µl of the solvent was added to 950 
µl of ABTS•+ solution. A calibration curve was constructed using different 
concentrations of the synthetic antioxidant trolox (0-20 µM). Uric acid was 
used as a positive control. The TEAC value of the methylxanthines was defined 
as the concentration (mM) of trolox having an antioxidant capacity equivalent 
to 1 mM methylxanthine. 
RESULTS 
Enzyme assay 
To asses the effect of the methylxanthines on PARP-1 activity, purified rPARP-1 
was incubated with various methylxanthines. In Table 1 data are shown of 
PARP-1 inhibition by the various methylxanthines (100 µM).  
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Table 1 Percentage PARP-1 inhibition and IC50 values of the tested compounds. 
Compound % inhibition 
(100 µM) 
IC50 (µM) 
xanthine n.i. n.d. 
hypoxanthine 16.2 ± 6.2 >200 
1-methylxanthine  46.2 ± 0.0 145.0 ± 2.8 
1-methyl uric acid n.i. n.d. 
3-methylxanthine 49.6 ± 4.3 115.2 ± 11.2 
7-methylxanthine 24.5 ± 4.2 172.3 ± 3.4 
8-methylxanthine  18.5 ± 4.1 >200 
theophylline  43.2 ± 2.0 194.8 ± 23.3 
1,7-dimethylxanthine 68.5 ± 1.2 15.0 ± 0.97 
1,7-dimethyl uric acid  n.i. n.d. 
theobromine  40.5 ± 1.3 160.2 ± 0.5 
biophylline  10.8 ± 5.5 >200 
caffeine 8.0 ± 4.7 >200 
inosine n.i. n.d. 
n.i.= no inhibition 
n.d.=not determined 
 
PARP-1 activity was measured after incubating 400 ng/ml human rPARP-1 for 
one hour in the presence of 50 µM β-NAD+, 1 mM DTT and 1.25 µg/ml nicked 
DNA at 4°C. Values are presented as averages ± SE of 2 replicate experiments 
with n=3 measurements. These results reveal 1,7-dimethylxanthine to be a very 
potent inhibitor of PARP-1 (68.5 ± 1.2%). The 1-, 3-, 7-, 1,3- and 3,7-
methylated xanthines (1-methylxanthine, 3-methylxanthine, 7-methylxanthine, 
theophylline and theobromine, respectively) moderately inhibited PARP-1. 
Xanthine, 1-methyl uric acid, 1,7-dimethyl uric acid and inosine showed no 
inhibition at all. The parent compound 1,3,7-trimethylxanthine (caffeine) 
showed only a very weak inhibition. For methylxanthines that inhibited PARP-1 
activity more than 50% at the tested concentrations, an IC50 was determined 
(Table 1). The strongest PARP-1 inhibitor was found to be 1,7-dimethylxanthine 
with an IC50 of 15.0 µM. Other IC50 were 115.2, 145.0, 160.2, 172.3 and 194.8 
µM for 3-methylxanthine, 1-methylxanthine, theobromine, 7-methylxanthine 
and theophylline, respectively. 
NAD+-levels 
Methylxanthines, which showed PARP-1 inhibition in the enzyme-assay 
(IC50<200 µM) , were also screened for their effect on NAD
+-levels in H2O2 
treated A549 cells. Also, the parent compound caffeine was further evaluated 
in the A549 cells. The H2O2-induced depletion of the intracellular NAD
+-stores 
was used as a measure of PARP-1 activation. In the A549 cells, pre-incubation 
with 100 µM 3-methylxanthine and 1,7-dimethylxanthine resulted in signifi-
cantly higher NAD+-levels, when compared to cells treated with 300 µM H2O2 
(Figure 3). 
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Figure 3. NAD+ levels in A549 human pulmonary epithelial cells after 30 min incubation with 300 
µM H2O2 with or without 15 min pretreatment with 100 µM of the indicated methylxanthines or 3-
aminobenzamide (3AB). Values are expressed as % of control incubation (without H2O2) and are 
averages ± SE of at least 2 replicate experiments with n=4 measurements. 
* indicates a statistically significant difference according to Student’s t-test (P<0.05) as compared to 
incubation with H2O2 without methylxanthines or 3-aminobenzamide 
 
To further evaluate the PARP-1 inhibiting activity of 1,7-dimethylxanthine, both 
A549 and RF24 cells were exposed for 30 minutes to 300 µM H2O2 after pre-
incubating for 15 minutes with different concentrations 1,7-dimethylxanthine 
(Figure 4). In these cells, 1,7-dimethylxanthine significantly prevented the 
H2O2-induced decrease in NAD
+-levels in a dose-dependent manner. 
 
0
20
40
60
80
100
control H2O2 +3AB +1 µM 
17X
+10 µM 
17X
+100 µM 
17X
%
 N
A
D
+
-l
e
v
e
ls * * * *
* *
*
*
 
Figure 4. NAD+ levels in A549 human pulmonary epithelial (black bars) and RF24 human vascular 
endothelial cells (white bars) after 30 min incubation with 300 µM H2O2 with or without 15 min 
pretreatment with 1, 10 and 100 µM 1,7-dimethylxanthine (17X) or 100 µM 3-aminobenzamide 
(3AB). Values are expressed as % of control incubation (without H2O2) and are averages ± SE of at 
least 2 replicate experiments with n=4 measurements. 
* indicates a statistically significant difference according to Student’s t-test (P<0.05) as compared to 
incubation with H2O2 without 1,7-dimethylxanthine or 3-aminobenzamide 
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PAR-polymer formation 
To further confirm the PARP-1 inhibiting activity of 1,7-dimethylxanthine, A549 
cells were exposed to 300 µM H2O2 for 5 minutes after pre-incubating for 15 
minutes with 1,7-dimethylxanthine (Figure 5). A significantly decreased number 
of PAR-polymer positive cells was observed after incubation with 100 µM 1,7-
dimethylxanthine, confirming the results of the enzyme assay and the NAD+-
measurements. 
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Figure 5. Percentage of PAR-polymer positive A549 cells after 5 min incubation with 300 µM H2O2 
with or without 15 min pretreatment with 1, 10 and 100 µM 1,7-dimethylxanthine (17X) or 2.5 mM 
3-aminobenzamide (3AB). Results are averages ± SE of 2 replicate experiments with n=2 measure-
ments. 
* indicates a statistically significant difference according to Student’s t-test (P<0.05) as compared to 
incubation with H2O2 without 1,7-dimethylxanthine or 3-aminobenzamide 
 
 
ADP:ATP ratio 
To investigate the effect of 1,7-dimethylxanthine on H2O2-induced cell death, 
the ADP:ATP ratio was determined. ADP:ATP ratios for cells undergoing 
apoptosis are expected to be higher than control values but below 1, while 
much higher values characterize necrotic cells [95]. Incubation of both the 
epithelial and the endothelial cells with 10 mM H2O2 increased the ADP:ATP 
ratio to values of 2.1 ± 0.4 and 9.1 ± 0.8 respectively, indicating necrotic cell 
death. Treatment of the cells with lower concentrations H2O2 failed to increase 
the ADP:ATP ratio. Pretreatment of epithelial and endothelial cells with 1 mM 
1,7-dimethylxanthine reduced necrosis, as shown by a statistically significant 
lower ADP:ATP ratio of 0.6 ± 0.4 and 2.0 ± 0.8 respectively (Figure 6). 
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Figure 6. ADP:ATP ratio in A549 (black bars) and RF24 (white bars) cells after 8 hours incubation 
with 10 mM H2O2 with or without 30 min pretreatment with 1 mM 1,7-dimethylxanthine (17X). 
Results are averages ± SE of 3 measurements. 
* indicates a statistically significant difference according to Student’s t-test (P<0.05) as compared to 
incubation with H2O2 without 1,7-dimethylxanthine 
 
Electron spin resonance spectroscopy 
To rule out antioxidant effects of the methylxanthines which were tested in the 
A549 and RF24 cells, scavenging of hydroxyl radicals was measured using ESR 
spectroscopy. First, hydroxyl radicals were generated by H2O2 in the presence 
of FeSO4. In combination with the spin-trap DMPO, stable DMPO-OH adducts 
were formed. Addition of the methylxanthines (100 µM) did not decrease the 
observed DMPO-OH signal (Figure 7). 
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Figure 7. Hydroxyl radicals, generated by FeSO4 and H2O2, are not scavenged by 100 µM 
methylxanthines. Values are expressed as % of control (FeSO4+ H2O2+DMPO) and are presented as 
averages ± SE of duplicate measurements. Q= quercetin (100 µM). Insert: ESR spectrum for the 
hydroxyl radical spin adduct (DMPO-OH). 
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TEAC assay 
The total radical scavenging capacity of the methylxanthines was assessed 
using the TEAC assay. In Table 2 TEAC values of the methylxanthines are 
presented. The TEAC values are very low and negligible, which indicates that 
these methylxanthines do not have significant antioxidant effects. 
 
Table 2. TEAC values for the methylxanthines. 
Compound TEAC 
1-methylxanthine  0.14 ± 0.02 
3-methylxanthine 0.06 ± 0.01 
7-methylxanthine 0.05 ± 0.01 
theophylline  0.06 ± 0.01 
1,7-dimethylxanthine 0.05 ± 0.01 
theobromine  0.05 ± 0.02 
caffeine 0.05 ± 0.01 
uric acid 1.06 ± 0.02 
Values are expressed as mM trolox equivalents for 1 mM methylxanthine and are presented as 
average ± S.E. of two duplicate measurements 
DISCUSSION 
The present study revealed that the major caffeine metabolite 1,7-
dimethylxanthine is a PARP-1 inhibitor and is more potent than the parent 
compound caffeine. The potency of caffeine, caffeine metabolites and other 
methylxanthines to inhibit PARP-1 was investigated using purified human 
rPARP-1 and cultured pulmonary epithelial and vascular endothelial cells. A 
previous study already reported that the methylxanthine theophylline can 
inhibit PARP-1 [89]. Results from our enzyme studies have shown that the 
major caffeine metabolite 1,7-dimethylxanthine is even more potent in inhibit-
ing PARP-1. The parent compound caffeine showed only very weak inhibition 
in spite of its application as a PARP-1 inhibitor [96, 97]. Other methylxanthines 
tested in this study, such as 1-methylxanthine and 3-methylxanthine, also 
inhibited the purified enzyme showing decreased formation of the PAR-
polymer, indicating a decreased consumption of the substrate NAD+. This 
decreased depletion of NAD+ was also observed in cultured epithelial and 
endothelial cells treated with a high concentration of H2O2. In both cell lines, 
the inhibiting activity of 1,7-dimethylxanthine was demonstrated by higher 
NAD+-levels upon treatment with H2O2 in presence of this methylxanthine. 
Also, a significantly reduced number of PAR-polymer positive cells was 
detected after pre-incubation with 1,7-dimethylxanthine. Results from these cell 
studies confirm that PARP-1 is significantly inhibited by the major caffeine 
metabolite 1,7-dimethylxanthine. Also, the caffeine metabolite 3-methyl-
CHAPTER 2 
 38 
xanthine prevented the decline in NAD+-levels in the A549 cells. 
The presence of one or two methyl groups appears important for inhibition of 
the purified PARP-1 enzyme. The dimethylxanthine 1,7-dimethylxanthine 
clearly inhibited PARP-1 (IC50: 15.0 µM). Also 1-methylxanthine, 3-
methylxanthine, 7-methylxanthine, theophylline (1,3-dimethylxanthine) and 
theobromine (3,7-dimethylxanthine) inhibited PARP-1 (IC50: 145.0, 115.2, 
172.3, 184.8 and 160.2 µM respectively), in contrast to xanthine which did not 
show any PARP-1 inhibition. However, this inhibition appeared not dependent 
solely on the number or the position of the methyl groups. 1-Methylxanthine 
and 3-methylxanthine showed stronger inhibition when compared to the 
dimethylxanthines theophylline and theobromine. 1,7-Dimethylxanthine could 
inhibit the enzyme stronger than theophylline (1,3-dimethylxanthine), while   
7-methylxanthine was less potent in inhibiting PARP-1 as compared to            
3-methylxanthine. Furthermore, the trimethylxanthine caffeine showed very 
weak inhibition. The metabolites of 1-methylxanthine and 1,7-dimethyl-
xanthine, 1-methyl uric acid and 1,7-dimethyl uric acid respectively, showed 
no inhibiting activity. Application of a Free-Wilson analysis could not indicate 
a strong association between specific methyl groups and inhibiting activity. In 
conclusion, no obvious structure-activity relationship with regard to the 
position of the methyl groups and PARP-1 inhibiting effects could be observed. 
The presence of a methyl group clearly increases the inhibiting potency of the 
xanthines, but the number of methyl groups also appears to be a limiting factor. 
Since the human body is exposed daily to oxygen radicals which can damage 
cells and tissues, treatment with hydrogen peroxide in this in vitro model is 
considered a physiologically relevant model of PARP-1 activation. Possible 
antioxidant activity of the methylxanthines, however, had to be ruled out, since 
the observed effects on cellular NAD+ could be due to scavenging activity of 
the methylxanthines. Using ESR-spectroscopy and the TEAC assay, scavenging 
of (hydroxyl) radicals by the methylxanthines was determined. None of the 
methylxanthines tested showed any relevant radical scavenging activity at the 
concentrations used in the cell studies, suggesting that even at concentrations 
of 1 or 10 µM the observed effects on the cellular NAD+-levels were most likely 
due to PARP-1 inhibition. 
We showed that incubation of epithelial and endothelial cells with 10 mM 
H2O2 for 8 hours induced necrotic cell death as indicated by a dramatically 
increased ADP:ATP ratio of approximately 2.1 ± 0.4 and 9.1 ± 0.8 respectively. 
Treatment of cells with 1,7-dimethylxanthine significantly reduced the 
ADP:ATP ratio. The H2O2 concentration used was rather high, but lower 
concentrations failed to significantly increase the ADP:ATP ratio in these cells 
(data not shown). After incubation with 1 mM 1,7-dimethylxanthine, necrotic 
cell death was reduced and, in the epithelial cells, also a shift to apoptosis 
could be observed, indicated by decreased ADP:ATP ratio values between 
CAFFEINE METABOLITES: IN VITRO PARP-1 INHIBITION 
 39 
control values and 1. Several studies showed that PARP-1 activation is required 
for a necrotic type of cell death and that PARP-1 inhibition or PARP-1 gene 
deletion can prevent or reduce induction of necrosis [37, 86, 98]. These studies 
indicate that inhibition of PARP-1 could have therapeutic value in patho-
physiology of diseases like ischemia-reperfusion injury or stroke. Complete 
inhibition of PARP-1 is not considered favourable, since PARP-1 has been 
demonstrated to be involved in repair of DNA damage [99, 100]. It is therefore 
thought advisable to have residual PARP-1 activity to allow for efficient repair 
of damaged DNA. Moderate inhibition of PARP-1 activation appears to be the 
best practice. 
In diabetes, PARP-1 has been reported to be involved in the development of 
diabetic vascular dysfunction. Animal studies showed that, in PARP-1 knock-
out mice or in wildtype mice treated with PARP-1 inhibitors, the endothelial 
dysfunction was reversed [27, 83]. Also, the importance of PARP-1 in the 
process of beta-cell death has already been extensively studied [101]. Recently, 
a number of epidemiological studies showed a strong relation between intake 
of specific food components and risk for type 2 diabetes [102, 103]. In the 
study of Salazar-Martinez et al. [103], long term coffee consumption was 
associated with a lower risk for type 2 diabetes. In their study, also a high 
intake of caffeine was related to a decreased risk for type 2 diabetes [103]. 
They suggested that a possible mechanism for the observed inverse association 
could be the presence of antioxidants in coffee and their effect on glucose 
metabolism and insulin resistance. Since caffeine is extensively metabolized in 
the human body after oral intake, the formation of caffeine metabolites and the 
possible effect of these metabolites on the risk of diabetes should also be taken 
into account. Results of our study demonstrate that 1,7-dimethylxanthine, the 
major metabolite of caffeine, and not caffeine itself has clear PARP-1 inhibiting 
activity. By inhibiting PARP-1, this caffeine metabolite could reduce endothe-
lial tissue damage and inflammatory processes, which are known features of 
diabetes [104, 105]. Even at concentrations as low as 10 and 1 µM, 1,7-
dimethylxanthine significantly prevented the H2O2-induced decrease in NAD
+-
levels in both pulmonary epithelial and in vascular endothelial cells. These 
concentrations are considered to be physiological plasma levels. Tang-Liu et al. 
[66] reported that oral intake of caffeine in a dose representing moderate coffee 
intake (4 cups/day), resulted in maximal plasma levels of approximately 20 µM 
1,7-dimethylxanthine lasting for several hours after intake. 
In conclusion, caffeine metabolites and in particular 1,7-dimethylxanthine have 
PARP-1 inhibiting activity at physiological concentrations. Inhibition of PARP-1 
could have important implications for the development of vascular dysfunction 
and inflammation, processes which are observed in the progression of diabetes. 
Furthermore, PARP-1 inhibition is also shown to be relevant in other patho-
logies like ischemia-reperfusion, stroke and pulmonary inflammatory diseases 
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such as COPD and asthma [26, 30, 37, 84]. It is therefore suggested that dietary 
PARP-1 inhibitors like the caffeine metabolite 1,7-dimethylxanthine may 
contribute to treatment or prevention of vascular complications in diabetes but 
also other pathologies like mild ischemia-reperfusion damage and stroke. 
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ABSTRACT 
The nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP-1) which was 
initially known to be highly activated by oxidative stress-induced DNA strand 
breaks, has been shown to be involved in the pathophysiology of acute and 
chronic inflammatory diseases. PARP-1 deficiency in mice led to the discovery 
of its co-activating function in the nuclear factor-kappa B (NF-κB) mediated 
gene-expression, and in addition, pharmaceutical inhibition of PARP-1 was 
shown to reduce the production of inflammatory mediators. In this study, the in 
vitro PARP-1 inhibiting effect of various flavonoids was investigated. The 
flavonoids myricetin, tricetin, gossypetin, delphinidin, quercetin and fisetin 
were identified as significant inhibitors of the purified enzyme. Further evalua-
tion of these compounds in MNNG-treated human pulmonary epithelial cells 
showed that the formation of the PAR-polymers, as well as the decrease in 
NAD+-levels was reduced by quercetin, fisetin and tricetin. Finally, interleukin 
(IL)-8 production of lipopolysaccharide (LPS)-stimulated human pulmonary 
epithelial cells could be significantly reduced by these flavonoids. The results 
of this study indicate that specific flavonoids have PARP-1 inhibiting activity in 
addition to the earlier described antioxidant effects. PARP-1 inhibition and 
preservation of cellular NAD+ and energy production could play a role in the 
anti-inflammatory activity of these specific flavonoids. In addition, these results 
indicate additional mechanisms by which flavonoids can exert anti-
inflammatory activity. Furthermore, these results indicate possibilities to use 
food-derived flavonoids in the treatment of chronic inflammatory diseases. 
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INTRODUCTION 
The nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP-1; E.C. 2.4.2.30), 
which catalyzes the formation of poly(ADP-ribose) polymers (PAR-polymers) 
from its substrate NAD+, has been described to be involved in the patho-
physiology of both acute as well as chronic inflammatory diseases [26, 29, 30, 
83, 84]. PARP-1 is known to be highly activated by oxidative stress-induced 
DNA strand breaks. Overactivation as a result of extensive DNA damage 
causes massive PAR-polymer formation and consequently a rapid depletion of 
cellular NAD+ and ATP levels. If the resulting cellular energy crisis cannot be 
resolved, PARP-1 overactivation may lead to cell death. 
Initially, the formation of the PAR-polymers was known to facilitate repair of 
damaged DNA [5, 6, 100]. Results of various studies indicate that the process 
of poly(ADP-ribosyl)ation may also facilitate transcriptional activity [106]. The 
formation of the negatively charged PAR-polymers and the transfer of these 
polymers to acceptor proteins like histones initiate electrostatic repulsion 
between histones and DNA. The subsequent remodeling of the chromatin 
architecture enhances the accessibility of genes for the transcriptional machin-
ery and thus enhances transcription [106]. More recently, PARP-1 has also 
been shown to be involved in the regulation of the nuclear factor-kappa B (NF-
κB) and activator protein-1 (AP-1) mediated transcription of inflammatory 
cytokines and chemokines [11, 15, 82]. Pharmaceutical inhibition of PARP-1 
was demonstrated to have beneficial effects in various animal models for 
inflammatory diseases such as endotoxic shock or pulmonary inflammation 
[29, 34]. The aim of this study was to evaluate dietary flavonoids for their 
PARP-1 inhibiting activity. Flavonoids are polyphenolic compounds found in 
fruits and vegetables and plant-derived products like red wine and tea, and can 
be divided into different subclasses like anthocyanidins, flavonols and flavones. 
The intake of dietary flavonoids has been related to a reduced risk for several 
diseases like cardiovascular and chronic inflammatory diseases [51, 57]. These 
positive health effects associated with the intake of flavonoids have been 
ascribed to their well-known antioxidant properties and to inhibiting effects on 
a wide range of enzymes [58, 59]. Also, anti-inflammatory effects of flavonoids 
could contribute to these beneficial effects [59]. 
In this study, in first instance the PARP-1 inhibiting activity of a wide range of 
flavonoids was investigated using the purified enzyme. Secondly, the most 
promising compounds were further evaluated in cultured pulmonary epithelial 
cells that were treated with N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) to 
induce PARP-1 activation and NAD+-depletion. Finally, the effect of the PARP-
1 inhibiting flavonoids on NF-κB mediated production of interleukin (IL)-8 was 
investigated in lipopolysaccharide (LPS)-stimulated pulmonary epithelial cells. 
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MATERIAL AND METHODS 
Materials 
Naringin, fisetin, rutin, morin, quercetin, taxifolin, (+)-catechin, myricetin, 
phenol, hydroquinone, resorcinol, Tween 20, acetic acid, 3,3’,5,5’-
tetramethylbenzidine, hydrogen peroxide (H2O2), 3-aminobenzamide, MNNG, 
bovine serum albumine (BSA), Dulbecco’s Modified Eagle’s Medium (DMEM) 
and LPS (O26:B6) were all obtained from Sigma (St. Louis, MO, USA). Baical-
ein, 4,2’,4’-trihydroxychalcone, fustin, tricetin, gossypetin, 3’,5,7-trihydroxy-
3,4’-dimethoxyflavone, 3,5,7,3’,4’-pentamethoxyflavone were obtained from 
ICC (Hillsborough, NJ, USA). Delphinidin and cyanidin were obtained from 
Extrasynthese (Genay, France). Genistein was obtained from Alexis (Lausen, 
Switzerland). Naringenin, kaempferol, β-NAD+ and 1,4-dithiothreitol (DTT) 
were obtained from MP Biomedicals (Irvine CA, USA). Catechol was obtained 
from Janssen Chimica (Geel, Belgium). Human rPARP-1 and biotinylated NAD+ 
were purchased from Trevigen (Gaithersburg, MD, USA). HBSS, fetal bovine 
serum, trypsine and Penicillin/Streptomycin were all obtained from Invitrogen 
Life Technologies (Grand Island, NY, USA). N-(6-oxo-5,6-dihydro-
phenanthridin-2-yl)-N,N-dimethyl-acetamide (PJ34) was obtained from Merck 
(Darmstadt, Germany). Peroxidase-labeled streptavidin was purchased from 
Zymed (San Francisco, CA, USA). Polyvinylchloride microtiter plates were 
obtained from BD Biosciences (San Jose, CA, USA). The 10H hybridoma was 
kindly provided by Dr. M. Miwa, via Riken Cell Bank, Tsukuba Institute 
BioResource Center (Ibaraki, Japan). The cell supernatant containing mouse 
monoclonal anti-PAR polymer antibody 10H was produced by Dr. W. Buur-
man (University of Maastricht, Maastricht, the Netherlands). FITC-conjugated 
goat anti-mouse immunoglobulin and fluorescent mounting medium were 
obtained from DAKO (Glostrup, Denmark). 
PARP-1 inhibition ELISA 
The capacity of the compounds to inhibit PARP-1 was first determined using an 
enzyme inhibition assay, as described by others [90, 91] with minor modifica-
tions as previously described [107]. In short, human rPARP was incubated in a 
96-well microtiterplate with a reaction mixture containing 50 µM β-NAD+ 
(10% biotinylated β-NAD+, 90% unlabelled β-NAD+), 1 mM DTT and 1.25 
mg/L nicked DNA. The formation of the PAR-polymers was detected with 
peroxidase-labeled streptavidin and 3,3’,5,5’-tetramethylbenzidine (TMB). 
PARP-1 activity was expressed as absorbance at 450 nm. PARP-1 inhibition of 
flavonoids was evaluated by addition of these compounds to the reaction 
mixture. The type of PARP-1 inhibition, specific or non-specific, by flavonoids 
was analyzed in incubations of PARP-1 and putative inhibitors with various 
concentrations of β-NAD+ after which Lineweaver Burk plots were constructed. 
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Cell culture 
A549 lung epithelial cells were grown at 37°C in a humidified 5% CO2 atmos-
phere and were cultured in Dulbecco’s Modified Eagles Medium (DMEM) with 
4.5 g/L glucose, 10% fetal bovine serum (FBS), 2 mM glutamine and 50000 
units/L of penicillin and 50 mg/L of streptomycin. 
Cellular NAD+ assay 
PARP-1 activation in cultured cells was measured as previously described 
[107]. MNNG was used to induce DNA strand breaks, activate PARP-1 and 
deplete intracellular NAD+ levels. Cells were incubated in a 96-well microtiter-
plate with 25 µM MNNG during 30 min in the presence or absence of flavon-
oids, added 15 minutes before the MNNG-treatment. The flavonoids used were 
not cytotoxic as demonstrated using the LDH leakage test with incubation 
periods up to 24h (data not shown) [108]. To minimize a possible indirect 
protective effect of the flavonoids via scavenging of hydroxyl radicals and 
reduced formation of DNA strand breaks, the alkylating agent MNNG instead 
of H2O2 was used in this assay to induce PARP-1 activity. The PARP-1 inhibitor 
3-aminobenzamide strongly prevented the decrease in NAD+-levels and served 
in all experiments as a positive control. Intracellular NAD+ was determined 
using the NAD+-cycling method based on the method from Jacobsen and 
Jacobsen (1997) [94]. 
Immunohistochemical staining of PAR-polymers 
To confirm the PARP-1 inhibiting effects of flavonoids, the formation of PAR–
polymers was measured. A549 cells (approximately 0.8x106 cells/well in a 6-
well plate) were treated with MNNG for 5 min in the presence or absence of 
flavonoids, which were added 15 min before the MNNG-treatment. The 
synthetic PARP-1 inhibitors 3-aminobenzamide and PJ34 were used as positive 
controls. After the incubation, the cells were trypsinized, washed with PBS and 
fixed in methanol. After fixation, cells were stained for PAR-polymers as 
previously described [107]. At least 100 cells per slide were evaluated for the 
presence of PAR-polymers in their nucleus using fluorescence microscopy and 
Lucia GF 4.80 software (Nikon, Düsseldorf, Germany). Subsequently, the 
percentage of PAR-polymer positive cells was calculated. 
LPS-treatment and IL-8 measurement 
A549 cells were treated with 100 µg/L LPS for 16h in absence or presence of 
flavonoids, which were added 30 min before the LPS-treatment. After incuba-
tion, medium was collected and centrifuged (10 min, 2000 x g, 4°C) and 
supernatant was stored at -80°C until measurement of IL-8 with ELISA kits 
(CLB/Sanquin, The Netherlands). Cells were trypsinized and processed for 
immunohistochemical staining of the PAR-polymer as described above. 
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Statistics 
Experiments were performed in triplicate and results are reported as means ± 
SEM. The effect of the various flavonoids on MNNG-induced NAD+-depletion 
and PAR-polymer formation and LPS-induced IL-8 release compared to the 
condition without flavonoids was statistically analysed using ANOVA followed 
by Dunnett’s post hoc testing. Differences were considered to be statistically 
significant if P < 0.05. 
RESULTS 
PARP-1 enzyme inhibition 
To determine the extent of PARP-1 inhibition by several flavonoids, human 
rPARP-1 was incubated with the flavonoids (100 µM) for one hour (Table 1). 
PARP-1 was potently inhibited by the flavonoids myricetin (93%) and tricetin 
(80%). Also flavonoids gossypetin (73%), delphinidin (62%), quercetin (62%) 
and fisetin (60%) were found to be strong PARP-1 inhibitors. Baicalein, nar-
ingin or (+)-catechin showed less than 10% inhibition. The phenolic com-
pounds phenol, catechol, resorcinol and hydroquinone were also evaluated for 
their PARP-1 inhibiting activity and showed respectively 8, 12, 9 and 5 % 
inhibition. The methylated metabolites of quercetin, 3’,5,7-trihydroxy-3,4’-
dimethoxyflavone and 3,5,7,3’,4’-pentamethoxyflavone, showed weak or no 
PARP-1 inhibition, whereas 4,2’,4’-trihydroxychalcone and rutin showed no 
inhibition at all. For the flavonoids myricetin, tricetin, quercetin and fisetin, 
which showed the most potent PARP-1 inhibiting activity, Lineweaver Burk 
plots were constructed using various concentrations NAD+. Inhibition of PARP-
1 by myricetin, quercetin and fisetin was revealed to be of a mixed type, with 
competitive as well as non-competitive characteristics. Inhibition of PARP-1 by 
tricetin was shown to be mostly competitive (data not shown). 
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Table 1 Characteristics and PARP-1 inhibition of flavonoids tested in this study 
Flavonoid Class Hydroxylation 
pattern 
Methoxylation 
pattern 
C2-C3 
double 
bond 
% PARP-1 
inhibition 
(100 µM) 
4,2’,4’-trihydroxychalcone chalcone 4,2’,4’  + n.i. 
baicalein flavone 5,6,7  + 5 ± 4 
naringenin flavanone 5,7,4’  - 21 ± 3 
naringin1 flavanone 5,4’  - 2 ± 0 
genistein Isoflavone 5,7,4’  + 14 ± 4 
kaempferol flavonol 3,5,7,4’  + 27 ± 4 
fisetin flavonol 3,7,3’,4’  + 60 ± 1 
fustin flavanone 3,7,3’,4’  - 11 ± 2 
morin flavonol 3,5,7,2’,4’  + 42 ± 7 
quercetin flavonol 3,5,7,3’,4’  + 62 ± 3 
rutin2 flavonol 5,7,3’,4’  + n.i. 
taxifolin flavanone 3,5,7,3’,4’  - 20 ± 2 
(+)-catechin flavanol 3,5,7,3’,4’  - 4 ± 4 
cyanidin anthocyanidin 3,5,7,3’,4’  - 20 ± 3 
tricetin flavone 5,7,3’,4’,5’  + 80 ± 0 
myricetin flavonol 3,5,7,3’,4’,5’  + 93 ± 3 
delphinidin anthocyanidin 3,5,7,3’,4’,5’  - 62 ± 4 
gossypetin flavone 3,5,7,8,3’,4’  + 73 ± 4 
3’,5,7,-trihydroxy-3,4’-
dimethoxyflavone 
 3’,5,7 3,4’ + 13 ± 2 
3,5,7,3’,4’-
pentamethoxyflavone 
  3,5,7,3’,4’ + n.i. 
1 naringin is a naringenin glycoside with a rhamnoglucoside group at position 7 
2 rutin is a quercetin glycoside with a rhamnoglucoside group at position 7 
n.i. = no inhibition 
PARP-1 activity was measured after incubating 400 µg/L PARP-1 for 1 h in the presence of 1.25 
mg/L nicked DNA, 50 µM NAD+ and 100 µM flavonoid at 4°C 
 
Effects on MNNG-induced NAD+-depletion 
Specific flavonoids, which showed most significant inhibition in the enzyme 
assay, were further evaluated for their PARP-1 inhibiting activity in MNNG-
treated human lung epithelial cells. Treatment of these cells with 25 µM 
MNNG activated PARP-1 and induced depletion of cellular NAD+-levels to 
approximately 23% of control levels after 30 min. MNNG-induced depletion of 
intracellular NAD+-stores was used as a parameter of PARP-1 activation. 
Depletion of the NAD+-levels was found to be significantly attenuated in 
presence of the flavonoids quercetin, fisetin and tricetin at a concentration of 
100 µM (Figure 1). Delphinidin, gossypetin, myricetin and morin, which also 
showed significant inhibition of the purified enzyme, failed to prevent the 
MNNG-induced decrease in NAD+-levels (data not shown). 
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Figure 1. NAD+ levels in MNNG-treated A549 lung epithelial cells exposed to 25 µM MNNG for 
30 min in the presence of 1, 10 and 100 µM of the flavonoids quercetin (Q), fisetin (F) and tricetin 
(T) or 100 µM 3-aminobenzamide (3AB). Values are expressed as a percentage of the control 
incubation (without MNNG and flavonoids or 3AB), and are the mean ± SEM of 3 replicate 
experiments. 
* P< 0.05 vs incubation with MNNG alone 
 
PAR-polymer formation 
To confirm the PARP-1 inhibiting effect of the flavonoids quercetin, fisetin and 
tricetin, A549 cells were treated with MNNG in the presence of these flavo-
noids. Subsequently, the formation of PAR-polymers was detected using 
immunocytochemical staining. Due to the very rapid catabolism of PAR-
polymers by poly(ADP-ribose) glycohydrolase (PARG) [106], incubation time of 
MNNG was reduced to 5 minutes. In control cells, no PAR-polymer formation 
was observed. Treatment of the cells with MNNG induced a massive increase 
in the number of PAR-polymer positive cells (24%). Preincubation of the cells 
with quercetin, fisetin and tricetin for 15 min dose-dependently inhibited PAR-
polymer formation after MNNG treatment (Figure 2A), indicating that the 
attenuated depletion in NAD+ levels was primarily due to direct PARP-1 
inhibition. The synthetic PARP-1 inhibitors PJ34 and 3-aminobenzamide were 
included as positive controls and PJ34 was found to almost completely reverse 
PAR-polymer formation (Figure 2B). 
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Figure 2. PAR-polymer formation in MNNG-treated A549 lung epithelial cells exposed to 25 µM 
MNNG for 5 min in the presence of A) the flavonoids quercetin (Q), fisetin (F) and tricetin (T) and 
B) the synthetic PARP-1 inhibitors PJ34 and 3-aminobenzamide (3AB). Values are the mean ± SEM 
of 3 replicate experiments. 
* P< 0.05 vs incubation with MNNG alone 
 
Effects on LPS-induced IL-8 production 
The flavonoids quercetin, fisetin and tricetin, which attenuated both the 
decrease in NAD+ levels as well as the formation of PAR-polymers, were further 
studied for their effect on LPS-induced IL-8 production in A549 cells. 
Quercetin, fisetin as well as tricetin significantly reduced IL-8 production 
(Figure 3A). The synthetic PARP-1 inhibitor PJ34 showed a similar anti-
inflammatory activity (Figure 3B). Immunohistochemical staining of PAR-
polymers was applied to determine PARP-1 activation during LPS treatment of 
A549 cells. No detectable PAR-polymer formation could be measured in the 
A549 cells after treatment with 100 µg/L LPS from 5 min up to 24h after 
stimulation (data not shown). 
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Figure 3. IL-8 production in LPS-stimulated A549 lung epithelial cells treated with 100 µg/L LPS for 
16h in the presence of A) the flavonoids quercetin (Q), fisetin (F) and tricetin (T) and B) the 
synthetic PARP-1 inhibitors PJ34 and 3-aminobenzamide (3AB). Values are expressed as the 
percentage of IL-8 production in LPS-stimulated A549 cells alone (control). Values are the mean ± 
SEM of 3 replicate experiments. 
* P< 0.05 vs incubation with LPS alone 
 
DISCUSSION 
In this study, the flavonoids quercetin, fisetin and tricetin were found to 
significantly inhibit the nuclear enzyme PARP-1. This inhibition was not only 
observed with the purified PARP-1 enzyme, but also in MNNG-treated human 
pulmonary epithelial cells. Furthermore, a dose-dependent decrease in IL-8 
production was observed after LPS-treatment of the A549 cells in presence of 
quercetin, fisetin and tricetin. These data indicated that their PARP-1 inhibiting 
activity may contribute to anti-inflammatory effects via inhibition of NF-κB 
mediated gene-expression. 
The inducible transcription factor NF-κB plays an important role in the inflam-
matory and immune response and regulates the production of pro-inflammatory 
cytokines and chemokines like IL-8 [109]. PARP-1 has been reported to be a 
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co-activator of NF-κB [11, 15]. However, whether PARP-1 enzyme activity or 
the protein itself is required for complete activation of NF-κB is still a matter of 
debate [16, 19]. Nevertheless, pharmaceutical PARP-1 inhibitors were success-
fully applied in various in vitro and in vivo models of inflammation and were 
found to reduce the production of NO and pro-inflammatory cytokines like 
TNF-α, IL-6 and IL-8 [26, 29, 33, 34]. 
The precise mechanisms through which flavonoids inhibit the production of 
pro-inflammatory cytokines remain to be elucidated. Their antioxidant proper-
ties are in general believed to be primarily responsible for the anti-
inflammatory effects. Reactive oxygen species (ROS) have been described to be 
involved in the pathology of inflammatory diseases [110, 111]. In addition, 
ROS have been described to induce activation of redox-sensitive transcription 
factors like AP-1 and NF-κB [112], subsequently leading to increased produc-
tion of several inflammatory mediators and chemokines, including IL-8. In 
various studies, the inhibiting effects of flavonoids on the production of pro-
inflammatory markers were observed. Reduced production of pro-inflammatory 
cytokines, iNOS expression and NO production have been observed after 
treatment with the flavonoids quercetin, apigenin and luteolin in LPS or PMA 
stimulated cultured cells [113-115]. These effects have been found to be 
associated with inhibition of the NF-κB pathway via reduced phosphorylation 
of IκBα and reduction of the nuclear translocation and DNA-binding of NF-κB 
[113-115]. In addition, these flavonoids attenuated the production of pro-
inflammatory mediators via regulation of the transcription factor AP-1 [114]. In 
the present study, specific flavonoids were shown to have significant PARP-1 
inhibiting activity. In an attempt to assess PARP-1 activation during LPS treat-
ment of A549 cells, we applied immunocytochemical staining of the cells at 
various time points, ranging from 5 min to 24h after treatment. However, no 
PAR-polymer formation could be detected in these cells, in contrast to cells 
treated with MNNG. This may be due to the application of a mild stimulus, i.e. 
100 ng/ml LPS, which most likely failed to induce high levels of ROS and 
measurable PAR-polymer formation. In addition, PAR-polymers are very rapidly 
catabolized by poly(ADP-ribose) glycohydrolase (PARG) [106], which may also 
result in non-detectable PAR-polymer formation. After stimulation of A549 cells 
with IL-1β and TNF-α, Erdelyi et al. (2005) also failed to detect PAR-polymer 
formation, in contrast to the massive PAR-polymer formation observed in H2O2-
treated cells [116]. It remains therefore inconclusive whether inhibition of PAR-
polymer formation is the mechanism by which flavonoids reduce IL-8 produc-
tion in LPS-treated A549 cells. 
In the present study, inhibition of PARP-1 by flavonoids was revealed to be not 
solely a competitive type of inhibition. Although inhibition of PARP-1 by 
tricetin was competitive, myricetin, quercetin and fisetin showed a mixed type 
of inhibition. These results indicate that PARP-1 activity was not solely reduced 
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by an interaction of these flavonoids with the catalytic site of PARP-1, but also 
by non-specific interactions of the flavonoids with PARP-1. Since it was also 
suggested by others that the presence of the enzyme and not the enzymatic 
activity of PARP-1 is required for complete NF-κB activation [16], non-specific 
binding of flavonoids to PARP-1 could probably prevent interaction of PARP-1 
with NF-κB and subsequently also reduce the NF-κB mediated gene-expression. 
When tested with the purified enzyme, the flavonoids myricetin, tricetin, 
gossypetin, delphinidin, quercetin and fisetin clearly inhibited PARP-1 at 100 
µmol/L (approximately ≥60%), whereas other flavonoids like kaempferol and 
naringenin showed considerably lower PARP-1 inhibiting activity. Given that in 
foods, most flavonoids occur predominantly as β-glycosides and upon in-
gestion become extensively metabolized into glucuronidated-, sulfated- or 
methylated conjugates [56, 117], a number of commercially available conju-
gated flavonoids were screened for their PARP-1 inhibiting activity. The 
addition of methyl groups to flavonoids like quercetin drastically reduced the 
inhibiting activity. 3’,5,7-Trihydroxy-3,4’-dimethoxyflavone showed only weak 
inhibition as compared to quercetin, and the inhibiting activity of 3,5,7,3’,4’-
pentamethoxyflavone was even more reduced. Glycosylation as in rutin and 
naringin considerably decreased inhibition as compared to the aglycones 
quercetin and naringenin. Evaluating the PARP-1 inhibiting activity of phenolic 
compounds like phenol, catechol, resorcinol and hydroquinone indicated that 
position of the hydroxyl groups (ortho, meta or para) did not clearly contribute 
to the PARP-1 inhibiting activity of these compounds. However, the presence 
of the C2-C3 double bond seemed to influence the PARP-1 inhibiting activity of 
some flavonoids, since both quercetin and fisetin showed substantially higher 
PARP-1 inhibiting activity as compared to the flavonoids taxifolin and fustin. 
Although myricetin showed the strongest PARP-1 inhibiting activity in the 
enzyme assay, it failed to significantly inhibit PARP-1 in the A549 cells. The 
Lineweaver Burk plot of myricetin indicated that the inhibition of the purified 
PARP-1 enzyme by myricetin showed both competitive as well as non-
competitive characteristics, indicating that myricetin also showed non-specific 
protein binding which might reduce the intranuclear concentration. Further-
more, several non-specific interactions between flavonoids and proteins have 
been reported [118, 119]. Since PARP-1 is located in the nucleus and PARP-1 
inhibitors first need to pass the cell membrane and enter the nucleus to inhibit 
the enzyme, non-specific interactions could decrease the final intracellular and 
-nuclear concentration of myricetin or other flavonoids. Alternatively, the 
flavonoids quercetin and fisetin, which also showed mixed type of inhibition 
similar to myricetin, did prevent the MNNG-induced PAR-polymer formation 
and decrease in NAD+-levels. This suggests that these flavonoids pass the cell 
membrane and enter the nucleus in sufficient amounts to exert PARP-1 inhibit-
ing effects. 
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Since PARP-1 is also involved in facilitating DNA-repair, complete inhibition of 
PARP-1 appears not desirable. For that reason, mild inhibition would be the 
preferred method of action. The flavonoids quercetin, fisetin and tricetin were 
found to inhibit PARP-1, both in the enzyme assay as well as in A549 cells. By 
mildly inhibiting the enzyme activity of PARP-1, these flavonoids would protect 
against NAD+- and ATP-depletion, reducing the risk of cell death-induced 
inflammation. Moreover, the reduction of LPS-induced IL-8 release at similar 
levels indicated an anti-inflammatory effect via NF-κB. Furthermore, low level 
of PARP-1 activity would allow for repair of DNA damage. In addition, it was 
previously observed that administration of the potent synthetic PARP-1 inhibitor 
INO-1001 in a porcine model of thoracic aortic cross-clamping-induced I/R 
injury did not impair DNA repair [120]. DNA damage in peripheral blood 
mononuclear cells was evaluated by the COMET assay, both in vivo as well as 
ex vivo, and no differences between the INO-1001 treated group and vehicle-
treated group were found. Also, expression of the cyclin-dependent kinase 
inhibitor (CDKI) gene p27 in the kidney was evaluated. Expression of p27 was 
increased equally in both the vehicle-treated and INO-1001 treated group and 
it was suggested that both DNA damage and repair was found not to be 
impaired by treatment with the PARP-1 inhibitor INO-1001 [120]. 
Apples, grapes, onions and Ginkgo Biloba are dietary sources of PARP-1 
inhibiting flavonoids quercetin, fisetin and tricetin [121]. In industrialized 
societies like Western Europe and USA, the estimated intake of flavonols and 
flavones is reported to range from 20 to 34 mg/day [52, 122, 123]. The re-
peated intake of food supplements containing high doses of flavonoids (e.g. 1 g 
quercetin/day) has been shown to increase plasma concentrations, reaching 
levels in the low micromolar range [55, 124, 125]. This implies that the 
observed in vitro effects were achieved at concentrations that may be reached 
in vivo after the use of supplements. 
Specifically in the treatment of chronic inflammatory diseases such as chronic 
obstructive pulmonary disease (COPD), long-term use of dietary supplements is 
considered to be promising, since no effective treatment has been developed 
yet. In COPD patients, we previously reported increased oxidative stress and 
increased inflammatory cytokines including IL-8, which were accompanied by 
an increased percentage of PAR-polymer positive peripheral blood mono-
nuclear cells, indicating a chronic and systemic PARP-1 activation [30]. As a 
consequence of chronic PARP-1 activation, NAD+ turnover will be increased 
implying an increased demand on ATP production for resynthesis of NAD+. 
This increased turnover of NAD+ and demand for energy may contribute to 
exercise intolerance and muscle weakness, which greatly impair the quality of 
life of COPD patients. Reduction of oxidative stress and inhibition of PARP-1 
by food-derived compounds might reduce this chronic state of energy con-
sumptive cycles and ameliorate systemic inflammatory conditions. Dietary 
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flavonoids like quercetin, fisetin and tricetin would be potential candidates, not 
only based on their antioxidant effects but also based on their PARP-1 inhibit-
ing as well as anti-inflammatory effects as described in this current study. 
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ABSTRACT 
The nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP-1) which was 
initially known for its role in the repair of oxidative stress-induced DNA 
damage, has also been reported to play a mediating role in the inflammatory 
response. Studies with PARP-1 knockout models have shown that PARP-1 is a 
co-activator of nuclear factor-kappa B (NF-κB), although this appears not to 
require its enzyme activity. In addition, drug-induced inhibition of the enzyme 
activity of PARP-1 was observed to reduce the production of pro-inflammatory 
mediators. In this study, the flavonoid compound flavone was demonstrated to 
significantly inhibit the enzyme activity of PARP-1. Further evaluation of 
flavone in N-methyl-N’-nitro-N-nitrosoguanidine (MNNG)-treated human 
pulmonary epithelial and vascular endothelial cells revealed that both the 
decrease in NAD+ levels, as well as the formation of PAR-polymers was dose-
dependently attenuated by flavone. In addition, flavone was found to reduce 
the lipopolysaccharide (LPS)-induced interleukin (IL)-8 production in pul-
monary epithelial cells, which was confirmed by transcription analysis. Further-
more, transcription of IκBα was significantly increased by flavone. The results 
of the present study indicate that the flavonoid flavone could be a potential 
candidate for application in treatment of chronic inflammatory diseases. PARP-
1 inhibition could have beneficial effects in such diseases as chronic obstruc-
tive pulmonary disease (COPD) and diabetes, by preservation of cellular NAD+ 
levels and attenuating inflammatory conditions. 
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INTRODUCTION 
The nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP-1; E.C. 2.4.2.30) 
which catalyzes the formation of poly(ADP-ribose) polymers (PAR-polymers) 
from its substrate NAD+, was initially known for its facilitating role in the repair 
of DNA damage [5]. Currently it is recognized that PARP-1 is also involved in 
the regulation of the nuclear factor-kappa B (NF-κB) and activator protein 1 
(AP-1) mediated production of pro-inflammatory cytokines. Studies with PARP-
1 knockout models showed that PARP-1 is a co-activator of NF-κB [11, 15]. It 
has been observed that the enzyme activity of PARP-1 was not required for full 
activation of NF-κB [16]. However, others reported that the synthesis of PAR-
polymers facilitated the transcriptional activation properties of NF-κB [19]. 
Moreover, inhibition of PARP-1 with synthetic inhibitors has been reported to 
reduce the DNA-binding activity of NF-κB and also the transcription of NF-κB 
mediated genes [20, 21]. 
The flavonoid quercetin has previously been reported to have PARP-1 inhibit-
ing activity [126]. In addition, for flavonoids in general, it was shown that their 
antioxidant effects and the enzyme inhibiting effects are largely dependent on 
their hydroxylation pattern [58, 59]. By screening specific polyphenolic 
compounds for their effect on PARP-1 activity, we identified a distinctive 
flavonoid compound, without hydroxyl groups, as a PARP-1 inhibitor. Further-
more, common structural features of competitive PARP-1 inhibitors include a 
carboxamide-group attached to an aromatic ring or the carbamoyl group built 
in a polyaromatic heterocyclic skeleton, and this is not characteristic of flavone 
or flavonoids in general. In the present study, data are presented which demon-
strate that this dietary flavonoid flavone (Figure 1), a polyphenolic compound 
reported to be present in dill weeds and oats [127], is a very potent PARP-1 
inhibitor. The aim of this study is to elaborate further on the PARP-1 inhibiting 
effect and to elucidate the supposed effect of this intriguing compound on NF-
κB mediated transcription of pro-inflammatory genes. 
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Figure 1. Chemical structure of the flavonoid flavone 
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In a series of in vitro experiments, the PARP-1 inhibiting capacity of flavone 
was first tested using the purified enzyme. Secondly, the effect of flavone on N-
methyl-N’-nitro-N-nitrosoguanidine (MNNG)-induced NAD+-depletion and 
PAR-polymer formation was tested in cultured pulmonary epithelial and 
vascular endothelial cells. Finally, the effect of flavone on expression and 
production of NF-κB mediated genes was tested in lipopolysaccharide (LPS)-
stimulated pulmonary epithelial cells. 
MATERIAL AND METHODS 
Materials 
Flavone was obtained from ICC (Hillsborough, NJ, USA). β-NAD+ and 1,4-
dithiothreitol (DTT) were obtained from MP Biomedicals (Irvine, CA, USA). 
Tween 20, acetic acid, 3,3’,5,5’-tetramethylbenzidine, hydrogen peroxide 
(H2O2), 3-aminobenzamide, bovine serum albumine (BSA), MNNG, heparin, 
Dulbecco’s Modified Eagle’s Medium (DMEM) and LPS (O26:B6) were all 
obtained from Sigma (St. Louis, MO, USA). Human rPARP-1 and biotinylated 
NAD were purchased from Trevigen (Gaithersburg, MD, USA). F-12K Nutrient 
Mixture (Kaighn’s Modification), fetal bovine serum, trypsine, Penicil-
lin/Streptomycin and HBSS were all obtained from Invitrogen Life Technologies 
(Grand Island, NY, USA). N-(6-oxo-5,6-dihydro-phenanthridin-2-yl)-N,N-
dimethylacetamide (PJ34) was obtained from Merck (Darmstadt, Germany). 
Peroxidase-labeled streptavidin was purchased from Zymed (San Francisco, 
CA, USA). Polyvinylchloride microtiter plates and endothelial cell growth 
supplement were obtained from BD Biosciences (San Jose, CA, USA). The 10H 
hybridoma was kindly provided by Dr. M. Miwa, via Riken Cell Bank, Tsukuba 
Institute BioResource Center (Ibaraki, Japan). The cell supernatant containing 
mouse monoclonal anti-PAR polymer antibody 10H was produced by Dr. W. 
Buurman (University of Maastricht, Maastricht, the Netherlands). FITC-
conjugated goat anti-mouse immunoglobulin and fluorescent mounting 
medium were obtained from DAKO (Glostrup, Denmark). 
PARP-1 inhibition ELISA 
The capacity of flavone to inhibit PARP-1 was first determined using an inhibi-
tion assay, as described by others [90, 91] with minor modifications as previ-
ously described [107]. In short, human rPARP was incubated in a 96-well 
microtiterplate with a reaction mixture containing 50 µM β-NAD+ (10% 
biotinylated β-NAD+, 90% unlabelled β-NAD+), 1 mM DTT and 1.25 µg/ml 
nicked DNA. Formation of PAR-polymers was detected using peroxidase-
labeled streptavidin and 3,3’,5,5’-tetramethylbenzidine (TMB). PARP-1 activity 
was expressed as absorbance at 450 nm. PARP-1 inhibition by flavone was 
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evaluated by addition of flavone to the reaction mixture. The type of PARP-1 
inhibition by flavone (competitive or non-competitive) was analyzed by 
incubating PARP-1 with various concentrations of β-NAD+ in the presence of 
flavone after which a Lineweaver Burk plot was constructed. 
Cell culture 
A549 lung epithelial cells were grown at 37°C in a humidified 5% CO2 atmos-
phere and were cultured in DMEM with 4.5 g/L glucose, 10% fetal bovine 
serum (FBS), 2 mM glutamine, 50 units/ml of penicillin and 50 µg/ml of 
streptomycin. RF24 cells were grown at 37°C in a humidified 5% CO2 atmos-
phere in gelatin-coated culture flasks and were cultured in F-12K Nutrient 
Mixture (Kaighn’s Modification) supplemented with 10% fetal bovine serum, 
0.1 mg/ml heparin and 50 units/ml of penicillin and 50 µg/ml of streptomycin. 
During culturing at low densities the medium was supplemented with 0.03 
mg/ml endothelial cell growth supplement. 
NAD+ assay to determine cellular PARP-1 activity 
PARP-1 activation in cultured cells was measured as previously described 
[107]. MNNG was used to induce DNA strand breaks, activate PARP-1 and 
deplete intracellular NAD+ levels. Cells were treated in a 96-well microtiter-
plate with 25 µM (A549 cells) or 100 µM (RF24 cells) MNNG during 30 min 
with or without flavone, added 15 minutes before the treatment. Flavone had 
no cytotoxic effects as demonstrated with the LDH leakage test following 
incubation periods of up to 24 h (data not shown) [108]. Intracellular NAD+ 
was determined with the NAD+-cycling method based on the method previ-
ously described [94]. 
Immunofluorescent staining of PAR-polymers 
To confirm the PARP-1 inhibiting effects of flavone, the formation of PAR-
polymers was evaluated by immunocytochemical staining of the polymers. 
A549 cells (approximately 0.8x106 cells/well in 6-well plate) were treated with 
25 µM MNNG or 100 ng/ml LPS with or without flavone, added 15 minutes 
before the treatment. The synthetic PARP-1 inhibitors 3-aminobenzamide and 
PJ34 were used as positive controls. Following the incubation, the cells were 
trypsinized, washed with PBS and fixed in methanol. After fixation, cells were 
stained for PAR-polymers as previously described [107]. Using fluorescence 
microscopy and Lucia GF 4.80 software (Nikon, Düsseldorf, Germany), a 
minimum of 100 cells per slide were evaluated for the presence of PAR- 
polymers within the nucleus. Subsequently, the percentage of PAR-polymer 
positive cells was calculated. 
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Treatment of cells with LPS 
To investigate the potential anti-inflammatory effect of flavone on the expres-
sion and production of NF-κB mediated genes, LPS-stimulated A549 cells were 
used. The effects of flavone on the NF-κB activation, PAR-polymer formation, 
gene-transcription of IL-8 and inhibitor kappa B alpha (IκBα), production of IL-
8, tumor necrosis factor-alpha (TNF-α) and IL-6 were determined at several time 
points ranging from 15 min to 24 h. Cells were first incubated in 6-well plates 
with flavone for 30 minutes, and then stimulated with 100 ng/ml LPS diluted in 
DMEM with 0.5% FBS. After treatment, medium was removed, centrifuged (10 
min, 5000 rpm) and stored at -80°C until analysis of IL-8, TNF-α and IL-6 with 
ELISA kits (CLB/Sanquin, The Netherlands). The sensitivity of these kits for IL-8, 
TNF-α and IL-6 were respectively 1 pg/ml, 1 pg/ml and 0.2 pg/ml. Cells were 
then washed with HBSS and trypsinized after which cells were either fixed in 
cold methanol for immunohistochemical staining of the PAR-polymer or 
nuclear extracts were prepared for NF-κB analysis or cells were resuspended in 
Trizol Reagent for stabilization of RNA for real time PCR analysis of IL-8 and 
IκBα. 
NF-κB nuclear translocation 
Nuclear extracts were prepared as previously described [128]. The nuclear 
proteins were immediately collected and stored at -80°C until analysis. The 
protein concentration was determined according to the method of Bradford 
(BioRad, Veenendaal, The Netherlands). NF-κB activity was determined using 
the TransAM NF-κB p50 Activation Assay (Active Motif, Rixensart, Belgium). 
Gene transcription analysis by quantitative real time PCR 
Total RNA was isolated with Trizol Reagent (Invitrogen, Carlsbad, CA, USA), 
according to the manufacturer’s instructions. Next, the RNeasy® Mini Kit and 
RNase free DNase set (Qiagen, Hilden, Germany) were used to purify RNA. 
Concentration of the total isolated RNA was determined spectrophotometrically 
at 260 and 280 nm. Reverse transcription reaction was performed using 1 µg of 
total RNA and reverse-transcribed into cDNA using iScriptTM cDNA Synthesis 
Kit (Biorad Laboratories, Hercules, CA, USA). Subsequently, real time PCR was 
performed with a MyiQ Single Colour real time PCR detection system (BioRad) 
using SYBR© Green Supermix (Biorad), 5 µl diluted (10x) cDNA, and 0.3 µM 
primers in a total volume of 25 µl. PCR was conducted as follows: denaturation 
at 95ºC for 3 min, followed by 40 cycles of 95ºC for 15 s and 60ºC for 45 s. 
After PCR a melt curve (60-95ºC) was produced for product identification and 
purity. Two stably expressed genes were included as internal controls; β-Actin 
and GAPDH. rtPCR primers were designed using Primer express software 
(Applied Biosystems). Primer sequences used were as follows: IL-8 5’-
GGACAAGAGCCAGGAAGAAA (forward) and 5’-AAATTTGGGGTGGAAAGG 
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TT (reverse), IκBα 5’-CTACACCTTGCCTGTGAGCA (forward) and 5’-TCCTGA 
GCATTGACATCAGC (reverse), GAPDH 5’-GAAGGTGAAGGTCGGAGTC 
(forward) and 5’-GAAGATGGTGATGGGATTTC (reverse), β-Actin 5’-CCTGGC 
ACCCAGCACAAT (forward) and 5’-GCCGATCCACACGGAGTACT (reverse). 
Data were analysed using the MyiQ Software system (BioRad) and were 
expressed as relative gene expression (fold increase) using the 2−∆∆Ct method 
[129]. 
TEAC assay 
The antioxidant capacity of flavone was tested using the TEAC assay (Trolox 
Equivalent Antioxidant Capacity assay), as previously described [130] with 
some minor modifications. This assay is based on the ability of a compound to 
scavenge the stable ABTS radical (ABTS•+). The blue-green ABTS•+ was 
produced through the reaction between 0.36 mM ABTS and 1.84 mM ABAP in 
145 mM sodium phosphate buffer, pH 7.4, at 70°C until the absorption of the 
solution reached 0.70 ± 0.02 at 734 nm. In the assay, 50 µl of the test com-
pound was added to 950 µl of the ABTS•+ solution. The reduction in absorb-
ance at 734 nm was measured in time for 5 min and was compared to a blank 
where 50 µl of the solvent was added to 950 µl of ABTS•+ solution. A calibra-
tion curve was constructed using different concentrations of the synthetic 
antioxidant Trolox (0-20 µM). 
Electron spin resonance spectroscopy 
Electron spin resonance (ESR) studies were performed to evaluate the hydroxyl 
radical scavenging activity of flavone. The experiments were done at room 
temperature using a Bruker EMX 1273 spectrometer equipped with an ER 
4119HS high sensitivity cavity and 12 kW power supply operating at X band 
frequencies as previously described [107]. 5,5-Dimethyl-1-pyrroline N-oxide 
(DMPO) was used for trapping hydroxyl radicals. Incubation mixtures (total 
volume 200 µl) consisted of FeSO4 (0.5 mM), H2O2 (0.55 mM) and DMPO (100 
mM) in the absence or presence of flavone. Quercetin (100 µM) was used as a 
positive control and was found to reduce the DMPO-OH adduct signal by 
approximately 87%. ESR spectra were recorded using 100 µl capillary glass 
tubes. Quantification of the spectra (in arbitrary units) was performed by peak 
integration using the WIN-EPR spectrum manipulation program. 
Statistics 
Experiments were performed in triplicate and results are reported as means ± 
S.E.M. . Statistical analysis was carried out with SPSS 14.0 using ANOVA. To 
locate the statistical differences, a Bonferroni post hoc test was used. Differ-
ences were considered to be statistically significant at P < 0.05. 
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RESULTS 
PARP-1 enzyme inhibition 
In an in vitro assay, using the purified enzyme the activity of PARP-1 was 
observed to be effectively inhibited by 100 µM flavone (91 ± 1% inhibition). In 
the same assay, the known PARP-1 inhibitor 3-aminobenzamide was used as a 
positive control and for this compound 85 ± 1% inhibition was found at a 
concentration of 100 µM. To determine the nature of the inhibition, the effect 
of flavone on PARP-1 inhibition was evaluated using concentrations of β-NAD+ 
concentrations ranging from 0 to 250 µM. The Lineweaver Burk plot, which 
was obtained, indicated a competitive type of inhibition for flavone (Figure 2). 
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Figure 2. Lineweaver Burk plot for flavone. Human PARP-1 was incubated for one hour in the 
presence of nicked DNA, 0-250 µM NAD+ and various concentrations (0-50-100 µM) of flavone. 
 
Effect of flavone on MNNG-induced NAD+-depletion 
To assess the effect of flavone on MNNG-induced NAD+-depletion in cultured 
cells, A549 pulmonary epithelial cells and RF24 vascular endothelial cells were 
exposed to MNNG in the presence of flavone. The alkylating agent MNNG 
induces DNA strand breaks, which subsequently leads to PARP-1 overactiva-
tion, extensive formation of PAR-polymers and reduced levels of its substrate 
NAD+. Because the PAR-polymers are rapidly broken down by poly(ADP-
ribose) glycohydrolase (PARG) [106], measuring changes in NAD+ levels is a 
reliable method for measuring PARP-1 activation in cells over longer time 
periods. Incubation of the A549 and RF24 cells with MNNG decreased the 
cellular NAD+ levels to 23 ± 3% and 10 ± 4% respectively of basal values 
(Figure 3A + Figure 3B). Treatment of the A549 cells with flavone inhibited the 
MNNG-induced decrease in NAD+-levels in a dose-dependent manner (Figure 
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3A). In the endothelial cells, 100 µM flavone attenuated the MNNG-induced 
decrease in NAD+-levels to 73 ± 13%, whereas lower concentrations (10 and 1 
µM) could not prevent the MNNG-induced decrease in NAD+-levels (Figure 
3B). 
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Figure 3. NAD+ levels in A549 human pulmonary epithelial (A) and RF24 human vascular 
endothelial (B) cells after 30 min incubation with 25 µM (A549) and 100 µM (RF24) MNNG with or 
without 15 min pretreatment with 1, 10 and 100 µM flavone or 100 µM 3-aminobenzamide (3AB) 
(positive control). Values are expressed as % NAD+, with 100% representing NAD+ levels of control 
incubation (without MNNG and flavone or 3AB) and are mean ± S.E.M. of 3 replicate experiments. 
* P < 0.05 vs incubation with MNNG without flavone or 3AB. 
 
Effect of flavone on PAR-polymer formation in MNNG-treated A549 cells 
To confirm the PARP-1 inhibiting effect of flavone, PAR-polymer formation was 
measured in MNNG-treated A549 cells. Due to the very rapid catabolism of 
PAR-polymers by poly(ADP-ribose) glycohydrolase (PARG) [106], MNNG 
incubation time was reduced to 5 minutes. No PAR-polymer formation was 
observed in control cells. Treatment of the cells with MNNG for 5 minutes 
induced a massive increase of the number of PAR-polymer positive cells to 24 
± 1% (Figure 4).  
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Figure 4. Detection of PAR-polymer formation in MNNG-treated A549 cells with or without 
pretreatment with flavone after immunohistochemical staining. (A) Visualization of all nuclei with 
propidium iodide; (B) Nuclei stained positive for PAR-polymers. Magnification: 400X 
 
A 15 min pretreatment with 100 µM flavone significantly reduced the number 
of PAR-polymer positive cells to 1 ± 1% and a dose-dependent effect could be 
observed (Figure 4 and Figure 5). The known PARP-inhibitors 3-
aminobenzamide and PJ34 were included as positive controls at similar 
concentrations and these also reduced the formation of PAR-polymers dose-
dependently (Figure 5). 
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Figure 5. PAR-polymer formation in A549 lung epithelial cells. Cells were exposed to 25 µM 
MNNG for 5 minutes and pre-exposed for 15 minutes to the flavonoid flavone or the synthetic 
PARP-1 inhibitors PJ34 or 3AB in concentrations of 0, 1, 10 and 100 µM. Values are expressed as 
percentage PAR-polymer positive cells and are mean ± S.E.M. of 3 replicate experiments. 
* P < 0.05 vs incubation with MNNG without flavone, PJ34 or 3AB. 
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Effect of flavone on LPS-stimulated A549 cells 
To investigate the effect of flavone on the inflammatory stress response medi-
ated by NF-κB, pulmonary epithelial cells were stimulated with LPS in the 
presence of flavone for 8, 16 and 24 h. Stimulation of A549 cells with 100 
ng/ml LPS resulted in the release of the chemokine IL-8, although other cyto-
kines such as IL-6 and TNF-α could not be detected following stimulation with 
LPS (data not shown). Treatment of A549 cells with 10 µM flavone significantly 
reduced the LPS-induced IL-8 release at 16 and 24h after stimulation to respec-
tively 53 ± 7% and 63 ± 3% of IL-8 levels of LPS-treated cells. At 24h after 
stimulation, 1 µM flavone also significantly reduced the LPS-induced IL-8 
release (Figure 6). 
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Figure 6. IL-8 production in LPS-stimulated A549 lung epithelial cells. Cells were exposed in a 6-
well plate to 100 ng/ml LPS for 8, 16 or 24h and pre-exposed for 30 minutes to 0, 0.1, 1 and 10 µM 
flavone. Values are expressed as percentage IL-8 production, with 100% representing IL-8 
production in LPS-stimulated A549 cells (without flavone) and are mean ± S.E.M. of 3 replicate 
experiments. 
* P < 0.05 vs incubation with LPS without flavone. 
 
Real time PCR analysis confirmed the inhibiting effect of flavone on IL-8 
transcription in LPS-stimulated A549 cells (Figure 7A). The transcription of IκBα 
was induced after stimulation by LPS, as shown in Figure 7B. At time points 8h 
and 16h, the transcription of IκBα was significantly increased by flavone.  
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Figure 7. Gene-expression of IL-8 (A) and IκBα (B) in LPS-stimulated A549 lung epithelial cells. 
Cells were exposed in a 6-well plate to 100 ng/ml LPS for 8, 16 or 24h and pre-exposed for 30 
minutes to 0 and 10 µM flavone. Gene expression was analysed using quantitative rtPCR and 
expressed as fold increase over control treatment (=0h -0 ng/ml LPS) and are mean ± S.E.M. of 3 
replicate experiments. 
* P < 0.05 vs incubation with LPS without flavone. 
 
 
However, no significant effect of flavone treatment on NF-κB nuclear trans-
location could be measured following various incubation times ranging from 
15 min up to 24h (Figure 8). Using immunocytochemical staining of the PAR-
polymers, no PARP-1 activation could be detected after treatment of the cells to 
LPS from 5 min up to 24h after stimulation (data not shown). 
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Figure 8. NF-κB nuclear translocation in LPS-stimulated A549 pulmonary epithelial cells after 
treatment with flavone. Cells were treated for various periods with 100 ng/ml LPS in the presence of 
0 and 10 µM flavone. Values are expressed as µg jurkat equivalents/µg protein and are mean ± 
S.E.M. of 3 replicate experiments. 
 
Determination of antioxidant activity of flavone 
To rule out any antioxidant effect of flavone, scavenging of hydroxyl radicals 
and quantification of the total antioxidant capacity were determined by ESR 
spectroscopy and the TEAC assay respectively. Hydroxyl radicals were gener-
ated by H2O2 in the presence of FeSO4. In combination with the spin-trap 
DMPO, stable DMPO-OH adducts were formed. Addition of flavone in various 
concentrations did not decrease the observed DMPO-OH signal (Figure 9). 
Addition of flavone to stable ABTS radicals in the TEAC assay did not cause a 
detectable reduction of the absorbance measured at 734 nm. The TEAC value 
of flavone could therefore not be quantified. 
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Figure 9. Hydroxyl radicals, generated by FeSO4 and H2O2, are not scavenged by flavone. Values 
are expressed as % of control (FeSO4+ H2O2+DMPO). Insert: ESR spectrum for the hydroxyl radical 
spin adduct (DMPO-OH). 
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DISCUSSION 
In this study, flavone was identified as an inhibitor of the nuclear enzyme 
PARP-1. Inhibition of the enzyme by flavone was also observed in experiments 
showing prevention of NAD+-depletion in MNNG-treated A549 and RF24 cells. 
This was further confirmed immunocytochemically, by a reduced PAR-polymer 
formation in MNNG-treated A549 cells in the presence of flavone. In addition, 
flavone was found to attenuate the LPS-induced inflammatory response in A549 
lung epithelial cells. 
Increased PARP-1 activation in chronic inflammation has been observed in 
endothelial cells of diabetes patients and in peripheral blood mononuclear cells 
of patients with the pulmonary disease COPD [30, 131]. In addition, inhibition 
of PARP-1 has been shown both in vitro and in vivo to reduce the production or 
expression of inflammatory mediators like iNOS, but also of pro-inflammatory 
cytokines like IL-6 and IL-8 in models for pulmonary inflammation, septic 
shock or streptozotocin-induced diabetes [26, 29, 33, 34]. PARP-1 was found 
to be required for DNA binding and to act as a co-activator of the transcription 
factor NF-κB [11, 19]. However, others reported that the protein itself rather 
than the enzyme activity was required for NF-κB-mediated transcription [16]. 
NF-κB mediates the gene expression of many cytokines, chemokines and 
enzymes, and activation of NF-κB was observed in pulmonary inflammatory 
diseases like asthma and COPD [132]. 
In this study, the effect of the PARP-1 inhibiting flavonoid flavone on LPS-
induced expression and production of pro-inflammatory cytokines was investi-
gated by measuring the production of IL-8, TNF-α and IL-6 in A549 pulmonary 
epithelial cells. These cells did not show an increased production of TNF-α and 
IL-6 in response to LPS, which has also been observed previously [133]. 
Therefore, evaluation of the anti-inflammatory effect of flavone focussed on IL-
8. IL-8 is a chemokine released during inflammation and is important in the 
recruitment and activation of immune and inflammatory cells such as neutro-
phils [134]. Increasing levels of IL-8 have been observed in plasma and 
broncheoalveolar lavage (BAL) fluids of patients with pulmonary inflammatory 
diseases like COPD and asthma [30, 135-137]. In the present study, it was 
found that flavone dose-dependently reduced IL-8 production and these results 
were confirmed by transcription analysis of IL-8. Since the transcription factor 
NF-κB is involved in the transcriptional regulation of IL-8 [109], the mechanism 
underlying the effect of flavone on NF-κB was investigated. A slight, but not 
significant, reduction in nuclear translocation and activation of NF-κB was 
observed after treatment with flavone. However, transcription analysis of the 
inhibitor protein IκBα revealed a stimulating effect of flavone on the expression 
of IκBα, which was found to be significantly increased at 8h and 16h. Inhibitor 
proteins IκBα and IκBβ regulate activation of NF-κB via a feedback effect. 
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Stimulation by extracellular inducers such as cytokines, γ-radiation or oxidants 
causes the rapid phosphorylation and degradation of IκB by IκB kinase (IKK). 
The unbound activated NF-κB translocates to the nucleus, where it binds to 
specific κB consensus sequences in the chromatin and upregulates expression 
of many genes involved in the immune and inflammatory response. In addition, 
due to the presence of a κB recognition sequence in the promotor region of the 
IκBα-gene, NF-κB activation induces the up-regulation of IκBα transcription 
which eventually leads to a termination of the NF-κB signal [138]. Since PAR-
polymer formation could not be detected in LPS-stimulated A549 cells, the 
PARP-1 inhibiting effect of flavone could not be demonstrated at the level of 
PAR-polymer formation. This may be due to the very rapid catabolism of PAR-
polymers by poly(ADP-ribose) glycohydrolase (PARG) [106] and the applica-
tion of a mild LPS-stimulus of 100 ng/ml. PAR-polymer formation was not 
detected either by Erdelyi et al. (2005) in TNF-α and IL-1β stimulated cells 
using immunohistochemistry [116]. 
Using ESR spectroscopy and the TEAC assay, scavenging of (hydroxyl) radicals 
by flavone was evaluated. As expected, flavone did not show any relevant 
radical scavenging activity. This implies that the observed anti-inflammatory 
effects could not be attributed to antioxidant properties. 
In conclusion, these data indicate that the flavonoid flavone has significant 
PARP-1 inhibiting activity, reduces the LPS-induced transcription and produc-
tion of the pro-inflammatory chemokine IL-8 and increases the transcription of 
IκBα. Since transcription of IL-8 and IκBα are mediated by NF-κB, these data 
indicate that flavone attenuates the NF-κB mediated inflammatory response. 
Whether this is due to its PARP-1 inhibiting activity remains to be determined, 
since in this study no PAR-polymer formation could be detected after LPS-
stimulation of A549 cells. 
Activation of PARP-1 has been observed in vascular dysfunction in diabetes 
and COPD [30, 83]. Under conditions of acute exacerbations in COPD and of 
high blood glucose levels in diabetes, increased oxidative stress and PARP-1-
mediated decline of intracellular NAD+ and ATP contribute to tissue damage 
and may enhance inflammation. Therefore, attenuation of PARP-1 activation in 
these conditions might reduce the increased demand for energy, decrease 
tissue damage and improve inflammatory conditions. Based on the results of 
the current study, the flavonoid flavone appears to be a promising candidate in 
the treatment of chronic inflammatory diseases such as COPD and vascular 
dysfunction in diabetes. 
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ABSTRACT 
Dietary flavonoids are currently extensively investigated for their putative 
positive health effects. Previously, we observed significant in vitro poly(ADP-
ribose) polymerase-1 (PARP-1) inhibiting effects of specific flavonoids in 
addition to the well-documented antioxidant and anti-inflammatory effects. In 
addition, it was observed that PARP-1 plays a mediating role in lipopolysaccha-
ride (LPS)-induced acute pulmonary inflammation. Therefore, in the present 
study, the anti-inflammatory effects of the PARP-1 inhibiting flavonoids flavone, 
fisetin and tricetin were evaluated in an in vivo mouse model of LPS-induced 
acute pulmonary inflammation. Furthermore, the effects of the flavonoids were 
compared to those of the anti-inflammatory glucocorticoid dexamethasone. 
The flavonoid fisetin significantly reduced lung myeloperoxidase (MPO)-levels 
and gene-expression of inflammatory mediators such as interleukin (IL)-6, 
tumor necrosis factor (TNF)-α, IL-1β, macrophage inflammatory protein (MIP)-
1α and MIP-2. The LPS-induced gene transcription of heme oxygenase (HO)-1 
and superoxide dismutase (SOD)2 was also significantly reduced by fisetin. 
Flavone and tricetin also showed attenuation of inflammatory markers, but 
appeared to have lower efficacy than fisetin. Both fisetin as well as dexa-
methasone attenuated the LPS-induced PARP-1 activation in pulmonary 
epithelial cells. Overall, the anti-inflammatory effects of fisetin in this in vivo 
model were much more pronounced as compared to the observed effects of 
dexamethasone. The results of this study indicate that flavonoids such as fisetin 
might be potential candidates as nutraceuticals in the treatment of pulmonary 
inflammatory diseases. 
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INTRODUCTION 
Flavonoids are a group of polyphenolic compounds, present in fruits, vegeta-
bles and beverages such as red wine and tea. Since the intake of flavonoids has 
been associated with a reduced risk for cardiovascular or chronic inflammatory 
diseases, this group of naturally occurring compounds is extensively investi-
gated for their putative positive health effects [51, 57]. Recently, we reported 
that the flavonoids quercetin, tricetin, fisetin and flavone exerted poly(ADP-
ribose) polymerase-1 (PARP-1) inhibiting activity and attenuated the lipopoly-
saccharide (LPS)-induced interleukin (IL)-8 release in pulmonary epithelial cells 
[139, 140]. Furthermore, flavone reduced the nuclear factor-kappa B (NF-κB) 
mediated gene-transcription of IL-8 and increased the transcription of IκBα in 
pulmonary epithelial cells, suggesting that the NF-κB mediated inflammatory 
response was attenuated by flavone [140]. Based on the PARP-1 inhibiting and 
anti-inflammatory activity, it was suggested that these food-derived compounds 
might be applied in the treatment of inflammatory diseases, such as chronic 
obstructive pulmonary disease (COPD). Until now, no effective treatment for 
these diseases has been developed yet, and these flavonoids may offer a new 
therapeutic potential. Previously, Liaudet et al. (2002) demonstrated that PARP-
1 inhibition by synthetic compounds attenuated the LPS-induced acute pulmo-
nary inflammation [29]. Therefore, we aimed at evaluating the PARP-1 inhibit-
ing flavonoids in a model for acute pulmonary inflammation. 
In the present study, the effect of the orally administered PARP-1 inhibiting 
flavonoids flavone, fisetin and tricetin was investigated on intratracheally LPS-
induced pulmonary inflammation and oxidative stress in mice. Furthermore, 
the effects were compared to the anti-inflammatory glucocorticoid dexa-
methasone. 
MATERIAL AND METHODS 
Animals 
Male C57BL/6 mice (12 weeks) were obtained from Charles River (Maastricht, 
The Netherlands). Animals were housed individually in standard laboratory 
cages and allowed food and water ad libitum during the experiments. The 
experiments were approved by the Ethics Committee for Animal Experiments of 
Maastricht University (Maastricht, The Netherlands). 
Experimental protocol 
On 4 consecutive days, mice (n=6/group) received the compounds via oral 
gavage (22.2 mg flavone, 28.6 mg fisetin, 30.2 mg tricetin or 2.0 mg dexa-
methasone/kg bodyweight). The daily administered doses of the flavonoids 
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were equal to 100 µmol/kg bodyweight. In a previous in vitro study we found 
that these flavonoids showed similar PARP-1 inhibiting activity as compared to 
the synthetic PARP-1 inhibitor 3-aminobenzamide [139, 140].  
The anti-inflammatory glucocorticoid dexamethasone was also applied in this 
model at a reported anti-inflammatory dose of 2 mg/kg bodyweight/day [141, 
142]. Prior to administration, each compound was freshly suspended in soy oil, 
which was also used as vehicle control (5 ml soy oil/kg bodyweight). Soy oil 
was chosen since previous findings indicated that co-administration of lipids 
such as soy bean or lecithin enhanced and accelerated the oral bioavailability 
of the flavonoid aglycone quercetin from the diet [143]. At day 4, one hour 
after the final oral administration mice received LPS intratracheally. Intratra-
cheal (IT) instillation technique was performed via a non-surgical procedure 
according to Vernooy et al. [144]. Mice were anesthesized by subcutaneous 
injection with ketamin hydrochloride (Nimatek; Eurovet, Bladel, The Nether-
lands) and xylazine hydrochloride (Xylaject; Dopharma, Raamsdonksveer, The 
Netherlands). LPS (O55:B5, Sigma, Darmstadt, Germany), dissolved in 50 µl 
sterile 0.9% NaCl, was instilled intratracheally (20 µg/mouse) via a canule and 
syringe (2x 25 µl), followed by 100 µl air. Sham-treated mice were instilled 
intratracheally with 50 µl sterile 0.9% NaCl. After IT treatment, mice were kept 
in an upright position for 10 minutes to allow the fluid to spread throughout the 
lungs. Mice were killed 4h and 24h after IT treatment while under pentobarbi-
tal (Nembutal, Ceva Sante Animale, Naaldwijck, The Netherlands) anesthesia. 
Blood was collected via heart puncture in EDTA-containing tubes, immediately 
centrifuged (2000xg, 10 min, 4oC) and plasma was stored at -80ºC. Lungs were 
removed and lung tissue was snap-frozen for RNA-isolation and myeloperoxi-
dase (MPO) analysis. For immunohistochemical analyses, lung tissue was 
inflated with 10% phosphate-buffered formalin (pH 7.4) through the trachea 
and subsequently fixed in formalin for 24 h after which it was further processed 
for immuno-histochemical staining. 
Dose and time finding study 
Initial data were obtained using various time points (2-4-6-8-12-24-48-72-96h) 
as well as various LPS concentrations (0-10-20-40 µg LPS), with MPO-activity 
in lung homogenates as primary parameter. These data revealed that the 
inflammatory response was starting to develop at 4h after LPS-treatment. At 24h 
after LPS-treatment (20 µg/mouse), the LPS-induced inflammatory processes 
reached maximum levels. Therefore, these time points were selected to investi-
gate whether oral administration of PARP-1 inhibitors might suppress early 
development of the inflammatory response as well as reduce its intensity. 
MPO-analysis 
MPO activity in the dose and time finding study was measured in homogenates 
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using a MPO activity assay kit (Cytostore, Calgary, Canada) according to the 
manufacturer’s instruction. Briefly, snap-frozen lung tissue was homogenized in 
hexadecyltri-methylammonium bromide (HTAB)-buffer. Approximately 50 µl 
HTAB-buffer was added to 1 mg of lung tissue. After centrifugation (10000xg, 
2min, 4ºC), lung homogenates were kept on ice and MPO-activity was deter-
mined according to the manufacturer’s protocol during 5 minutes at 450 nm. 
However, to exclude any interference of the applied compounds with the 
activity measurements, MPO protein levels were further determined quantita-
tively using a mouse MPO ELISA kit (HBT, Uden, The Netherlands) according 
to the manufacturer’s instruction. Prior to this analysis, snap-frozen lung tissue 
was ground to a powder in a stainless steel mortar under liquid nitrogen and 
homogenized in a lysis buffer containing 200 mM NaCl, 5 mM EDTA, 10 mM 
tris, 10% glycine, 1 mM PMSF, 1 µg/ml leupeptide and 28 µg/ml aprotinine (pH 
7.4). Approximately 20 µl lysisbuffer was added to 1 mg tissue. After centrifuga-
tion (10000xg, 15 min, 4ºC), lung homogenates were stored at -80ºC. Myelop-
eroxidase protein levels in lung tissue homogenate were quantitatively deter-
mined using the ELISA kit. The protein concentration was determined accord-
ing to the BCA method (Pierce, Rockford, IL, USA). The amount of MPO was 
expressed as ng MPO/mg protein. Measurement of MPO-activity in the dose 
and time finding study revealed that in addition to increased MPO-protein 
levels, MPO-activity was also increased after LPS-treatment (data not shown). 
Gene transcription analysis by quantitative PCR 
Snap-frozen lung tissue was ground to a powder in a stainless steel mortar 
under liquid nitrogen and homogenized in Trizol Reagent (Invitrogen, Carlsbad, 
CA, USA). Total RNA isolation was performed according to the manufacturer’s 
instructions. Concentration of the isolated total RNA was determined spectro-
photometrically at 260 and 280 nm. Reverse transcription reaction was per-
formed using 1 µg of total RNA and reverse-transcribed into cDNA using 
iScriptTM cDNA Synthesis Kit (Biorad Laboratories, Hercules, CA, USA). Subse-
quently, real time PCR was performed with a MyiQ Single Colour real time 
PCR detection system (BioRad) using SYBR© Green Supermix (Biorad), 5 µl 
diluted (10x) cDNA, and 0.3 µM primers in a total volume of 25 µl. PCR was 
conducted as follows: denaturing at 95ºC for 3 min, followed by 40 cycles of 
95ºC for 15 seconds and 60ºC for 45 seconds. After the PCR procedure, a melt 
curve (60-95ºC) was produced for product identification and control of purity.  
β-Actin was included as an internal control gene, since the various treatments 
did not influence its gene-expression. rtPCR primers were designed using 
Primer express software (Applied Biosystems). Primer sequences used were as 
follows: 
TNF-α 5’-GACCCTCACACTCAGATCATCTTCT (forward) and 5’-CCACTTGGT 
GGTTTGCTACGA (reverse), IL-6 5’-ACAAGTCGGAGGCTTAATTACACAT 
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(forward) and 5’-AATCAGAATTGCCATTGCACAA (reverse), MIP-2 5’-GAACAT 
CCAGAGCTTGAGTGTGA (forward) and 5’-CTTGAGAGTGGCTATGACTTCTG 
TC (reverse), MIP-1α 5’-ACTATTTTGAAACCAGCAGCCTTT (forward)  and  5’-
GATCTGCCGGTTTCTCTTAGTCA (reverse), IκBα 5’-CGGAGGACGGAGACTC 
GTT (forward) and 5’-TTCACCTGACCAATGACTTCCA (reverse),  IL-1β 5’-
AATCTATACCTGTCCTGTGTAATGAAAGAC (forward) and 5’-TGGGTATTGCT 
TGGGATCCA (reverse), heme oxygenase (HO)-1 5’-CCGCCTTCCTGCTCAAC 
AT (forward) and 5’-CATCTGTGAGGGACTCTGGTCTT (reverse), superoxide 
dismutase (SOD)2 5’-AGGCTATCAAGCGTGACTTTGG (forward) and  5’-
TGAACCTTGGACTCCCACAGA (reverse), β-Actin 5’-CGTGAAAAGATGACCC 
AGATCA (forward) and 5’-CACAGCCTGGATGGCTACGT (reverse). Data were 
analysed using the MyiQ Software system (BioRad) and were expressed as 
relative gene expression (fold increase) using the 2−∆∆Ct method [129]. 
Immunohistochemical staining of poly ADP-ribose (PAR)-polymers 
The presence of PAR-polymers was determined using immunohistochemical 
staining. Briefly, paraffin sections were deparaffinized and rehydrated. Endoge-
nous peroxidase was quenched with 0.3% hydrogen peroxidase. For antigen 
retrieval, sections were incubated with trypsin for 10 min at 37°C. After 
blocking the sections with 10% non fat dry milk for 10 min and 10% goat 
serum for 15 min, sections were incubated overnight with the primary poly-
clonal antibody to PAR (96-10-04, Alexis, Lausen, Switserland). Next, sections 
were incubated with a biotinylated goat anti-rabbit immunoglobulin (Dako, 
Glostrup, Denmark), followed by incubation with avidin-peroxidase (ABC-kit, 
Vectastain) for 30 min and 3,3’diaminobenzidine for 10 min. Sections were 
counterstained with hematoxylin, dehydrated and mounted with Entellan 
(Merck). Slides containing the stained lung section were encoded and at least 
200 epithelial cells were evaluated for the presence of PAR-polymers in their 
nuclei. 
Mice plasma serum amyloid p component and IL-6 analysis 
Plasma serum amyloid p component (SAP) levels were determined using a 
quantitative ELISA-based test kit (Gentaur, Brussels, Belgium). Plasma IL-6 
levels were determined using a Mouse IL-6 Immunoassay kit (R&D Systems, 
Minneapolis, USA). 
Statistical Analysis 
Results are reported as mean ± SEM. Statistical analyses were carried out using 
SPSS 14.0. Data appeared not normally distributed and were therefore evalu-
ated with non-parametric tests. The data of the LPS-treated mice at 4h and 24h 
after IT LPS-treatment compared to the NaCl-treated mice were evaluated using 
Mann-Whitney test. Furthermore, the effect of treatment with the flavonoids 
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flavone, fisetin and tricetin or dexamethasone on the LPS-induced changes of 
inflammatory markers and the efficiency between fisetin and dexamethasone 
was evaluated using Kruskal-Wallis test followed by posthoc test of Siegel and 
Castellan [145]. Differences were considered to be statistically significant at P 
< 0.05. 
RESULTS 
Neutrophil infiltration in lungs 
The amount of MPO protein in lung tissue homogenates was determined as a 
measure for influx of neutrophils (Figure 1). At 4h after LPS-stimulation, slightly 
but not significantly increased levels of MPO were observed. Intratracheal 
instillation of mice with LPS significantly increased lung MPO-levels at 24h 
after LPS-treatment. Previous oral administration of flavone, fisetin and tricetin 
significantly reduced MPO-levels in lungs at 24h after LPS-treatment. Pretreat-
ment of the mice with dexamethasone also significantly attenuated lung MPO-
levels at 24h after IT LPS treatment. Fisetin pretreatment had a significantly 
stronger reducing effect on MPO-levels than dexamethasone pretreatment. 
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Figure 1. MPO-protein levels in lungs after IT LPS instillation of C57BL/6 mice. Mice orally 
received flavone (FLA), fisetin (FIS), tricetin (TRI) and dexamethasone (DEX) for 4 consecutive days 
prior to the LPS-challenge. MPO-levels were determined at 4h and 24h after LPS-treatment. MPO 
levels are expressed as ng MPO/mg protein and are mean ± SEM of 6 mice. 
++ P < 0.05 vs 24h NaCl-treated mice 
** P < 0.05 vs 24h LPS-treated mice without flavonoids or DEX 
## P < 0.05 vs 24h LPS+DEX-treated mice 
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Gene-expression in lung tissue 
Chemokine and cytokine expression in lung tissue 
Since PARP-1 is involved in both the NF-κB and activator protein-1 (AP-1) 
pathways [11, 15, 82], the effect of oral administration of PARP-1 inhibiting 
flavonoids on these pathways was evaluated by measuring transcription of 
IkBα, IL-1β, IL-6 and TNF-α and also of the chemokines MIP-1α and MIP-2 
(Figure 2). 
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Figure 2. Transcription of the chemokines and cytokines IL-6, TNF-α, MIP-1α, MIP-2, IL-1β, IκBα in 
lungs of IT LPS-treated C57BL/6 mice. Mice orally received flavone (FLA), fisetin (FIS), tricetin (TRI) 
and dexamethasone (DEX) for 4 consecutive days prior to the LPS-challenge. Gene expression was 
determined 4h and 24h after LPS-challenge and was analysed using quantitative PCR and 
expressed as fold increase over control treatment (=NaCl) and are mean ± SEM of 6 mice. 
* P < 0.05 vs 4h LPS-treated mice without flavonoids or DEX 
** P < 0.05 vs 24h LPS-treated mice without flavonoids or DEX 
## P < 0.05 vs 24h LPS+DEX-treated mice 
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IT LPS-treatment increased gene-expression of IL-6, TNF-α, IL-1β and IκBα, 
MIP-1α and MIP-2 both at 4h and 24h. A 4-day oral administration of fisetin 
significantly reduced transcription of IL-6, TNF-α, MIP-1α, MIP-2, IL-1β, IκBα at 
24h after IT LPS. Oral administration of mice with flavone and tricetin signifi-
cantly increased gene transcription of IL-6 at 4h after LPS treatment, whereas 
TNF-α gene transcription was reduced at 24h after LPS treatment in mice 
receiving flavone. Flavone pretreatment also reduced MIP-2 gene-transcription 
at 24h after LPS treatment, but at 4h after LPS-treatment an increased transcrip-
tion was observed. Tricetin reduced transcription of IL-1β and IκBα at 24h after 
LPS treatment. Dexamethasone treatment reduced the transcription of the IL-6 
gene at 24h and of TNF-α at 4h after LPS-treatment. An increased IκBα gene-
transcription was observed at 4h after LPS treatment in the dexamethasone 
pretreated mice. 
 
Antioxidant expression in lung tissue 
Since the administered flavonoids fisetin and tricetin are known to have 
antioxidant effects, transcription of the redox-regulated HO-1 and the anti-
oxidant SOD2 genes was also investigated. Both genes were significantly up-
regulated following LPS-treatment (Figure 3). HO-1 gene transcription was 
significantly reduced in fisetin pretreated mice at 4h and 24h and in flavone 
pretreated mice at 24h after LPS-treatment. Dexamethasone pretreatment 
significantly increased HO-1 gene transcription at both time points, indicating 
increased oxidative stress. SOD2 gene transcription was significantly reduced 
in mice receiving fisetin (4h and 24h), flavone (24h), tricetin (24h). At 4h after 
LPS-treatment, flavone as well as dexamethasone administration increased gene 
transcription of SOD2. 
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Figure 3. Transcription of HO-1 and SOD2 in lungs of IT LPS-treated C57BL/6 mice. Mice orally 
received flavone (FLA), fisetin (FIS), tricetin (TRI) and dexamethasone (DEX) for 4 consecutive days 
prior to the LPS-challenge. Gene expression was determined 4h and 24h after LPS-challenge and 
was analysed using quantitative PCR and expressed as fold increase over control treatment (=NaCl) 
and are mean ± SEM of 6 mice. 
 * P < 0.05 vs 4h LPS-treated mice without flavonoids or DEX 
** P < 0.05 vs 24h LPS-treated mice without flavonoids or DEX 
# P < 0.05 vs 4h LPS+DEX-treated mice 
## P < 0.05 vs 24h LPS+DEX-treated mice 
 
PAR-polymer formation in LPS-exposed lungs 
The extent of PARP-1 activation in LPS-exposed lungs was determined by 
evaluating the presence of PAR-polymers in the nuclei of pulmonary epithelial 
cells. It was observed that intratracheal treatment of mice with LPS induced 
PARP-1 activation, as was indicated by the presence of PAR-polymers in the 
epithelial cells. This was most apparent at 24h after LPS-exposure. At 4h after 
LPS-exposure, a small number of epithelial cells showed PAR-polymers in the 
nuclei (data not shown). Furthermore, at 24h after LPS-exposure it was ob-
served that lungs of LPS-exposed mice contained infiltrated leukocytes, of 
which most were also positive for the presence of PAR-polymers (Figure 4). 
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Figure 4. PAR-polymer formation in lungs of IT LPS-treated C57BL/6 mice. PARP-1 activation was 
determined immunohistochemically 24h after LPS exposure. Magnification 400x. 
 
Since most consistent anti-inflammatory effects were observed for fisetin, the 
effect of this flavonoid on PARP-1 activation in pulmonary epithelial cells was 
studied. LPS treatment induced a significant increase in the frequency of PAR-
polymer positive nuclei after 24h which was attenuated in mice that orally 
received fisetin and dexamethasone (Figure 5). For fisetin a reduction of 67.2% 
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± 16.2% and for dexamethasone a reduction of 39.4% ± 31% was found. Since 
a high variability was found between mice these differences were not statisti-
cally significant.  
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Figure 5. Percentage PAR-polymer positive epithelial cells in lungs of IT LPS-treated C57BL/6 mice 
24h after LPS-exposure. Mice orally received fisetin (FIS) and dexamethasone (DEX) for 4 consecu-
tive days prior to the LPS-challenge. Data shown are mean + SEM of 4-6 mice per group and are 
based on at least 200 cells per animal. 
++ P < 0.05 vs 24h NaCl-treated mice 
 
 
Plasma SAP and IL-6 levels 
Plasma levels of the acute phase reactant SAP and cytokine IL-6 were measured 
to investigate whether treatment of the LPS-exposed mice with the putative 
anti-inflammatory flavonoids fisetin, tricetin and flavone or the anti-
inflammatory glucocorticoid dexamethasone also reduced the systemic in-
flammatory response. 
Plasma SAP-levels were significantly increased at 24h after IT treatment with 
LPS. However, no significant changes were observed for mice receiving the 
flavonoids flavone, fisetin or tricetin, nor for mice pre-treated with the anti-
inflammatory drug dexamethasone (Figure 6). 
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Figure 6. Plasma SAP levels of IT LPS-treated C57BL/6 mice. Mice orally received flavone (FLA), 
fisetin (FIS), tricetin (TRI) and dexamethasone (DEX) for 4 consecutive days prior to the LPS-
challenge. Plasma SAP-levels are measured 24h after LPS-exposure and expressed as µg/ml and are 
mean ± SEM of 6 mice. 
++ P < 0.05 vs 24h NaCl-treated mice 
 
Increased plasma IL-6 levels were observed at 4h and 24h after LPS-treatment. 
In mice that received flavone and fisetin significantly further increased plasma 
IL-6 levels were observed at 4h after IT LPS-treatment. At 24h after IT LPS-
treatment, tricetin and dexamethasone administration to mice significantly 
reduced plasma IL-6 levels. Dexamethasone pre-treatment showed a stronger 
reducing effect on LPS-induced plasma IL-6 release (Figure 7). 
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Figure 7. Plasma IL-6 levels of IT LPS-treated C57BL/6 mice. Mice orally received flavone (FLA), 
fisetin (FIS), tricetin (TRI) and dexamethasone (DEX) for 4 consecutive days prior to the LPS-
challenge. Plasma IL-6 levels are measured 4h and 24h after LPS-exposure and are expressed as 
pg/ml and are mean ± SEM of 6 mice. 
+ P < 0.05 vs 4h NaCl-treated mice 
++ P < 0.05 vs 24h NaCl-treated mice 
* P < 0.05 vs 4h LPS-treated mice without flavonoids or DEX 
** P < 0.05 vs 24h LPS-treated mice without flavonoids or DEX 
## P < 0.05 vs 24h LPS+DEX-treated mice 
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DISCUSSION 
In this study the orally administered PARP-1 inhibiting flavonoids flavone, 
fisetin and tricetin appeared to differ to a great extent with respect to their 
efficacy. Most consistent anti-inflammatory effects were found for fisetin, 
specifically in the lungs. The anti-inflammatory effects of fisetin in the lungs 
were more pronounced then the effects of the anti-inflammatory glucocorticoid 
dexamethasone. 
Oral administration of flavonoids in IT LPS-induced acute pulmonary inflam-
mation was used to evaluate the potential application of these compounds as 
nutraceuticals or as ingredients of functional foods for patients with pulmonary 
diseases. The flavonoids which were evaluated in the present study can be 
found in apples, onions, grapes and strawberries (fisetin), Ginkgo Biloba 
(tricetin), dill weeds and oats (flavone) [121]. 
In the present study, flavone, fisetin and tricetin were all administered to the 
mice as their aglycone. In plants and foods, flavonoids are mainly present as 
glycosides, and initially it was thought that the aglycones were the only form 
that was able to be taken up in the gastro-intestinal tract [53]. However, 
currently it is considered that also flavonoid glycosides can be absorbed 
without preceding hydrolysis [54, 55]. After absorption, flavonoids are exten-
sively metabolized in various organs such as small intestine and liver, resulting 
in the formation of sulfated, glucuronidated and methylated compounds [56]. 
The tissue distribution of specific flavonoids has been recently evaluated in 
various studies. The tissue distribution of quercetin and quercetin metabolites 
was assessed in rats fed a quercetin-rich diet for 11 weeks [146]. High 
quercetin levels were found in rat lung tissue. In the present study, plasma or 
tissue levels of the various flavonoids and metabolites were not determined. 
However, clear effects were observed in fisetin pretreated mice, implying that 
fisetin or its metabolites are absorbed from the gastrointestinal tract and 
distributed throughout the body. Whether fisetin or its metabolites also accu-
mulate in the lungs of mice, as has been reported for quercetin in rat lungs, 
remains to be investigated. 
Recently, the mechanism of the in vitro anti-inflammatory effects of fisetin was 
extensively investigated [147]. Fisetin was found to suppress activation of NF-
κB by inhibiting activation of IκBα kinase (IKK). Fisetin was reported to block 
phosphorylation and degradation of IκBα and subsequently induce suppression 
of the nuclear translocation of p65 subunit [147]. In a study by Chen et al. 
(2004) [114], the anti-inflammatory effects of various flavonoids were investi-
gated in respiratory epithelial cells. It was found that the flavones luteolin and 
apigenin inhibited IKK activity, IκBα degradation and NF-κB DNA-protein 
binding [114]. In the present study, pretreatment of mice with the flavonoid 
fisetin significantly suppressed the LPS-induced acute pulmonary inflammation. 
FLAVONOIDS: IN VIVO ANTI-INFLAMMATORY EFFECTS 
 85 
At 4h after LPS-treatment, fisetin pretreatment did not significantly modulate 
any of the tested NF-κB dependent genes. However, at 24h after LPS-treatment, 
fisetin reduced transcription of the cytokines IL-1β, IL-6 and TNF-α and also of 
the chemokines MIP-1α and MIP-2, suggesting that at this time point NF-κB 
dependent transcription was attenuated. In addition, fisetin reduced transcrip-
tion of the NF-κB inhibitor protein IκBα at 24h after LPS-treatment, which 
appears to imply that at this time point the LPS-induced activation of NF-κB 
was no longer enhanced. Flavone and tricetin also showed attenuation of 
inflammatory markers, but appeared to have lower efficacy than fisetin. 
In this study, significant increases in IL-6 levels in plasma and IL-6 transcription 
in lung tissue were observed at 4h after IT LPS-treatment in the flavone (plasma 
and lung), fisetin (plasma) and tricetin (lung) pretreated mice. Xing et al (1998) 
[148] postulated that in mouse models of LPS-induced acute pulmonary 
inflammation and endotoxaemia, the cytokine IL-6 plays an anti-inflammatory 
role in acute inflammatory responses, as an upstream signal leading to a 
downregulation of proinflammatory cytokines [148]. The elevated IL-6 levels at 
4h in these mice might therefore indicate that increased production of IL-6 in 
the earlier phase may lead to a enhanced downregulation of the inflammatory 
response. Particularly for fisetin, this might be an explanation for the potent 
anti-inflammatory effects at 24h after LPS-treatment in lungs as well as in 
blood. 
Transcription of HO-1 and SOD2 genes was determined in this study as a 
marker for oxidative stress. HO-1 expression is upregulated in response to 
agents that generate ROS, and induction of HO-1 is generally regarded as a 
protective mechanism against oxidative tissue injury [149]. In the present study, 
both HO-1 and SOD2 transcription were elevated at 4h as well as 24h after IT 
LPS-treatment. Pretreatment with fisetin significantly reduced HO-1 and SOD2 
transcription at these time points and after pretreatment with tricetin a reduced 
HO-1 and SOD2 transcription was observed at 24h after LPS treatment. 
Flavone also reduced HO-1 and SOD2 transcription at 24h after LPS treatment, 
although it has no antioxidant activity. In contrast, the anti-inflammatory 
glucocorticoid dexamethasone significantly increased HO-1 and SOD2 
transcriptional activities. Despite the fact that a much cited explanation for the 
anti-inflammatory effects of flavonoids is their antioxidant effect, results of the 
present study imply that other mechanisms are more likely to underlie the anti-
inflammatory effects described in the present study. 
Pretreatment of the LPS-exposed mice with the anti-inflammatory glucocorti-
coid dexamethasone (2mg/kg bodyweight) did not affect the expression of the 
anti-inflammatory genes in the lungs. Lung MPO-levels and plasma IL-6 levels 
at 24h after LPS exposure were significantly reduced in the dexamethasone 
treated group. In comparison to the flavonoids, dexamethasone was applied at 
a much lower concentration, which has been applied before in mouse models. 
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The potential inhibiting effects of fisetin on PARP-1 in the lungs were deter-
mined by immunohistochemical staining of the PAR-polymer in the pulmonary 
epithelial cells. Increased PAR-polymer formation was observed at 24h after 
LPS-exposure, which was also consistent with the results of Liaudet et al. (2002) 
[29]. Both fisetin as well as dexamethasone tended to attenuate the number of 
PAR-polymer positive pulmonary epithelial cells. 
Altogether, the evaluated flavonoids and specifically fisetin exerted potent anti-
inflammatory effects in an in vivo model of LPS-induced acute pulmonary 
inflammation. The anti-inflammatory effects were not only observed in the 
lungs but also systemic effects were found. The flavonoids flavone and tricetin 
also showed attenuation of inflammatory markers, but appeared to be less 
potent than fisetin; the order of potency was fisetin > tricetin > flavone. Fur-
thermore, fisetin was found to have a higher efficacy in reducing pulmonary 
inflammation as compared to the well-established anti-inflammatory glucocor-
ticoid dexamethasone. Since long-term intake of corticosteroids is known to be 
accompanied with serious side-effects, and no effective treatment for chronic 
inflammatory diseases such as COPD has been developed yet, alternative 
treatments are needed. The results obtained indicate that functionals foods or 
nutraceuticals containing fisetin may be promising candidates for the applica-
tion in the treatment of inflammatory pulmonary diseases. 
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ABSTRACT 
The nuclear enzyme poly(ADP-ribose) polymerse-1 (PARP-1) has previously 
been reported to play an important role in lipopolysaccharide (LPS)-induced 
pulmonary inflammation. Therefore, PARP-1 inhibitors are considered to have 
a potential application in the treatment of inflammatory lung diseases such as 
chronic obstructive pulmonary disease (COPD). 
In the present study, the anti-inflammatory effects of a previously identified 
PARP-1 inhibiting caffeine metabolite, 1,7-dimethylxanthine, were evaluated 
using two different models. First, orally administered 1,7-dimethylxanthine was 
tested in vivo in a mouse model of LPS-induced acute pulmonary inflammation. 
1,7-Dimethylxanthine significantly attenuated the LPS-induced increased lung 
myeloperoxidase (MPO)-levels and gene-transcription of interleukin (IL)-6, 
tumor necrosis factor (TNF)-α, macrophage inflammatory protein (MIP)-1α and 
MIP-2. Reduced systemic levels of both serum amyloid P component (SAP) as 
well as IL-6 were observed in plasma of 1,7-dimethylxanthine treated mice. 
Furthermore, 1,7-dimethylxanthine tended to attenuate the LPS-induced PAR-
polymer formation. In addition, the anti-inflammatory effects at 24h were more 
pronounced when compared to the synthetic PARP-1 inhibitor 3-amino-
benzamide. In the second model, blood of COPD patients and healthy controls 
was stimulated ex vivo with LPS in the presence or absence of 1,7-dimethyl-
xanthine at a physiological concentration. In this model, 1,7-dimethylxanthine 
significantly suppressed the LPS-induced production of the cytokines IL-6 and 
TNF-α. 
Since no effective treatment for chronic inflammatory diseases such as COPD 
has been developed yet, there is an urgent need for novel therapeutic strategies. 
These results suggest that the PARP-1 inhibitor 1,7-dimethylxanthine may be 
applied as anti-inflammatory treatment in inflammatory diseases such as 
COPD. 
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INTRODUCTION 
Exposure of the respiratory system to airborne particles from cigarette smoke 
and air pollution is a major etiologic factor in the development of chronic 
pulmonary diseases [150-152]. The bacterial cell wall component lipopoly-
saccharide (LPS), present as contaminant in cigarette smoke or organic dusts, 
has been shown to induce acute and chronic lung inflammation [153]. 
Previously, activation of the nuclear enzyme poly(ADP-ribose) polymerase-1 
(PARP-1) has been demonstrated to play a central role in LPS-induced acute 
pulmonary inflammation [29]. PARP-1 is activated during oxidative stress [85] 
and is involved in regulation of transcription and stress response via the 
transcription factors nuclear factor kappa B (NF-κB) and activator protein-1 (AP-
1) [21, 24, 81]. PARP-1 appears to be not only involved in acute inflammatory 
responses, but also in chronic inflammatory conditions [23, 29, 30, 83, 84, 
154]. Consequently, the therapeutic potential of PARP-1 has extended to 
alleviation of chronic inflammatory conditions as well. Previously, increased 
activity of PARP-1 has been observed in peripheral blood mononuclear cells in 
patients with chronic obstructive pulmonary disease (COPD) [30]. COPD is not 
only characterized by pulmonary inflammation and airflow limitation, but also 
by systemic inflammation as is evident from an increased number of circulating 
lymphocytes and increased serum levels of the cytokines tumor necrosis factor-
alpha (TNF-α), interleukin (IL)-6 and IL-8 as well as from increased markers of 
oxidative stress [155, 156]. Current therapies for COPD are aimed at improving 
airflow limitation and reducing exacerbations, while no effective treatment for 
the pulmonary nor for the systemic inflammatory manifestations of COPD has 
been established yet. 
Previously, we observed that several methylxanthines, among which the 
caffeine metabolite 1,7-dimethylxanthine (paraxanthine) and to a lesser extent 
theophylline, which is still used in the treatment of COPD, have PARP-1 
inhibiting effects in vitro in pulmonary epithelial cells. Furthermore, it was 
suggested that these compounds may offer potential therapeutic application in 
reducing pulmonary and systemic inflammation [89, 107]. 
The aim of the present study, therefore, was to investigate the effect of oral 
administration of the PARP-1 inhibitor 1,7-dimethylxanthine in a mouse model 
with LPS-induced acute pulmonary and systemic inflammation. The anti-
inflammatory effects of 1,7-dimethylxanthine were compared to the orally 
administered synthetic PARP-1 inhibitor 3-aminobenzamide. Furthermore, we 
investigated the effect of 1,7-dimethylxanthine on cytokine release in ex vivo 
LPS-stimulated whole blood of COPD patients and healthy controls. 
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MATERIAL AND METHODS 
LPS-induced pulmonary inflammation in mice 
Animals 
Male C57BL/6 mice (12 weeks) were obtained from Charles River (Maastricht, 
The Netherlands). Animals were housed individually in standard laboratory 
cages and allowed food and water ad libitum during the experiments. The 
experiments were approved by the Ethics Committee for Animal Experiments of 
Maastricht University (Maastricht, The Netherlands). 
Experimental protocol 
On 4 consecutive days, mice (n=6/group) received the PARP-1 inhibitors via 
oral gavage (18 mg 1,7-dimethylxanthine or 13.6 mg 3-aminobenzamide/kg 
bodyweight/day). The daily administered doses of 1,7-dimethylxanthine and 
the PARP-1 inhibitor 3-aminobenzamide were equal to 100 µmol/kg body-
weight. In a previous in vitro study, we found that 1,7-dimethylxanthine 
showed a similar PARP-1 inhibiting activity as compared to the synthetic PARP-
1 inhibitor 3-aminobenzamide [107]. Prior to administration, each compound 
was freshly suspended in soy oil, which was also used as vehicle control (5 ml 
soy oil/kg bodyweight). At day 4, one hour after the final oral administration 
mice received LPS intratracheally. Intratracheal (IT) instillation technique was 
performed via a non-surgical procedure according to Vernooy et al [144]. Mice 
were anesthesized by subcutaneous injection with ketamin hydrochloride 
(Nimatek; Eurovet, Bladel, The Netherlands) and xylazine hydrochloride 
(Xylaject; Dopharma, Raamsdonksveer, The Netherlands). LPS (O55:B5, Sigma, 
Darmstadt, Germany), dissolved in 50 µL sterile 0.9% NaCl, was instilled 
intratracheally (20 µg/mouse) via a canule and syringe (2x 25 µl), followed by 
100 µl air. Sham-treated mice were instilled intratracheally with 50 µL sterile 
0.9% NaCl. After IT treatment, mice were kept in an upright position for 10 
minutes to allow the fluid to spread throughout the lungs. Mice were killed 4h 
and 24h after IT treatment while under pentobarbital (Nembutal, Ceva Sante 
Animale, Naaldwijck, The Netherlands) anesthesia. Blood was collected via 
heart puncture in EDTA-containing tubes, immediately centrifuged (2000xg, 10 
min, 4oC) and plasma was stored at -80ºC. Lungs were removed and lung tissue 
was snap-frozen for RNA-isolation and MPO analysis. For immunohistochemi-
cal analyses, lung tissue was inflated with 10% phosphate-buffered formalin 
(pH 7.4) through the trachea and subsequently fixed in formalin for 24 h after 
which it was further processed for immunohistochemical staining. 
Dose and time finding study 
Initial data were obtained using various time points (2-4-6-8-12-24-48-72-96h) 
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as well as various LPS concentrations (0-10-20-40 µg LPS), with MPO-activity 
in lung homogenates as primary parameter. These data revealed that the 
inflammatory response was starting to develop at 4h after LPS-treatment. At 24h 
after LPS-treatment (20 µg/mouse), the LPS-induced inflammatory processes 
reached maximum levels. Therefore, these time points were selected to investi-
gate whether oral administration of PARP-1 inhibitors might suppress early 
development of the inflammatory response as well as reduce its intensity. 
Myeloperoxidase (MPO)-analysis 
MPO activity in the dose and time finding study was measured in homogenates 
using a MPO activity assay kit (Cytostore, Calgary, Canada) according to the 
manufacturer’s instruction. Briefly, lung tissue was homogenized in hexadecyl-
tri-methylammonium bromide (HTAB)-buffer. Approximately 50 µl HTAB-
buffer was added to 1 mg of lung tissue. After centrifugation (10000xg, 2min, 
4ºC), lung homogenates were kept on ice and MPO-activity was determined 
according to the manufacturer’s protocol during 5 minutes at 450 nm. How-
ever, to exclude any interference of the applied compounds with the activity 
measurements, MPO protein levels were further determined quantitatively 
using a mouse MPO ELISA kit (HBT, Uden, The Netherlands) according to the 
manufacturer’s instruction. Prior to this analysis, snap-frozen lung tissue was 
ground to a powder in a stainless steel mortar under liquid nitrogen and 
homogenized in a lysis buffer containing 200 mM NaCl, 5 mM EDTA, 10 mM 
tris, 10% glycine, 1 mM PMSF, 1 µg/ml leupeptide and 28 µg/ml aprotinine (pH 
7.4). Approximately 20 µl lysisbuffer was added to 1 mg tissue. After centrifuga-
tion (10000xg, 15 min, 4ºC), lung homogenates were stored at -80ºC. Myelop-
eroxidase protein levels in lung tissue homogenate were quantitatively deter-
mined using the ELISA kit. The protein concentration was determined accord-
ing to the BCA method (Pierce, Rockford, IL, USA). The amount of MPO was 
expressed as ng MPO/mg protein. Measurement of MPO-activity in the dose 
and time finding study revealed that in addition to increased MPO-protein 
levels, MPO-activity was also increased after LPS-treatment (data not shown). 
Gene transcription analysis by quantitative PCR 
Snap-frozen lung tissue was ground to a powder in a stainless steel mortar 
under liquid nitrogen and homogenized in Trizol Reagent (Invitrogen, Carlsbad, 
CA, USA). Total RNA isolation was performed according to the manufacturer’s 
instructions. Concentration of the isolated total RNA was determined spectro-
photometrically at 260 and 280 nm. Reverse transcription reaction was per-
formed using 1 µg of total RNA and reverse-transcribed into cDNA using 
iScriptTM cDNA Synthesis Kit (Biorad Laboratories, Hercules, CA, USA). Subse-
quently, real time PCR was performed with a MyiQ Single Colour real time 
PCR detection system (BioRad) using SYBR© Green Supermix (Biorad), 5 µl 
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diluted (10x) cDNA, and 0.3 µM primers in a total volume of 25 µl. PCR was 
conducted as follows: denaturing at 95ºC for 3 min, followed by 40 cycles of 
95ºC for 15 seconds and 60ºC for 45 seconds. After the PCR procedure, a melt 
curve (60-95ºC) was produced for product identification and control of purity. 
β-Actin was included as an internal control gene, since the various treatments 
did not influence its gene-expression. rtPCR primers were designed using 
Primer express software (Applied Biosystems). Primer sequences used were as 
follows: 
TNF-α 5’-GACCCTCACACTCAGATCATCTTCT (forward) and 5’-CCACTTGGT 
GGTTTGCTACGA (reverse), IL-6 5’-ACAAGTCGGAGGCTTAATTACACAT 
(forward) and 5’-AATCAGAATTGCCATTGCACAA (reverse), MIP-2 5’-GAACAT 
CCAGAGCTTGAGTGTGA (forward) and 5’-CTTGAGAGTGGCTATGACTTCTG 
TC (reverse), MIP-1α 5’-ACTATTTTGAAACCAGCAGCCTTT (forward) and 5’-
GATCTGCCGGTTTCTCTTAGTCA (reverse), IκBα 5’-CGGAGGACGGAGACTC 
GTT (forward) and 5’-TTCACCTGACCAATGACTTCCA (reverse), IL-1β  5’-AAT 
CTATACCTGTCCTGTGTAATGAAAGAC (forward) and 5’-TGGGTATTGCTTG 
GGATCCA (reverse), β-Actin 5’-CGTGAAAAGATGACCCAGATCA (forward) 
and 5’-CACAGCCTGGATGGCTACGT (reverse). 
Data were analyzed using the MyiQ Software system (BioRad) and were 
expressed as relative gene expression (fold increase) using the 2−∆∆Ct method 
[129]. 
Immunohistochemical staining 
The presence of PAR-polymers was determined using immunohistochemical 
staining. Briefly, paraffin sections were deparaffinized and rehydrated. Endoge-
nous peroxidase was quenched with 0.3% hydrogen peroxidase. For antigen 
retrieval, sections were incubated with trypsin for 10 min at 37°C. After 
blocking the sections with 10% non fat dry milk for 10 min and 10% goat 
serum for 15 min, sections were incubated overnight with the primary poly-
clonal antibody to PAR (96-10-04, Alexis, Lausen, Switserland). Next, sections 
were incubated with a biotinylated goat anti-rabbit immunoglobulin (Dako, 
Glostrup, Denmark), followed by incubation with avidin-peroxidase (ABC-kit, 
Vectastain) for 30 min and 3,3’diaminobenzidine for 10 min. Sections were 
counterstained with hematoxylin, dehydrated and mounted with Entellan 
(Merck). Slides containing the stained lung section were encoded and at least 
200 epithelial cells were evaluated for the presence of PAR-polymers in their 
nuclei. 
Plasma serum amyloid p component (SAP) and IL-6 analysis 
Plasma SAP levels were determined using a quantitative ELISA-based test kit 
(Gentaur, Brussels, Belgium). Plasma IL-6 levels were determined using a 
Mouse IL-6 Immunoassay kit (R&D Systems, Minneapolis, USA). 
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Statistical analysis 
Results are reported as mean ± SEM. Statistical analyses were carried out using 
SPSS 14.0. Data appeared not normally distributed and were therefore evalu-
ated with non-parametric tests. The data of the LPS-treated mice at 4h and 24h 
after IT LPS-treatment compared to the NaCl-treated mice were evaluated using 
Mann-Whitney test. Furthermore, the effect of treatment with 1,7-dimethyl-
xanthine or 3-aminobenzamide on the LPS-induced changes of inflammatory 
markers and the efficiency between 1,7-dimethylxanthine and 3-aminobenza-
mide was evaluated using Kruskal-Wallis test followed by posthoc test of Siegel 
and Castellan [145]. Differences were considered to be statistically significant 
at P < 0.05. 
Ex vivo LPS-stimulated human whole blood 
Human whole blood assay 
The study protocol was approved by the Medical Ethics Committee for Clinical 
Experiments of Maastricht University (Maastricht, The Netherlands). Informed 
consent was obtained from all participants prior to inclusion. N=10 healthy 
volunteers and n=10 COPD patients were included in this study.  
COPD patients (GOLD stage: II-IV, FEV1: 43.8±3.8 %, FVC: 83.2±4.8 %, 
number of pack years: 22.9±4.8 y) were recruited from the Astmacenter 
Hornerheide in Haelen, The Netherlands, between August 2006 and December 
2006. The bronchodilatory medication of the COPD patients was restricted to 
the use of anticholinergics and beta-2 sympathomimetics. The use of theophyl-
line as well as inhaled corticosteroids was to be avoided for at least one week 
prior to the blood collection scheduled. 
Blood was collected after an overnight fast in heparin-containing vacutainer 
tubes and was kept on ice until further processing. Whole blood was aliquoted 
into 24-well sterile plates and diluted 1:4 with RPMI 1640 (supplemented with 
L-glutamine, Invitrogen). To induce cytokine production, LPS (O26:B6, Sigma) 
was added to the diluted whole blood at 1 ng/ml and thereafter the plates were 
incubated at 5% CO2 at 37°C for 16 h. A pilot study in which whole blood was 
incubated with LPS for various time points (8h-24h), indicated that TNF-α 
release reached maximal levels at 16h. Cell-free supernatants were collected 
after centrifugation (19000xg, 5 min) and stored at -20°C until cytokine analy-
ses. 1,7-Dimethylxanthine (Sigma) was added to the blood at a concentration of 
10 µM, 30 min before stimulation with LPS. All incubations were performed in 
triplicate. 
Human cytokine analysis 
TNF-α, IL-8 and IL-6 were quantified by means of PeliKine Compact human 
ELISA kits (CLB/Sanquin, The Netherlands). Assays were performed as de-
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scribed in the manufacturer’s instructions. The sensitivities for TNF-α, IL-8 and 
IL-6 were 1 pg/ml, 1 pg/ml and 0.2 pg/ml, respectively. 
Statistical Analysis 
Results are reported as mean ± SEM. Statistical analyses were carried out using 
SPSS 14.0. Data were not normally distributed and were therefore evaluated 
with non-parametric tests. To compare the baseline characteristics and the 
sensitivity in response to LPS between the COPD patients and healthy controls, 
the Mann-Whitney U test was used. The effect of 1,7-dimethylxanthine on the 
LPS-induced cytokine production was determined using Wilcoxon signed rank 
test. Two-tailed P values of 0.05 or less were considered statistically significant. 
RESULTS 
LPS-induced pulmonary inflammation in mice 
MPO-levels in lung tissue 
The amount of MPO protein in lung tissue homogenates was determined as a 
measure of neutrophil influx. At 4h after LPS-stimulation, no significantly 
increased amount of MPO was observed. MPO-levels were significantly 
increased at 24h after IT LPS-treatment. Treatment of the mice with 1,7-
dimethylxanthine significantly reduced MPO-levels at 24h. Significant reduc-
tions in MPO-levels at 24h after LPS-stimulation were also observed in mice 
pretreated with 3-aminobenzamide (Figure 1). 
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Figure 1. MPO-levels in lungs of IT LPS-treated C57BL/6 mice. Mice orally received 1,7-
dimethylxanthine (17X) and 3-aminobenzamide (3AB) for 4 consecutive days prior to the LPS-
challenge. MPO-levels were determined at 4h and 24h after LPS-treatment. MPO levels are 
expressed as ng MPO/mg protein and are mean ± SEM of 6 mice. 
++ P < 0.05 vs 24h NaCl-treated mice 
** P < 0.05 vs 24h LPS-treated mice without 17X or 3AB  
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Gene-transcription analysis in lung tissue 
Using qPCR, transcription of various inflammatory genes was evaluated. Since 
PARP-1 is involved in mediating the NF-κB and AP-1 regulated genes [11, 15, 
82], the effect of oral administration of 1,7-dimethylxanthine on these genes 
was evaluated by measuring transcription of IκBα, IL-1β, IL-6 and TNF-α. Gene 
transcription of the chemokines MIP-1α and MIP-2, that are produced by 
activated macrophages and that are also reported to be NF-κB dependent, was 
also determined. IT LPS-treatment increased gene-expression of IL-6, TNF-α, IL-
1β and IκBα, as well as of MIP-1α and MIP-2, at 4h and 24h (Figure 2).  
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Figure 2. Gene-transcription of IL-6, TNF-α, MIP-1α, MIP-2, IL-1β and IκBα in lungs of IT LPS 
treated C57BL/6 mice. Mice orally received 1,7-dimethylxanthine (17X) or 3-aminobenzamide 
(3AB) for 4 consecutive days prior to the LPS-challenge. Gene expression was determined 4h and 
24h after LPS-challenge and was analysed using qPCR and expressed as fold increase over control 
treatment (intratracheal instillation of NaCl) and are mean ± SEM of 6 mice. 
* P < 0.05 vs 4h LPS-treated mice without 17X or 3AB 
** P < 0.05 vs 24h LPS-treated mice without 17X or 3AB 
‡ P < 0.05 vs 4h LPS+3AB-treated mice 
‡‡ P < 0.05 vs 24h LPS+3AB-treated mice 
 
 
In mice treated with 1,7-dimethylxanthine TNF-α gene-transcription was 
significantly reduced at both 4h as well as 24h after IT LPS-treatment and IL-6 
gene transcription was significantly reduced at 24h after IT LPS treatment. In 
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the 1,7-dimethylxanthine treated mice, transcription of MIP-1α and MIP-2 was 
significantly reduced at 4h after LPS treatment. MIP-2 gene transcription was 
also reduced at 24h after LPS treatment in these mice. No effect of 1,7-
dimethylxanthine treatment on LPS-induced IL-1β transcription was observed. 
In the 3-aminobenzamide treated mice, IL-1β transcription was attenuated at 4h 
after LPS-treatment. 
Finally, transcription of IκBα was significantly reduced by 1,7-dimethylxanthine 
treatment at 4h after LPS-instillation and by 3-aminobenzamide treatment at 
24h after IT LPS-treatment. 
PAR-polymer formation in lung tissue 
To investigate whether intratracheal LPS-exposure resulted in pulmonary PARP-
1 activation, and whether oral administration of the PARP-1 inhibitor 1,7-
dimethylxanthine had a reducing effect on PAR-polymer formation, pulmonary 
epithelial cells were immunohistochemically evaluated for the presence of 
PAR-polymers in their nuclei. Intratracheal instillation of mice with LPS resulted 
in PARP-1 activation, as can be shown by formation of PAR-polymers in the 
epithelial cells.  
 
NaCl
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Figure 3. PAR-polymer formation in lungs of IT LPS-exposed C57BL/6 mice. PARP-1 activation was 
determined immunohistochemically 24h after LPS exposure. Magnification 400x. 
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At 4h after LPS-exposure, a small number of epithelial cells showed PAR-
polymers in the nuclei (data not shown). However, at 24h after LPS-exposure 
PARP-1 activation was apparent (Figure 3). A significant increase in the fre-
quency of PAR-positive nuclei was observed at 24h after LPS treatment. 
Furthermore, at 24h after LPS-exposure it was observed that lungs of LPS-
exposed mice contained infiltrated leukocytes, of which most were positive for 
the presence of PAR-polymers. Oral administration of 1,7-dimethylxanthine 
attenuated the frequency of PAR-polymer positive pulmonary epithelial cells at 
24h after LPS treatment, which was not observed for 3-aminobenzamide 
(Figure 4). Since the lungs of only 4 mice could be analysed, the effect of 1,7-
dimethylxanthine was not statistically significant. 
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Figure 4. Percentage PAR-polymer positive epithelial cells in lungs of IT LPS-treated C57BL/6 mice. 
Mice orally received 1,7-dimethylxanthine (17X) or 3-aminobenzamide (3AB) for 4 consecutive 
days prior to LPS-challenge. Data shown are mean + SEM of 4-6 mice per group and are based on 
at least 200 cells per animal. 
++ P < 0.05 vs 24h NaCl-treated mice 
Plasma SAP and IL-6 levels 
To investigate whether 1,7-dimethylxanthine treatment also reduced the 
systemic inflammatory response, plasma levels of the acute phase reactant SAP 
and cytokine IL-6 were measured. Plasma SAP levels were not increased at 4h 
after LPS-treatment, but at 24h after LPS-treatment, significantly increased SAP-
levels were observed. Treatment of the mice with 1,7-dimethylxanthine 
significantly reduced plasma SAP-levels (Figure 5). 3-Aminobenzamide treat-
ment did not significantly reduce plasma SAP-levels. 
Intratracheal instillation of mice with LPS significantly increased plasma IL-6 
levels both at 4h and 24h after treatment. At 24h, IL-6 levels were significantly 
attenuated following 1,7-dimethylxanthine treatment. Administration of 3-
aminobenzamide did not result in a significant change in plasma IL-6 levels 
(Figure 6). 
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Figure 5. SAP levels in plasma of IT LPS-treated C57BL/6 mice. Mice orally received 1,7-
dimethylxanthine (17X) or 3-aminobenzamide (3AB) for 4 consecutive days prior to the LPS-
challenge. Plasma SAP-levels are determined 24h after LPS-challenge and are expressed as µg/ml 
and are mean ± SEM of 6 mice. 
++ P < 0.05 vs 24h NaCl-treated mice 
** P < 0.05 vs 24h LPS-treated mice without 17X or 3AB  
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Figure 6. Plasma IL-6 levels 4h and 24h after IT LPS-treatment of C57BL/6 mice. Mice orally 
received 1,7-dimethylxanthine(17X) or 3-aminobenzamide (3AB) for 4 consecutive days prior to 
the LPS-challenge. Plasma IL-6 levels are expressed as pg/ml and are mean ± SEM of 6 mice. 
+ P < 0.05 vs 4h NaCl-treated mice 
++ P < 0.05 vs 24h NaCl-treated mice 
** P < 0.05 vs 24h LPS-treated mice without 17X or 3AB  
‡‡ P < 0.05 vs 24h LPS+3AB-treated mice 
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Ex vivo LPS-stimulated human whole blood 
Cytokine levels 
Characteristics and baseline blood parameters of both COPD patients as well as 
healthy controls are summarized in Table 1. Significant differences in the 
numbers of leukocytes and monocytes were observed between COPD patients 
and healthy controls, indicating the presence of systemic inflammation in 
COPD. 
 
Table 1 Subjects’ characteristics  
 Controls COPD 
N 10 10 
Gender 10 males 10 males 
Age (yrs) 65.3±1.5 64.7±2.5 
Body weight (kg) 75.6±1.6 74.3±5.8 
Height (m) 1.72±0.02 1.72±0.02 
BMI (kg/m2) 25.6±0.8 25.0±1.7 
Leukocytes (109/l) 5.67±0.43 9.12±1.16 * 
Lymphocytes (109/l) 1.85±0.15 2.26±0.28 
Monocytes (109/l) 0.47±0.06 0.9±0.13 * 
*p<0.05 compared to controls 
 
Stimulation of whole blood of both COPD patients and healthy controls with 
LPS significantly increased cytokine and chemokine levels. The LPS-induced 
increase in TNF-α, IL-6 and IL-8 levels was significantly higher in COPD 
patients as compared to healthy controls (Figure 7A). The differences in IL-6 
and IL-8 levels between COPD patients and healthy controls disappeared after 
adjusting for the number of leukocytes and monocytes. However, after adjust-
ing for the number of leukocytes TNF-α levels produced by blood cells of 
COPD patients were still higher than those of healthy controls (data not 
shown). In blood of COPD patients, 1,7-dimethylxanthine significantly reduced 
the LPS-induced TNF-α levels, whereas in blood of healthy subjects LPS-
induced IL-6 levels but not TNF-α levels were significantly reduced by 1,7-
dimethylxanthine (Figure 7B). 
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Figure 7 
A. LPS-induced increases in TNF-α, IL-6 and IL-8 levels in blood of COPD patients (n=10) and 
healthy controls (n=10). Plasma cytokine levels are expressed as pg/ml and are expressed as mean ± 
SEM of n=10 subjects. 
* P < 0.05 vs control subjects 
B. Effect of 1,7-dimethylxanthine on LPS-induced TNF-α, IL-6 and IL-8 levels production in blood of 
COPD patients (n=10) and healthy controls (n=10).Results are expressed as percentage, with 100% 
representing cytokine levels of LPS-stimulated blood, and are expressed as mean ± SEM of n=10 
subjects. 
* P < 0.05 vs LPS-stimulated blood 
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DISCUSSION 
Anti-inflammatory effects of 1,7-dimethylxanthine on LPS-induced inflam-
mation 
In the present study, oral administration of the PARP-1 inhibiting methyl-
xanthine 1,7-dimethylxanthine reduced markers of local and systemic inflam-
mation in a mouse model of LPS-induced acute pulmonary inflammation. 
Furthermore, 1,7-dimethylxanthine reduced the ex vivo LPS-stimulated TNF-α 
release in whole blood of COPD patients and IL-6 release in whole blood of 
healthy controls. 
Previously, it was demonstrated that the LPS-induced acute pulmonary inflam-
mation was significantly attenuated in PARP-1 knock-out mice [29]. In addi-
tion, it was also observed that the pharmaceutical PARP-1 inhibitor PJ34 
reduced levels of the cytokines TNF-α, MIP-1α and IL-6 and diminished MPO 
activity in broncheoalveolar lavage (BAL) fluid in LPS-challenged wild-type 
mice [29]. In various animal models of endotoxic shock, PARP-1 inhibition 
with 3-aminobenzamide was found to suppress pulmonary leukocyte recruit-
ment, expression of adhesion molecules such as ICAM-1 and pulmonary iNOS 
gene- and protein-expression [82, 157]. 
In the present study, IT LPS treatment significantly increased lung MPO-levels 
at 24h after treatment, which were significantly reduced in mice that received 
1,7-dimethylxanthine. MPO is abundantly present in intracellular granules of 
neutrophils and is released upon activation of neutrophils [158]. Therefore, 
pulmonary MPO-levels are considered to be an indication of neutrophil influx 
in the lungs. The observed reduction in levels of MPO indicated that 1,7-
dimethylxanthine decreased the neutrophil influx at 24 h after IT LPS-treatment.  
Furthermore, 1,7-dimethylxanthine significantly reduced transcription of MIP-
1α and IκBα (4h), IL-6 (24h) and TNF-α and MIP-2 (4h and 24h) after LPS-
treatment. From these data it can be concluded that administration of 1,7-
dimethylxanthine attenuated the NF-κB mediated gene-transcription during the 
early phase of the inflammatory response. At 24h after LPS treatment major 
reductions were still observed for both NF-κB and AP-1 mediated genes. In 
addition, the LPS-induced systemic inflammatory response was reduced by 1,7-
dimethylxanthine treatment, as indicated by reduced levels of the acute phase 
reactant SAP and the cytokine IL-6 at 24h after LPS-treatment. 
Anti-inflammatory efficacy of 1,7-dimethylxanthine as compared with 3-
aminobenzamide 
In this study, the effect of 1,7-dimethylxanthine on LPS-induced pulmonary 
inflammation was compared with the effects of the synthetic PARP-1 inhibitor 
3-aminobenzamide. 1,7-Dimethylxanthine and 3-aminobenzamide were 
administered at doses equal to 100 µmol/kg bodyweight for 4 consecutive days. 
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3-Aminobenzamide attenuated the LPS-induced increase in pulmonary MPO-
levels and gene transcription of IκBα and slightly reduced plasma IL-6 levels. It 
was observed that the anti-inflammatory effects of 1,7-dimethylxanthine were 
more pronounced when compared to the effects of 3-aminobenzamide, 
especially at 24h after LPS treatment.  
However, it should be noted that diverse mechanisms are likely to be responsi-
ble for the observed anti-inflammatory effects of the various compounds. In 
addition to the PARP-1 inhibiting effects which is the main characteristic of 3-
aminobenzamide, 1,7-dimethylxanthine has been reported to exert anti-
inflammatory effects via adenosine receptor antagonism and inhibition of 
phosphodiesterase 4 (PDE4) [159, 160]. 
The potential inhibiting effects of 1,7-dimethylxanthine on PARP-1 in the lungs 
were determined by immunohistochemical staining of the PAR-polymer in the 
pulmonary epithelial cells. Increased PAR-polymer formation was observed at 
24h after LPS-exposure, which was also consistent with the results of Liaudet et 
al. (2002) [29]. In addition, in the lungs of the LPS-exposed mice, many 
infiltrating leukocytes were also positive for the presence of PAR-polymers. In 
contrast to 1,7-dimethylxanthine which tended to attenuate the frequency of 
PAR-polymer positive cells at 24h, the PARP-1 inhibitor 3-aminobenzamide did 
not affect the PAR-polymer formation in lung epithelial cells.  
In the present study, 3-aminobenzamide was orally administered at a dose of 
13.6 mg/kg bodyweight for 4 consecutive days. In other studies similar or even 
lower concentrations of 3-aminobenzamide have been applied intravenously or 
intraperitoneally and clear effects were observed such as reduced airway 
inflammation in ovalbumin-sensitized mice, suppressed pulmonary leukocyte 
recruitment, expression of ICAM-1 and reduced pulmonary iNOS gene- and 
protein-expression in LPS-induced endotoxic shock in rabbits, or reduced 
neutrophil accumulation in zymosan-induced peritonitis in mice [26, 80, 82, 
161]. In most of these studies, anti-inflammatory effects were measured at a 
short period (2-6h) after exposure to the inflammatory stimulus, in contrast to 
the time point of 24h after LPS-exposure in the present study. Furthermore, 3-
aminobenzamide was administered intravenously or intraperitoneally in those 
studies. Since, the half life of 3-aminobenzamide was reported to be 90 min 
[162], the absence of clear PARP-inhibiting effects of 3-aminobenzamide at 
24h in the present study may be explained by a low oral availability and 
rapidly decreasing tissue concentrations. 
The ex vivo anti-inflammatory effects of 1,7-dimethylxanthine 
In the ex vivo model, whole blood of COPD patients and healthy controls was 
stimulated with LPS after pretreatment with 1,7-dimethylxanthine. Differences 
in sensitivity in response to LPS were observed between the COPD patients and 
healthy controls. The observed higher numbers of leukocytes and monocytes in 
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COPD patients very likely explained the higher response to LPS. However, 
differences in TNF-α levels between COPD patients and healthy controls were 
still observed after adjusting for the number of leukocytes (data not shown). For 
1,7-dimethylxanthine a clear attenuating effect on the ex vivo LPS-stimulated 
production of TNF-α was found for COPD patients and not for healthy controls, 
indicating that 1,7 dimethylxanthine may especially be effective under condi-
tions of systemic inflammation. The cytokine TNF-α is considered to contribute 
importantly to the pathogenesis of COPD. A study by Keatings et al. showed 
that the levels of TNF-α in sputum were significantly higher in patients with 
COPD compared with both smokers and nonsmokers, suggesting that increased 
levels of TNF-α were related to COPD [163]. Although synthetic TNF-α block-
ers, such as infliximab, were proven to be efficient therapeutic agents in various 
inflammatory diseases such as rheumatoid arthritis [164, 165], it was recently 
shown that subjects with moderate to severe COPD did not benefit from 
treatment with infliximab [49, 50]. Therefore the need for more effective anti-
inflammatory treatments still exists. Moreover, it should be noted that PARP-1 
inhibitors act via different mechanisms than synthetic TNF-α blockers such as 
infliximab that bind with high affinity to TNF-α and block its biological activity. 
PARP-1 has been reported to modulate the transcriptional level of TNF-α and 
other inflammatory mediators [11, 20]. 
Differences between human and murine caffeine metabolism 
In this study, the caffeine metabolite 1,7-dimethylxanthine was applied in both 
an in vivo and an ex vivo model of LPS-induced inflammation. In humans, 
caffeine is readily absorbed and metabolized in the liver by the hepatic enzyme 
cytochrome P4501A2 (CYP1A2) to its major metabolites 1,7-dimethylxanthine 
(paraxanthine), theophylline (1,3-dimethylxanthine) and theobromine (3,7-
dimethylxanthine). N-3 demethylation is the major pathway in humans result-
ing in the predominant formation of 1,7-dimethylxanthine. Lelo et al (1986) 
reported that 1,7-dimethylxanthine accounts for 67.3% of total dimethylxanthi-
nes in plasma after oral caffeine intake, while theobromine and theophylline 
account for 24.4% and 8.3% respectively [166]. Plasma 1,7-dimethylxanthine 
levels of 20 µM have been reported after the intake of coffee, which indicates 
that the concentrations used in the present study were physiologically relevant 
levels [66]. Also in mice, caffeine clearance depends largely on activity of 
CYP1A2 [167]. However, 1,7-dimethylxanthine is not the major metabolite of 
caffeine found in blood of mice, since the N-1, N-3 and N-7 demethylation 
pathways are equally important for metabolizing caffeine in mice, resulting in 
the formation of equivalent amounts of theobromine, 1,7-dimethylxanthine and 
theophylline in mice [168]. Altogether, it is therefore considered likely that 
administration of caffeine to humans is able to exert anti-inflammatory effects 
via its metabolites. 
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Conclusion 
Based on the results of the present study it can be concluded that oral admini-
stration of PARP-1 inhibiting methylxanthines such as 1,7-dimethylxanthine is 
efficacious in reducing local and systemic inflammation in a mouse model of 
LPS-induced acute pulmonary inflammation. Furthermore, 1,7-dimethyl-
xanthine efficiently reduced the ex vivo LPS-induced TNF-α production in 
blood of COPD patients at a physiological relevant concentration. The results 
of this study indicate that the application of the PARP-1 inhibiting caffeine 
metabolite 1,7-dimethylxanthine might be a promising extension to the cur-
rently available therapeutics in the treatment of inflammatory diseases such as 
COPD. 
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General Discussion 
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GENERAL DISCUSSION 
The hypothesis of the PhD research described in this thesis was that dietary 
mild PARP-1 inhibitors are able to attenuate NF-κB mediated gene-expression 
and therefore may be applied as anti-inflammatory treatment in inflammatory 
diseases such as COPD. These inhibitors can be potential ingredients for 
medicinal foods and nutraceuticals. The screening process of identifying dietary 
inhibitors of the nuclear enzyme PARP-1 was an important part of this project 
and is described in chapter 2, 3 and 4. Furthermore, the potential application 
of these compounds as anti-inflammatory agents was also evaluated and 
described in chapters 5 and 6 of this thesis. 
In this final chapter a general discussion is presented: 
-  the main findings will be summarized and discussed 
-  a benefit risk evaluation of food-derived PARP-1 inhibitors will be 
presented together with potential implications and suggestions for fur-
ther evaluation 
-  the conclusions of the study described in this thesis will be presented 
MAIN FINDINGS 
Identification of PARP-1 inhibiting dietary compounds 
In order to identify potential dietary mild PARP-1 inhibitors, we started screen-
ing various compounds for their PARP-1 inhibiting activity with an enzyme-
based ELISA method using the purified human recombinant PARP-1 enzyme. 
With this assay, we could relatively easy and efficiently test various com-
pounds, but also compare them to the classical PARP-1 inhibitor 3-amino-
benzamide. In a next step, the PARP-1 inhibiting compounds were further 
evaluated in cultured lung epithelial and vascular endothelial cells exposed to 
hydrogen peroxide (H2O2) or N-methyl-N’-nitro-N-nitroso-guanidine (MNNG), 
as inducers of DNA strand breaks and PARP-1 over-activation. PARP-activation 
was measured as a decrease in intracellular NAD+ levels and as PAR-polymer 
formation. Although PAR-polymers are known to be very rapidly degraded, 
measurement of the PAR-polymer formation after a short incubation period of 
5-10 min can be used to indicate PARP-1 activation. In combination with the 
determination of intracellular NAD+ levels, this provides a reliable assessment 
of the extent of PARP-1 activation or inhibition. 
After an initial screening of a variety of compounds including chlorogenic acid, 
resveratrol and folic acid, two groups of dietary compounds were selected for 
further in vitro screening processes: 1) methylxanthines and 2) flavonoids. 
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Methylxanthines as PARP-1 inhibitors 
In chapter 2, we described the research on the PARP-1 inhibiting activity of 
methylxanthines. 1,7-Dimethylxanthine (the major metabolite of caffeine in 
humans) was found to inhibit the purified PARP-1 enzyme with high efficacy. 
Also other methylxanthines such as theophylline, theobromine, 1-methyl-
xanthine and 3-methylxanthine were found to inhibit PARP-1. Furthermore, it 
was observed that oxidative stress-induced depletion of intracellular NAD+-
levels and PAR-polymer formation in cultured pulmonary epithelial cells as 
well as vascular endothelial cells was most efficiently prevented by 1,7-
dimethylxanthine. Since PARP-1 has been implicated in necrotic cell death 
[86], the effect of PARP-1 inhibitors on oxidative-stress induced necrosis was 
subsequently investigated. Since cell death processes may influence the cellular 
energy levels in a specific way, variations in the ADP:ATP ratio are used to 
distinguish between the different modes of cell death. ADP:ATP ratios for cells 
undergoing apoptosis are expected to be higher than control values but below 
1, while values above 1 characterize necrotic cells [95]. By measuring this 
ratio, it was found that oxidative stress-induced necrotic cell death was reduced 
and shifted to apoptotic cell-death processes in presence of 1,7-dimethyl-
xanthine in pulmonary epithelial and vascular endothelial cells respectively. 
Flavonoids: PARP-1 inhibiting and anti-inflammatory activity 
In chapter 3 we described the screening of flavonoids for their potential PARP-
1 inhibiting activity. Especially, the flavonoids fisetin, tricetin and quercetin 
were found to inhibit the purified enzyme as well as to prevent the MNNG-
induced depletion of intracellular NAD+-levels and formation of PAR-polymers 
in pulmonary epithelial cells. In a final series of in vitro experiments described 
in this chapter, the influence of PARP-1 inhibition on the NF-κB mediated gene 
expression was evaluated. Since PARP-1 acts as a co-activator of NF-κB and the 
poly(ADP-ribosyl)ation process promotes the accessibility of genes for the 
transcription machinery and increases gene-transcription [14, 17], the potential 
anti-inflammatory effect of dietary PARP-1 inhibiting compounds was investi-
gated. We used an in vitro model in which the production and gene-
transcription of the cytokine IL-8 was determined in LPS-stimulated cultured 
pulmonary epithelial cells pretreated with the various PARP-1 inhibiting 
compounds. Although IL-8 is considered to be an important cytokine in 
inflammatory diseases such as COPD, also other cytokines are involved. These 
cytokines were measured in the ex vivo assay as described in chapter 6 and in 
an ex vivo study in which the anti-inflammatory effects of flavonoids were 
investigated [169]. 
At present, there is still much controversy about the exact role of PARP-1 in NF-
κB mediated gene-expression. It has been suggested that solely the PARP-1 
protein and not its activity is important in facilitating the acetylation of the p65 
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subunit of NF-κB, which is required for full activation of NF-κB [16, 18]. 
Conversely, others reported that the synthesis of PAR-polymers facilitated the 
transcriptional activation properties of NF-κB, probably via chromatin relaxa-
tion and recruitment of other proteins of the transcription complex [14, 19]. 
Nonetheless, several studies indicated the attenuating activity of various 
synthetic PARP-1 inhibitors on the NF-κB mediated gene-expression [20, 21]. 
In the study presented in chapter 3, the LPS-induced NF-κB mediated produc-
tion of IL-8 in pulmonary epithelial cells was found to be reduced by the 
flavonoids fisetin, tricetin and quercetin. Furthermore, the synthetic PARP-1 
inhibitor PJ34 showed a comparable anti-inflammatory activity. 
The in vitro anti-inflammatory effects of the PARP-1 inhibiting flavonoid flavone 
were described in chapter 4. Flavone inhibited the purified PARP-1 enzyme 
and also prevented the MNNG-induced depletion of intracellular NAD+-levels 
and formation of the PAR-polymers. Furthermore, flavone was found to attenu-
ate the LPS-induced production and transcription of the NF-κB mediated 
cytokine IL-8. Also, a significant increased gene transcription of IκBα, the 
inhibiting protein of NF-κB, was observed in the flavone-pretreated cells after 
LPS-stimulation. This may indicate an enhancement of feed-back pathways, 
leading to a resolution of the inflammatory response. Finally, flavone did not 
show any relevant radical scavenging activity, as determined with ESR spec-
troscopy and the TEAC assay. This implies that the observed anti-inflammatory 
effects of flavone could not be explained by antioxidant properties.  
In the LPS-stimulated pulmonary epithelial cells no nuclear translocation of NF-
κB could be detected, which made it difficult to elucidate the potential in-
volvement of NF-κB-related mechanisms in the observed reduction in IL-8 
gene-expression after treatment with flavone. The AP-1 pathway could also be 
involved, though the possible anti-inflammatory effect of PARP-1 inhibitors on 
this pathway, for instance by inhibition of MAPK activity was not further tested. 
It was decided to focus on potential effects of PARP-1 inhibitors on the NF-κB 
mediated gene-expression. Recently, the mechanism of the anti-inflammatory 
effects of the flavonoid fisetin was extensively investigated using various cell 
lines such as human lung adenocarcinoma cells and human fibroblasts. Fisetin 
was found to suppress NF-κB activation. By inhibiting activation of IKK, fisetin 
blocked the phosphorylation and degradation of IκB and subsequently induced 
suppression of the nuclear translocation of p65 subunit [147]. However, since 
no nuclear translocation of NF-κB could be detected in our in vitro model, we 
were unable to evaluate the contribution of this potential mechanism in 
pulmonary epithelial cells. 
Structure-activity requirements of PARP-1 inhibiting flavonoids 
This distinctive flavonoid compound flavone was identified as PARP-1 inhibitor 
and anti-inflammatory compound, which was rather unexpected since flavone 
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has a flavonoid structure without any hydroxyl groups. For flavonoids in 
general, it was previously shown that their antioxidant effects and various 
enzyme inhibiting effects are largely dependent on their hydroxylation pattern 
[58, 59, 170]. As mentioned in chapter 3, general structural characteristics of 
competitive synthetic PARP-1 inhibitors include a carboxamide-group attached 
to an aromatic ring or the carbamoyl group built in a polyaromatic heterocyclic 
skeleton. However, this is not characteristic of flavone or flavonoids in general. 
This implies that flavonoids and/or flavone may be considered to reflect a 
group of compounds with structural characteristics that enable them to interact 
with the catalytic site of PARP-1. Since a mix of competitive and non-
competitive inhibition of the PARP-1 enzyme was observed, interaction of 
flavonoids with other sites of the PARP-1 enzyme that may affect its catalytic 
activity, such as the automodification site, cannot be excluded. 
Many different structures were screened for their PARP-1 inhibiting activity. 
Nevertheless, based on our results no specific statement about a possible 
structure-activity relationship for PARP1 inhibiting activity of flavonoids can be 
given. 
Evaluation of PARP-1 inhibition in vivo 
Based on the results of our in vitro studies described in chapters 2, 3 and 4, 
four compounds were selected for further in vivo mouse and ex vivo human 
evaluation: the flavonoids 1) flavone, 2) fisetin and 3) tricetin and the methylx-
anthine 4) 1,7-dimethylxanthine. 
In chapter 5 the in vivo application of the flavonoids flavone, fisetin and 
tricetin in a mouse model of LPS-induced acute pulmonary inflammation was 
described. Based on MPO-analysis in a dose- and time-finding study, 2 time 
points after LPS-exposure, 4h and 24h, were chosen to investigate whether oral 
administration of PARP-1 inhibitors might suppress early development of the 
inflammatory response as well as reduce its intensity. The flavonoid fisetin 
significantly reduced lung MPO-levels and gene-expression of inflammatory 
mediators such as IL-6, TNF-α, IL-1β, MIP-1α and MIP-2 at 24h after LPS-
stimulation. The LPS-induced gene transcription of the HO-1 and SOD2 genes 
was also significantly reduced by fisetin, indicating less oxidative stress was 
induced in mice that received fisetin. Flavone and tricetin also showed attenua-
tion of inflammatory markers, although most consistent effects were observed 
for fisetin. Furthermore, fisetin was found to have a higher efficacy in reducing 
pulmonary inflammation as compared to the well-established anti-
inflammatory glucocorticoid dexamethasone. Dexamethasone was able to 
efficiently reduce systemic but not pulmonary inflammation in this in vivo 
mouse model. Finally, oral administration of fisetin as well as dexamethasone 
was found to attenuate the number of PAR-polymer positive pulmonary 
epithelial cells. 
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In chapter 6 we described the results of the in vivo application of the PARP-1 
inhibitor 1,7-dimethylxanthine in a mouse model of LPS-induced acute pulmo-
nary inflammation. 1,7-Dimethylxanthine significantly attenuated both pulmo-
nary as well as systemic inflammation which was indicated by reduced pulmo-
nary MPO-levels, attenuated gene transcription of the pro-inflammatory 
cytokines IL-6, TNF-α, MIP-1α and MIP-2 in lungs and reduced plasma levels of 
SAP and IL-6 at 24h. The anti-inflammatory effects of 1,7-dimethylxanthine 
were more pronounced when compared to the synthetic PARP-1 inhibitor 3-
aminobenzamide. 3-Aminobenzamide also failed to attenuate the LPS-induced 
increase in the number of PAR-polymer positive pulmonary epithelial cells. The 
reported short half-life of 3-aminobenzamide [162] and a poor oral availability 
are probably responsible for the lack of clear effects at 24h after LPS treatment. 
The ex vivo anti-inflammatory effects of 1,7-dimethylxanthine in LPS-stimulated 
blood of COPD patients and healthy controls were also assessed and described 
in chapter 6. In this ex vivo model, 1,7-dimethylxanthine significantly sup-
pressed the LPS-induced production of the cytokines IL-6 and TNF-α at physio-
logically relevant levels that can be reached after consumption of 2 cups of 
coffee. 
Finally, it should be noted that inhibition of PARP-1 is probably not the sole 
mechanism responsible for the observed anti-inflammatory effects of the 
various compounds. In addition to the PARP-1 inhibiting effects which is the 
main characteristic of 3-aminobenzamide, 1,7-dimethylxanthine has been 
reported to exert anti-inflammatory effects via adenosine receptor antagonism 
and inhibition of phosphodiesterase 4 (PDE4) [159, 160]. Flavonoids, such as 
fisetin, have been reported to modulate signal transduction pathways, including 
MAPK [60]. Moreover, dexamethasone is not acting via PARP-inhibition, but by 
binding to the cytoplasmatic glucocorticoid receptor. Subsequent nuclear 
localization of this complex controls transcription of multiple inflammatory 
genes encoding cytokines, chemokines, adhesion molecules and inflammatory 
enzymes such as iNOS [171]. So, various mechanisms are likely to be respon-
sible for the observed anti-inflammatory effects. 
DISCUSSION 
Several aspects of the potential application of food-derived PARP-1 inhibiting 
flavonoids and methylxanthines as described in the current thesis require 
further discussion. Therefore, the following issues will be discussed in more 
detail in this paragraph: 
- Possible adverse effects of PARP-1 inhibition in general 
- Benefit risk considerations of flavonoids and methylxanthines 
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Possible adverse effects of the use of PARP-1 inhibitors 
As indicated in chapter 1, PARP-1 has a facilitating role in DNA repair and it 
has been suggested that PARP-1 inhibition might interfere with this repair-
facilitating function. However, the importance of the DNA-repair facilitating 
function of PARP-1 in normal cellular physiology is still not clear. The sugges-
tions that PARP-1 inhibition has some important side-effects on DNA-repair 
were based mainly on studies with PARP-1 knockout cells and mice [5, 172]. 
PARP-1 knockout mice were found to be hypersensitive to alkylating agents or 
ionising radiation [5, 172]. Using these knockout models, no difference can be 
made between the physical absence of the enzyme and a reduced catalytic 
activity. Recently, evidence was presented that PARP-1 has probably a rela-
tively minor role in DNA repair pathways in animals with functional PARP-1 
under conditions of increased oxidative stress. This was supported by a study of 
Hauser et al (2006) in which the potent PARP-1 inhibitor INO-1001 was 
applied in a porcine model of thoracic aortic cross-clamping. No increased 
DNA damage or adverse effect on DNA repair was observed after treatment 
with INO-1001 [120]. PARP-1 has also been reported to be involved in telo-
mere stability, and maintenance of telomere length. In humans, telomere length 
is considered an indicator of the biological age, and telomere attrition is 
associated with a shorter life expectancy in population groups with a high risk 
for cardiovascular diseases [173]. PARP-1 knock-out mice were found to have 
shorter telomeres than wild-type mice [174]. The importance of PARP-1 in 
maintaining genomic integrity, which is required for functional cells and 
organs, is also indicated by the positive correlation between cellular poly(ADP-
ribosyl)ation capacity and mammalian lifespan [175]. However, the exact 
consequences of PARP-1 inhibition for telomere stability need to be deter-
mined. 
Benefit risk considerations of flavonoids 
The effects of flavonoids observed on LPS-induced inflammatory response in 
the studies described in the current thesis are most likely the result of combina-
tion of several effects such as PARP-1 inhibition, antioxidant and anti-
inflammatory effects. Since flavonoids are extensively metabolized in intestine 
and liver in vivo, resulting in conjugation with glucuronides, sulfates and in 
methylation, the PARP-1 inhibiting activity of these metabolites should also be 
evaluated. 
Besides the positive health effects of flavonoids such as reduced risk for 
cardiovascular and chronic inflammatory diseases as mentioned in chapter 1 
[51, 57], some toxic effects of flavonoids have also been reported. As a conse-
quence of their antioxidant activities, flavonoids become oxidized into different 
oxidation products, which can react with cellular constituents such as proteins, 
DNA and lipids. Flavonoids have been identified to antagonize DNA topoi-
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somerases, which can lead to mutagenesis and chromosomal aberrations [176-
178]. 
No studies are available to date, however, that evaluate the potential health 
effects of long-term use of dietary supplements or functional foods with high 
concentrations of flavonoids. Whether long-term supplementation of the 
flavonoids fisetin, tricetin and flavone, in people suffering a chronic inflamma-
tory disease is associated with a high risk for serious side-effects, needs to be 
carefully evaluated. 
Benefit risk considerations of methylxanthines 
Coffee is nowadays the most important source of methylxanthines, such as 
caffeine. Coffee is a complex chemical mixture containing more than a thou-
sand different chemicals, including carbohydrates, lipids, nitrogenous com-
pounds, vitamins, minerals, phenolic compounds, and alkaloids such as the 
methylxanthine caffeine. Various studies have been conducted to evaluate 
health effects of long-term intake of coffee. Based on observational, epidemio-
logical studies, coffee intake in humans has been associated with various health 
effects, both beneficial as well as adverse effects [179]. In the past, concerns 
about potential health risks of coffee and caffeine intake were likely to be 
influenced by associations between high coffee intake and unhealthy behaviour 
such as cigarette smoking and physical inactivity. More recently, coffee 
consumption and caffeine intake has been associated with a reduced risk for 
various chronic metabolic disorders, such as type 2 diabetes mellitus and liver 
cirrhosis, but also neurological disorders such as Parkinson’s disease [103, 180, 
181]. Although coffee consumption is associated with increases in risk factors 
for cardiovascular diseases including blood pressure and plasma homocysteine 
levels, most studies have not found coffee consumption to be associated with 
significantly increased cardiovascular risk [182]. According to the World 
Cancer Research Fund, it is not expected that coffee has any significant effect 
on the risk of pancreatic or kidney cancer [183]. This would suggest that 
chronic use of beverages with a high concentration PARP-1 inhibitor is not 
associated with a high cancer risk. Previously, emphasis was put on the 
teratogenic effect of caffeine in rodents. Based on epidemiological studies it 
was subsequently concluded that caffeine does not present any teratogenic risk 
in humans [184]. However, a recent published study showed a positive cor-
relation between high doses of caffeine intake during pregnancy and the risk of 
a miscarriage [185]. Chronic caffeine intake to increase levels of 1,7-
dimethylxanthine should therefore be discouraged for specific groups like 
pregnant women, but it might have beneficial effects in patients with chronic 
inflammatory diseases such as COPD. 
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IMPLICATIONS AND SUGGESTIONS 
The research described in this thesis indicates that both in vivo administration 
of, as well as in vitro and ex vivo incubation with, dietary PARP-1 inhibitors 
such as fisetin and 1,7-dimethylxanthine exert anti-inflammatory effects. This 
needs to be further evaluated in an intervention study with humans suffering 
from an inflammatory disease such as COPD. The mouse model for acute LPS-
induced pulmonary inflammation allowed us not only to evaluate local pul-
monary effects, but also systemic anti-inflammatory effects of orally adminis-
tered PARP-1 inhibitors under standardized conditions. Although the applied in 
vivo mouse model was a model of acute inflammation, the relevance for more 
chronic situations might therefore be debatable. The combined results of the in 
vivo animal study and of the ex vivo study of blood of COPD patients and 
healthy controls however suggest that these compounds might have potential 
anti-inflammatory effects in COPD patients. It should be noted here that in 
addition to the ex vivo evaluation of 1,7-dimethylxantine as described in 
chapter 6, the anti-inflammatory effects of the flavonoids fisetin, tricetin and 
flavone were also ex vivo evaluated. Both fisetin and tricetin significantly 
decreased the LPS-induced production of TNF-α in blood of COPD patients 
[169]. 
To confirm our results and to investigate the potential beneficial effects on 
clinical parameters and quality of life of COPD patients, supplementation with 
these compounds as nutraceuticals or with medicinal foods needs to be 
evaluated in this patient group. For flavonoids, it should be noted that the 
dietary matrix in which these compounds are administered can significantly 
influence the expected results. In the in vivo animal study, the flavonoids were 
suspended in soy oil, which is known to increase the bioavailability of these 
compounds [143]. For the flavonoid tricetin it was found that this compound is 
not stabile in aqueous medium, since it is degraded into oxidation products 
within 45 min (unpublished data). Furthermore, the form of flavonoids (agly-
cone or flavonoid glycosides) can have an important effect on the bioavailabil-
ity of these compounds. In addition, in order to achieve relatively higher 
plasma flavonoid levels, it is necessary to use food enriched with flavonoids, 
since these cannot be reached with a normal diet. 
Another issue which requires to be discussed is that in order to improve health 
status of patients suffering a chronic inflammatory disease such as COPD, long 
term use of supplements is needed. There are no data available about chronic 
use of flavonoids such as fisetin in patients suffering a chronic disease such as 
COPD. The long term effects of these compounds should also be examined to 
evaluate the safety of chronic supplementation in this patient group. 
CHAPTER 7 
 114 
CONCLUSIONS 
Based on the results presented in this thesis, it can be concluded that dietary 
PARP-1 inhibitors such as 1,7-dimethylxanthine and fisetin are able to attenu-
ate NF-κB mediated gene-expression and exert anti-inflammatory effects, both 
in vitro as well as in vivo in the mouse and ex vivo in human blood. Based on 
these effects, they are considered potential candidates for nutraceutical treat-
ment of inflammatory diseases such as COPD. 
Up to now, no successful treatment for COPD, in particular treatment for the 
local and systemic inflammation in COPD, has been developed yet. Dietary 
mild PARP-1 inhibitors such as 1,7-dimethylxanthine or fisetin might be 
applied as supplements, in order to reduce both pulmonary as well as systemic 
inflammation and improve quality of life of COPD patients. 
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Dit proefschrift beschrijft de in vitro identificatie, de in vitro en ex vivo evaluatie 
en de in vivo toepassing van voedingscomponenten met een milde remmende 
activiteit van het enzym poly(ADP-ribose) polymerase-1 (PARP-1). 
De hypothese van het in dit proefschrift beschreven onderzoek is dat milde 
PARP-1 remmers afkomstig uit de voeding gunstige effecten kunnen hebben bij 
inflammatoire aandoeningen zoals chronisch obstructief longlijden (COPD). 
Het onderliggende mechanisme is gebaseerd op het remmen van genexpressie 
die gemedieerd wordt door de transcriptiefactor NF-κB. Hierbij speelt PARP-1 
een rol als co-activator. Door deze co-activatie te verminderen zou de 
inflammatoire respons geremd worden. Deze voedingscomponenten zouden 
mogelijk toegepast kunnen worden als ingrediënten van functional foods of 
nutraceuticals voor patiënten met inflammatoire aandoeningen. 
 
 
Alvorens de belangrijkste bevindingen te beschrijven dienen een aantal begrippen en processen 
nader uitgelegd te worden: 
- Genexpressie is het proces waarbij de erfelijke informatie van een gen dat in het DNA 
opgesloten is vertaald wordt in een genproduct. Dit product kan een eiwit zoals een 
cytokine (signaalstof) zijn. 
- Een transcriptiefactor is een eiwit dat bindt aan specifieke delen van het DNA en onderdeel 
uitmaakt van het genexpressie-syteem dat het aflezen van de erfelijke informatie van het 
DNA controleert. NF-κB is zo’n transcriptiefactor en medieert de expressie van vele genen 
zoals de cytokines TNF-α of IL-8. 
- Een co-activator is een eiwit dat de genexpressie verhoogd door interactie met een 
transcriptiefactor. 
- Chronisch obstructief longlijden of COPD (de verzamelnaam voor chronische bronchitis en 
longemfyseem) is een aandoening aan de luchtwegen en longen, die zich vaak pas op latere 
leeftijd openbaart. Hierbij worden de luchtwegen vernauwd door een langdurige ontsteking 
(longinflammatie) en de longen beschadigd waardoor een grotendeels onomkeerbare 
verslechtering van de longfunctie ontstaat. Roken wordt gezien als de belangrijkste 
risicofactor voor het ontstaan van COPD. Naast een steeds verdergaande verminderde 
longfunctie wordt deze aandoening ook gekenmerkt door extrapulmonale effecten, ook wel 
systemische effecten genoemd (effecten in de weefsels en organen buiten de longen). Deze 
systemische effecten dragen bij aan de ernst van het ziektebeeld en kunnen de kwaliteit van 
leven ernstig schaden. 
- Poly(ADP-ribose) polymerase-1 (PARP-1) is een enzym dat aanvankelijk bekend was 
vanwege de facilitaire rol in herstel van DNA schade. Momenteel wordt steeds duidelijker 
dat PARP-1 beschouwd kan worden als een belangrijke co-activator van de transcriptie 
factor NF-κB. Door te binden aan het NF-κB transcriptie complex, beïnvloedt PARP-1 de 
NF-κB gemedieerde genexpressie. Remming van PARP-1 zou mogelijk deze genexpressie 
kunnen verminderen waardoor inflammatieprocessen gereduceerd kunnen worden. Recent 
is bij COPD patiënten naast longinflammatie en systemische inflammatie, een verhoogde 
systemische PARP-1 activiteit aangetoond in witte bloedcellen. Mogelijk zou milde PARP-1 
remming middels voedingscomponenten een positieve bijdrage kunnen leveren aan het 
verminderen van de inflammatoire respons  bij COPD patiënten. 
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De in vitro studies (hoofdstukken 2, 3 en 4) laten zien dat diverse 
voedingscomponenten in staat zijn om het enzym PARP-1 te remmen. 
Cafeïnemetabolieten zoals 1,7-dimethylxanthine, en in mindere mate 
theofylline en theobromine (afbraakproducten van cafeïne die in het lichaam 
gevormd kunnen worden na consumptie van cafeïne of cafeïne bevattende 
producten zoals koffie en chocolade) zijn uitstekende kandidaten. Ook 
flavonoïden zoals fisetine, tricetine, quercetine en flavone, die vooral 
voorkomen in appels, druiven, uien, ginkgo biloba, haver en dille, zijn in staat 
om PARP-1 te remmen. Niet alleen remming van het zuivere geïsoleerde 
enzym, maar ook enzymremming in humane longepitheelcellen en vasculaire 
endotheelcellen zijn kenmerkend voor deze componenten. Daarnaast 
vermindert 1,7-dimethylxanthine in vitro de door oxidative stress geïnduceerde 
celnecrose in humane vasculaire endotheelcellen en verschuift het 
celdoodproces in pulmonaire epitheelcellen naar apoptose. Omdat celnecrose 
ook leidt tot inflammatie, wordt een verschuiving van het celdoodproces naar 
apoptose als gunstig gezien. De flavonoïden fisetine, tricetine, quercetine en 
flavone verminderen in vitro de LPS-geïnduceerde inflammatoire respons in 
longepitheelcellen. Tot slot verlaagt de flavonoïd flavone in vitro de LPS-
geïnduceerde NF-κB gemedieerde transcriptie en productie van IL-8 en 
verhoogt het de transcriptie van IκBα. Op basis van deze resultaten wordt een 
indirect effect, zoals een effect op de co-activator functie van PARP-1, het 
meest waarschijnlijk geacht. 
De geselecteerde componenten 1,7-dimethylxanthine, fisetine, tricetine en 
flavone laten niet alleen in vitro veelbelovende resultaten zien, maar ook uit de 
in vivo en ex vivo studies (hoofdstukken 5 en 6) blijkt dat deze componenten 
mogelijkheden bieden voor mogelijke toepassingen bij de mens. De 
muizenstudies beschreven in dit proefschrift laten zien dat zowel 1,7-
dimethylxanthine als fisetine de LPS-geïnduceeerde acute longinflammatie als 
ook de systemische inflammatie bij muizen kunnen verminderen. Op basis van 
de resultaten die beschreven zijn in dit proefschrift, kan geconcludeerd worden 
dat PARP-1 remmers afkomstig uit de voeding, zoals 1,7-dimethylxanthine en 
fisetine in staat zijn om de NF-κB gemedieerde genexpressie te verminderen. 
Op die manier laten ze anti-inflammatoire effecten zien, zowel in vitro, als ook 
in vivo in de muis. Wanneer in witte bloedcellen van COPD patiënten ex vivo 
met LPS een inflammatoire respons wordt opgewekt, blijkt deze ook geremd te 
kunnen worden door 1,7-dimethylxanthine (hoofdstuk 6). Aanvullend 
onderzoek heeft laten zien dat deze ex vivo respons ook geremd kan worden 
door fisetine, tricetine en flavone. Gebaseerd op deze bevindingen, zou 
suppletie met deze componenten in aanvulling op de reeds toegepaste 
behandeling van inflammatoire aandoeningen zoals COPD veelbelovende 
efecten kunnen hebben. Tot nu toe is er nog steeds geen succesvolle 
behandeling voor COPD ontwikkeld. Door het toepassen van PARP-1 remmers 
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afkomstig uit de voeding, zoals 1,7-dimethylxanthine of fisetine zou mogelijk 
zowel de inflammatie in de longen als de systemische inflammatie verminderd 
kunnen worden en de kwaliteit van leven van COPD patiënten verbeterd 
worden. 
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